securities exchange commission washington dc mark annual report pursuant section security exchange act fiscal year end december cidcidcidcid transition report pursuant section security exchange act transition period commission file gilead sciences inc exact registrant specify charter delaware state jurisdiction incorporation organization irs employer identification lakeside drive foster city california address principal executive office zip code registrant telephone number include area code security register pursuant section b act security register pursuant section g act common stock par value title class indicate check mark registrant file report require file section security exchange act precede month short period registrant require file report subject filing requirement past day yes cid indicate check mark disclosure delinquent filer pursuant item regulation sk section chapter contain contain good registrant knowledge definitive proxy information statement incorporate reference iii amendment cid indicate check mark registrant accelerate filer define rule b act yes cid aggregate market value vote stock hold nonaffiliate registrant base closing price common stock nasdaq stock market june number share outstanding registrant common stock february document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant september registrant implement twoforone stock split form stock dividend share share amount period present restate reflect stock splitgilead sciences inc annual report table content item business item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead science hepsera viread vistide daunoxome ambisome emtriva truvada macugen registered trademark belong eyetech pharmaceuticals inc sustiva register trademark bristolmyer squibb company tamiflu register trademark belong hoffmannla roche report include trademark service mark trade name companiespart item business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor affect gilead beginning give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision forward look statement reflect future event development report indicate refer gilead subsidiary overview gilead sciences inc biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company approve product focus research clinical program antiinfective seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy worldwide headquarters foster city california european headquarters paris france incorporate delaware june product viread oral formulation nucleotide analogue reverse transcriptase inhibitor dose day combination therapy treat human immunodeficiency virus hiv infection adult sell viread united states commercial team wholesaler major european country european commercial team distributor japan corporate partner japan tobacco w e exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult sell emtriva united states commercial team wholesaler major european country european commercial team distributor exclusive worldwide license patent right relate technology emtriva emory university truvada oral tablet dose day combination therapy treat hiv infection adult fixeddose combination antihiv medication emtriva viread truvada combine mg emtricitabine emtriva mg tenofovir disoproxil fumarate viread truvada currently sell united states commercial team wholesaler international commercial team begin launch truvada european union follow recent regulatory approval february exclusive worldwide license patent right relate technology component truvada iocbrega emory university ambisome proprietary liposomal formulation amphotericin b powerful antifungal agent treat invasive fungal infection cause fungal specie deliver amphotericin b proprietary liposomal formulation ambisome reduce rate severity kidney toxicity injectionrelate reaction associate amphotericin b allow patient receive high dose amphotericin b ambisome approve sale country include united states countries european union country ambisome approve include united states authorize promote ambisome empirical treatment fungal infection treatment patient strong suspicion definite confirmation exist potentially lifethreatene invasive fungal infection remain country ambisome approve use firstline treatment invasive fungal infection secondline treatment conventional amphotericin b therapy fail conventional amphotericin b tolerate market ambisome major country europe copromote ambisome united states fujisawa healthcare inc fujisawa hepsera oral formulation nucleotide analogue hepatitis b virus hbv dna polymerase inhibitor dose day treat chronic hepatitis b hepsera approve sale united states treatment chronic hepatitis b adult evidence active viral replication evidence persistent elevation serum aminotransferase alt ast histologically active liver disease commercial team wholesaler sell hepsera united states sell hepsera major european union country european commercial team distributor license right commercialize hepsera solely treatment hepatitis b china japan korea taiwan rest asia latin america certain territory glaxosmithkline gsk launch hepsera japan south korea taiwan exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega vistide antiviral medication treatment cytomegalovirus cmv retinitis patient aid cmv retinitis condition characterize lesion form patient retina affect person weaken immune system common patient aid vistide approve sale sell united states commercial team gilead exus partner pfizer inc pfizer pharmacia corporation country treatment cmv retinitis patient aid daunoxome liposomal formulation anticancer agent daunorubicin approve sale sell country treatment aidsrelate kaposis sarcoma sell united states commercial team independent distributor abroad december decide discontinue selling product subsequently receive unanticipated request europe reconsider sell daunoxome continue sell product limited number country currently evaluate supply sale strategy regard product royalty source macugen antiangiogenic injection treatment neovascular agerelate macular degeneration amd drug inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease macugen approve fda united states december begin sell january product approve outside united states macugen develop eyetech pharmaceuticals inc eyetech technology license eyetech hold exclusive right manufacture sell macugen worldwide subject eyetechs obligation pay percentage net revenue eyetech generate macugen sale patent technology license eyetech expire united states europe tamiflu oral pill treatment prevention influenza b tamiflu class prescription drug call neuraminidase inhibitor tamiflu approve country include united states japan countries european union treatment influenza child adult tamiflu approve united states european union prevention influenza adolescent adult develop tamiflu f hoffmannlaroche ltd roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay percentage net revenue roche generate tamiflu sale subject reduction certain define manufacturing cost follow table list aggregate product sale major product thousand product product product sale sale sale viread emtriva truvada total hiv product ambisome total product sale note consolidated financial statement financial information geographic area product market product clinical trial research development seek add exist portfolio product internal discovery clinical development program active product acquisition inlicense strategy acquisition triangle pharmaceuticals inc complete january research scientist foster city san dimas california durham north carolina engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area life threaten infectious disease research include work proprietary nucleotide analogue develop treatment viral infection particularly hiv hepatitis c infection total research development rd expense million compare million million research effort area hepatitis c viral infection hcv include collaboration chiron corporation chiron genelabs technologies genelabs achillion pharmaceuticals inc achillion august enter agreement chiron research develop commercialize small molecule therapeutic certain hcv drug target october enter research development agreement genelabs technologies genelabs discover develop commercialize nucleoside rna polymerase inhibitor treatment hcv infection november enter research development agreement achillion discover commercialize novel inhibitor hcv replication addition inhouse program design discover small molecule inhibitor hcv rna polymerase hcv protease believe small molecule therapeutic treatment hcv infection day lead well treatment outcome patient program require extensive investment year note consolidated financial statement discussion commercial operation international commercial sale operation marketing subsidiary australia canada france germany greece ireland italy new zealand portugal spain united kingdom commercial team promote hiv hbv product viread emtriva truvada hepsera direct field contact physician hospital clinic healthcare provider involve treatment patient hiv hiv product chronic hepatitis b hepsera team promote ambisome infectious disease specialist hematologist intensive care unit hospital home health care provider cancer specialist country outside united states agreement thirdparty distributor include distributor certain country market operation promote sell distribute product international distribution agreement generally provide distributor exclusive right sell product particular country country specify period time december announce program pursuant sell viread cost country africa country designate develop united nations expand program august include truvada take step ensure viread truvada product sell program serve patient develop world divert market international distribution collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company description accounting relationship find note consolidated financial statement include report follow list representative collaborative relationship collaborator program area year signing bristolmyer squibb hiv achillion hcv genelab hcv japan tobacco hiv glaxosmithkline hepsera archemix selex technology eyetech macugen roche tamiflu pfizer vistide fujisawa ambisome bristolmyers squibb company december enter collaboration agreement bristolmyer squibb company bm develop commercialize fixeddose combination gilead truvada bmss sustiva efavirenz united states structure joint venture gilead bms form limited liability company bristolmyers squibb gilead sciences llc approve new product complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider joint venture company work partnership complete development regulatory filing fixeddose regimen subject receive marketing approval fixeddose regimen company share responsibility commercialize product united states company provide fund fieldbased sale representative support promotional effort combination product term collaboration gilead bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license use jointly create intellectual property gilead bms ownership interest joint venture reflect respective economic interest base fraction net selling price fixeddose combination product attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva joint venturer respective economic interest joint venture vary annually academic consulting relationship supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right emory university university georgia research foundation inc emtricitabine april triangle obtain january acquire acquisition triangle exclusive worldwide license emory universitys right purify form emtricitabine use hiv hbv field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology united states year registration grant antihbv product incorporate emtricitabine technology certain major market country hiv hbv indication respectively triangle begin pay license maintenance fee development milestone achieve emory gsk settle litigation pende united states district court relate emtricitabine exclusive licensee foreign patent patent application file burrough wellcome co use emtricitabine treat hepatitis b settlement agreement obligate pay royalty gsk net sale product contain emtricitabine addition emory receive access development clinical datum drug substance hold gsk relate emtricitabine emory gsk shire pharmaceuticals group plc shire settle worldwide patent dispute involve lamivudine emtricitabine term settlement emory receive exclusive license shire shire patent relate emtricitabine method use manufacture shire gsk receive exclusive license emorys patent relate lamivudine term license agreement emory automatically acquire exclusive sublicense shire patent relate emtricitabine grant term settlement resolve previously pende patent dispute emtricitabine md anderson cancer center enter agreement md anderson cancer center relate hepsera agreement currently pay md anderson cancer center percentage net revenue base sale hepsera agreement md anderson cancer center terminate later patent expiration year commercial sale iocbrega enter agreement iocbrega relate viread hepsera vistide subsequently amend agreement include truvada agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement agreement pay percentage net revenue base sale viread truvada hepsera vistide iocbrega agreement iocbrega terminate individual country basis later patent expiration year commercial sale addition iocbrega terminate license particular product key market absence commercial sale product month regulatory approval university license equity holdings inc ongoing collaborative arrangement university license equity holdings inc ulehi successor university technology corporation predecessor university research corporation technology hold company university colorado boulder relate selex technology identify aptamer arrangement ulehi grant present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology computer software relate selex technology require pay ulehi certain variable royalty base revenue generate sale product derive selex technology include revenue base license agreement eyetech relate macugen develop world collaboration bill melinda gates foundation family health international october enter agreement bill melinda gates foundation family health international fhi provide viread fhis multinational clinical trial evaluate viread effectiveness method reduce risk hiv infection sexually active adult regularly expose hiv clinical trial conduct fhi fund million threeyear grant gates foundation dart study november enter collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection fiveyear clinical study conduct mrc antiretroviral hiv therapy africa trial call dart trial evelopment nti r etroviral herapy africa aim study clinical versus laboratory monitoring practice structure treatment interruption versus continuous antiretroviral therapy adult hiv infection subsaharan africa agree provide viread cost dart study institute world health january enter agreement institute world health pursuant provide ambisome cost phase clinical trial evaluate ambisome treatment visceral leishmaniasis paromomycin india great global burden visceral leishmaniasis clinical trial conduct institute world health partnership world health organization international distribution agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell viread emtriva hepsera ambisome daunoxome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor manufacture ambisome manufacture ambisome commercial quantity separate adjacent facility san dimas california medicines control agency united kingdom fda approve commercial production ambisome facility produce import ambisome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging distribution european union use commercially available material equipment manufacture product currently obtain amphotericin b cholesterol use manufacture ambisome single approve supplier ambisome sell freezedrie product currently freezedry ambisome san dimas manufacturing facility use party freezedry additional product need give current projection ambisome demand believe sufficient capacity meet future demand option instal additional freezedrying capacity san dimas additional supply necessary unable install additional freezedrying capacity san dimas locate appropriate party meet need ability meet increase ambisome demand diminish macugen manufacture macugen commercial quantity fda approve facilities san dimas california manufacturing agreement eyetech use commercially available material equipment manufacture product currently eyetech provide raw material manufacture macugen include pegaptanib sodium active ingredient macugen single approve supplier contract eyetech manufacturing process currently produce fill macugen san dimas manufacturing facility give eyetechs current projection macugen demand believe sufficient capacity meet future demand option instal additional production filling capacity san dimas additional supply necessary unable install additional production filling capacity san dimas locate appropriate party meet need ability meet increase macugen demand diminish macugen sell liquid form fill syrinx san dimas facility syrinx supply single approve supplier contract eyetech antiviral product contract party manufacture antiviral drug clinical commercial purpose include viread emtriva truvada hepsera vistide manufacture tenofovir disoproxil fumarate bulk drug substance contract manufacturer viread tablet manufacture contract manufacturer manufacture emtricitabine bulk drug substance contract manufacturer emtriva tablet manufacture contract manufacturer second contract manufacturer currently qualified manufacture truvada tablet single contract manufacturer united states second contract manufacturer currently qualify obtain qualification united states european union contract manufacturer adefovir dipivoxil bulk drug substance contract manufacturer hepsera tablet commercial supply europe contract manufacturer qualified commercial supply united states second currently qualified supplier approve fda european union manufacture cidofovir bulk drug substance vistide single fda emea approve supplier vistide drug product roche responsible manufacturing tamiflu january roche announce production problem liquid suspension form tamiflu approve treatment child young yearold available liquid suspension form tamiflu return market time flu season production issue affect availability tablet form tamiflu adult adolescent year old japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem november chugai announce recall tamiflu result reduce net sale royalty roche royalty income tamiflu net sale increase substantially primarily severe flu season united states late commercialscale manufacturing facility antiviral product future antiviral product need develop additional manufacturing capability establish additional party supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date united states europe primary patent patent issue pende application cover compound market product product candidate product patent expiration european patent expiration vistide hepsera ambisome tamiflu viread emtriva truvada patent cover viread hepsera vistide emtriva truvada hold party acquire exclusive right patent agreement party collaborative relationship academic consulting relationship patent cover active ingredient ambisome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form hepsera china certain asian country application pende asian country include china relate specific form formulation hepsera asia major market hbv therapy obtain patent compound year obtain marketing approval patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension example extension patent vistide grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license thirdparty technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include united states patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop develop addition certain country permit enforcement patent manufacturer able sell generic version product country rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competition product development program target number disease condition include viral fungal infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily efficacy safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum improve characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product hiv product hiv competitive landscape crowd complicated treatment trend continue evolve grow number antihiv drug currently sell advanced stage clinical development twentysix brand drug available united states zerit stavudine dt sell bristolmyer squibb bms fix combination product combivir azt tc trizivir azt tc abc sell gsk represent direct competition hiv product company process launch formulation exist drug indicate fda oncedaily oral dosing include gsk mg dose epivir lamivudine tc recently approve antiretroviral product include epzicom fix dose combination ziagen epivir gsk approve united states european union fuzeon injectable integrase inhibitor rochetrimeris reyataz atazanivir sulfate onceaday protease inhibitor bms tipranavir nonpeptidic protease inhibitor boehringeringelheim gsk file application approval oncedaily dose ziagen abacavir sulfate company compete hiv therapeutic category pfizer merck abbott bmss videx ec didanosine generic hiv product united states gsk retrovir azt expect face generic competition early united states effect overall market hiv product unknown price decrease hiv product result ambisome ambisome face strong competition current expect competitor current competitor include conventional amphotericin b bms numerous generic manufacturer caspofungin product develop merck market cancidas united states caspofungin voriconazole develop pfizer market vfend lipidbase amphotericin b product approve sale united states europe include abelcet sell enzon corp united states canada japan medeus pharma ltd europe amphotec sell intermune pharmaceutical inc presently unapproved expect competitor include class treatment call echinocandin include fujisawa micafungin receive marketing approval japan october review regulatory approval united states canada anidulafungin vicuron inc versicor inc product candidate evaluate multiple latestage clinical trial finally schere plough develop noxafil posaconazole currently phase trial competition current expect competitor erode likely continue erode revenue receive sale ambisome hepsera hepsera face significant competition exist expect therapy treat patient infect hbv significantly entecavir oral nucleoside analogue develop bms expect launch late daily oral antiviral bms file approval fda prescription drug user fee act pdufa action date april epivirhbv lamivudine develop gsk collaboration shire pharmaceutical sell major country north south america europe asia orally administer nucleoside analogue inhibit hbv dna polymerase introna interferon alfab sell schere plough major country north south america europe asia introna injectable drug immunomodulatory effect hepsera face competition clinicalstage candidate include idenixs ldt oral nucleoside analogue currently phase trial roche pegasys pegylate interferon alfaa expect approve chronic hepatitis b united states late tamiflu tamiflu competes relenza antiflu drug sell gsk relenza neuraminidase inhibitor deliver orallyinhale dry powder generic competitor include amantadine oral tablet inhibit replication influenza virus rimantadine oral antiviral vistide vistide compete number drug treat cmv retinitis include ganciclovir sell intravenous oral formulation roche ocular implant bausch lomb incorporate valganciclovir market roche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority united states countries united states drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell united states general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase compound appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase clinical trial fda approval process believe datum phase clinical trial adequate level safety effectiveness file new drug application nda fda seek approval sell drug particular use fda review nda hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound meet require level safety effectiveness particular use allow sell drug united states use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible accelerate sixmonth review accelerate approval case viread truvada drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread hepsera emtriva february truvada approve european union centralize procedure viread hiv drug review accelerate approval european union hepsera receive traditional review emtriva march apply marketing application truvada treatment hiv european union begin european launch truvada follow regulatory approval receive february pricing reimbursement insurance company health maintenance organization hmos thirdparty payor federal state government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product united states expect continue number federal state proposal implement drug price control addition manage care organization common united state continue seek low drug price announcement proposal effort cause stock price decrease proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly hivaid indication subject reimbursement issue certain product obtain regulatory approval reimburse government insurance company regulatory approval price require foreign country certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain foreign country require price approve product reduce product market period time certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country european government notably germany italy implement consider legislation require pharmaceutical company sell product subject reimbursement mandatory discount mandatory discount reduce revenue receive drug sale certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share viread addition government regulatory action disallow pricing combination product truvada sum price component drug market particular country employee february approximately fulltime employee believe good relation employee website website address wwwgileadcom available free charge website annual report quarterly report form q current report form k director officer section report require sec filing amendment report soon reasonably practicable filing provide hyperlink edgar website contain report risk factor affect gilead evaluate business carefully consider follow risk addition information report follow risk materially adversely affect business operating result financial condition substantially revenue derive sale limited number product unable maintain continue grow sale hiv product maintain sale ambisome result operation adversely affect currently dependent sale hiv product especially viread ambisome support exist operation viread comprise hiv product sale important consider viread emtriva truvada collectively future sale product intimately tie sale hiv product ambisome account approximately total product revenue year end december unable continue grow hiv product revenue maintain ambisome sale result operation likely suffer need scale operation hiv product sale year end december million total revenue ambisome product sale royalty year end december million total revenue able continue growth rate sale hiv product current sale level ambisome reason state risk factor section particular follow reason face significant competition business substantially great resource merck pfizer release new product compete ambisome glaxosmithkline market fixeddose combination product compete truvada competitor product operate field compete long ambisome sale volume relatively flat compare hiv product ambisome long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning label narrow approve indication halt sale product reduce revenue product mature private insurer government reimburser reduce reimburse patient product increase pressure reduce price large market hiv product patient take hiv drug successful encourage physician change patient prescription hiv product sale hiv product limit generic hiv product introduce major market ability maintain pricing affect fail commercialize new product expand indication exist product prospect future revenue stock price adversely affect introduce new product increase revenue exist product able grow revenue fail increase sale hiv product able increase revenue expand research development effort successful effort collaboration bristol myers squibb company formulate onceaday pill combination truvada sustiva failure achieve objective expect material adverse effect business result operation significant safety issue arise market product sale decline adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case limit postapproval use component truvada emtriva viread study individually safety efficacy study truvada ongoing follow approval product long period time patient take numerous medicine underlie health problem monitor dose compliance drug long period time patient find expect continue find new issue safety resistance drug interaction issue require provide additional warning label narrow approve indication reduce market acceptance product safety resistance interaction issue arise market product sale product limit halt regulatory authority operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda comparable regulatory agency country continue clinical trial ambisome viread hepsera emtriva truvada currently approve additional use anticipate file marketing approval additional country additional product year product fail receive marketing approval timely basis addition market product manufacture sell product subject extensive continue regulation review discovery previously unknown problem market product problem manufacture promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution recently formation independent drug safety office announce tasked monitoring safety approve product new office increase difficulty length time require new drug obtain marketing approval office create postapproval obligation require comply result clinical trial uncertain support continue development product pipeline adversely affect prospect future revenue growth require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product product development fail achieve primary endpoint clinical trial safety issue arise commercialization drug candidate delay halt addition clinical trial involve commercial product raise new safety issue exist product reduce revenue manufacturing problem delay product shipment regulatory approval adversely affect result operation depend party perform manufacturing activity effectively timely basis party fail perform require impair ability deliver product timely basis cause delay clinical trial application regulatory approval event harm competitive position manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation manufacturer subject fda current good manufacturing practice extensive regulation govern manufacturing process stability testing recordkeeping quality standard similar regulation effect country addition manufacturing operation subject routine inspection regulatory agency viread hepsera vistide emtriva truvada rely party manufacture bulk drug substance final drug product clinical commercial purpose addition roche responsible manufacturing tamiflu thirdparty manufacturer develop problem control problem adversely affect business example january roche announce production problem liquid suspension form tamiflu approve treatment child young year old available japan flu season particularly severe roche sublicensee chugai corporation unable meet heighten demand satisfactorily january chugai issue press release attribute failure manufacturing problem problem japan reduce net sale tamiflu royalty roche manufacture ambisome facility san dimas california formulation manufacturing facilities united states manufacturing facility ireland conduct quality control testing labeling packaging addition use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need able obtain material necessary manufacture product limit ability generate revenue material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship viread ambisome hepsera emtriva truvada vistide supply product development clinical trial depend relationship company sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance include collaboration fujisawa sumitomo ambisome gsk hepsera roche tamiflu pfizer vistide japan tobacco viread emtriva truvada recently announce joint venture bristolmyer squibb develop commercialize fixeddose combination truvada sustiva certain country rely international distributor sale ambisome viread emtriva european country intend rely international distributor sale hepsera relationship involve clinical development product partner reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product decline april licensing agreement gsk give gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major market hepsera china japan taiwan korea success hepsera territory depend entirely effort gsk regard gsk promote epivirhbv product compete hepsera consequently gsk marketing strategy hepsera influence promotion epivirhbv receive royalty gsk equal percentage gsk net sale hepsera net sale gsk epivirhbv gsk fail devote sufficient resource succeed develop commercialize hepsera territory potential revenue sale hepsera substantially reduce expense associate clinical trial sale fluctuation result inventory level hold wholesaler cause earning fluctuate adversely affect stock price clinical trial require regulatory approval product clinical trial require conduct approval extremely expensive difficult accurately predict control timing expense uneven unexpected spending program cause operating result fluctuate quarter quarter addition approximately product sale united states distributor amerisourcebergen corp cardinal health inc mckesson corp inventory level hold wholesaler fluctuate significantly cause sale result operating result fluctuate unexpectedly quarter quarter example base review ndc health corp prescription trend ims health inc inventory datum actual viread sale believe quarter end june wholesaler build inventory level estimate month believe inventory buildup follow equivalent possibly great inventory reduction quarter end september know inventory management agreement enter year major wholesaler continue effective match inventory level end user demand rely wholesaler estimate end user demand approximately half product sale occur outside united states currency fluctuation cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar equivalent sale negatively impact financial condition result operation use foreign currency forward contract hedge percentage forecast international sale primarily denominate euro currency hedge portion account receivable balance denominate foreign currency reduce eliminate exposure currency fluctuation date sale record date cash collected additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable use forward contract reduce impact foreign currency fluctuation future result effort successful fluctuation adversely affect result operation face credit risk european customer adversely affect result operation particularly subject credit risk european customer european product sale government own support customer greece italy portugal spain subject significant payment delay government funding reimbursement practice account receivable government own support customer country total million december significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect plan supply viread truvada cost certain develop country expose liability material adverse affect result operation financial condition launch distribution program pursuant supply viread truvada cost countries africa country designate develop united nations supply distribution drug resourcepoor environment complicated undertaking program develop face unforeseen challenge risk rise unforeseen liability example patient develop country viread truvada closely supervise doctor develop nation accordingly increase likelihood viread truvadarelate complication go undetected untreated result significant liability gilead product revenue reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly viread truvada agree provide cost country africa country designate develop country united nations revenue adversely affect addition european union require permit cross border sale allow buyer country government approve price product relatively high purchase product legally country sell low price additionally consumer able purchase product include hiv medicine internet pharmacy country substantial discount crossborder sale adversely affect revenue country require grant compulsory license hiv product face generic competition hiv product number develop country government official group suggest pharmaceutical company drug hiv infection available low cost alternatively government country require grant compulsory license allow competitor manufacture sell version product reduce sale certain country permit enforcement patent manufacturer able sell generic version product country compulsory license sale generic version product significantly reduce sale adversely affect result operation exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide significant percentage sale viread hepsera subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement policy price general europe success hepsera tamiflu emtriva viread truvada depend largely obtain maintain government reimbursement european country include united kingdom france patient use prescription drug reimburse government addition negotiate price governmental authority delay commercialization month expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis example europe international market government control price prescription pharmaceutical expect price prescription pharmaceutical decline life product volume increase previous year see significant price decrease product europe believe continue foreseeable future government struggle escalate health care spending result pricing practice difficult maintain historic level profitability achieve expect rate growth result operation adversely affect future health care reform unite states recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary recently pass congress additionally state enact health care reform legislation federal state development possible impact propose legislation reform unclear result pricing reimbursement restriction adversely impact revenue able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right number foreign patent patent application right patent relate compound product technology risk issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time united states patent issue result know competitor file patent application technology cover pende application invent technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing china certain asian country cover form adefovir dipivoxil active ingredient hepsera asia major market therapie hbv indication hepsera develop obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive ultimately successful approval process product fda determine product grant exclusivity period manufacturer application approval generic version product grant generic manufacture wait challenge patent protect product grant exclusivity year prior end exclusivity period near end exclusivity period grant product patent subject challenge need spend significant resource defend able defend patent successfully success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company maintain product liability insurance successful product liability claim cover insurance require pay amount provide insurance impair financial condition ability clinically test market product expensive litigation reduce earning name defendant number lawsuit use average wholesale price reimbursement rate medicaid name lawsuit allege violation federal security law adverse result lawsuit result material damage significantly reduce earning cash flow change effective income tax rate reduce earning factor favorable unfavorable effect effective income tax rate factor include limited interpretation exist tax law change tax law rate future level research development spending change accounting rule future level capital expenditure changes mix earning tax jurisdiction operate change overall level pretax earning impact income tax provision result abovementione factor significant negative impact result operation recently adopt change account stock option affect earning financial accounting standard board fasb recently issue statement financial accounting standard revise sharebased payment sfas r require implement quarter provide new guidance accounting stock option new accounting guidance require record additional compensation expense relate stock option equity incentive currently evaluate option valuation methodology include blackschole method binomial method method allow fas r impact earning result new standard significant negative impact result operation item property corporate headquarters include principal executive office research facility locate foster city california location approximately square foot space proximately locate building currently occupy building tenant occupy remain building addition lease office building approximately square foot space house commercial clinical development activity lease building expire june respectively gilead option renew fiveyear term addition june gilead option purchase building specify amount occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november renewal option present addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire november renewal option durham north carolina lease approximately square foot administrative office laboratory space sublease approximately square foot party lease expire october gilead option renew lease sevenyear term addition lease approximately square foot space aggregate sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future need item legal proceeding complaint follow case allege large number defendant include gilead overcharge governmental entity name plaintiff pharmaceutical product furnish participant medicaid program general complaint assert claim federal state law alabama state action include state law claim seek treble damage attorney fee litigation preliminary stage possible predict outcome date gilead serve process case county westchester v abbott laboratories et al intend defend case vigorously outcome case predict time amount accrue county westchester v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend include approximately defendant january city new york v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend approximately defendant january county rockland v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit originally gilead defendant amend include claim gilead approximately defendant january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit file gilead approximately defendant january purport class action complaint file november united states district court northern district california gilead certain executive officer complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allegedly false misleading statement omission plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december february court issue order appoint lead plaintiff consolidated action april lead plaintiff behalf purport class file consolidated amend complaint june gilead individual defendant file motion dismiss consolidated amend complaint january court grant defendant motion dismiss leave amend december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january similar case file february later consolidate prior case plaintiff file consolidated complaint amend time recently november gilead demur consolidated complaint court grant demurrer december plaintiff file motion leave file consolidated amend complaint january court grant plaintiff motion render complaint operative complaint intend demur complaint trial schedule june party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position item submission matter vote security holder matter submit vote security holder quarter end december ii item market registrant common equity relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter september implement twoforone stock split form stock dividend share share amount period present restate reflect stock split february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue purchase inprocess research development total cost expense income loss operation gain sale oncology asset provision benefit income taxis income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute gilead sciences inc select consolidated financial datum continue december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible debt accumulate deficit total stockholder equity gilead record gain million relate warrant eyetech complete initial public offering record makewhole payment million relate redemption million convertible senior debt gilead complete acquisition net asset triangle aggregate purchase price million approximately million purchase price allocate purchase inprocess research development record income tax benefit million relate reduction valuation allowance certain net defer tax asset sell share osi common stock recognize loss sale marketable security million share partial consideration sale oncology asset complete sale oncology asset relate technology osi pharmaceuticals inc record nonoperate gain million record nonoperate gain million sale percent interest proligo gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle effective quarter gilead adopt secs staff accounting bulletin sab revenue recognition financial statement change account change accounting principle february march september gilead implement twoforone stock split form stock dividend share share amount period present restate reflect stock split cash dividend declare pay common stock item management discussion analysis financial condition result operation executive summary operating result mark year growth total revenue reach billion high end cash cash equivalent marketable security billion drive large operate cash flow million year factor contribute improve financial performance important driver continue growth experience hiv product portfolio comprise viread emtriva truvada maintenance ambisome revenue amidst increase competition give increase international sale favorable foreign currency environment europe viread sale increase year year comprise total product sale august launch truvada coformulation viread emtriva united states begin launch truvada european union follow regulatory approval february time depend treatment regimen prescribe physician expect truvada sale partially replace product sale viread emtriva increase future sale hiv product enter joint venture collaboration agreement bms december develop commercialize fixeddose combination gilead truvada bms sustiva united states understand importance clear view wholesaler channel inventory sign inventory management agreement major wholesaler keep strategy active product acquisition inlicense rounded enter collaboration agreement area hcv operating result impact acquisition asset triangle n january complete acquisition expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aid hbv aggregate purchase price million include cash pay million fair value stock option assume million direct transaction cost million employee relate cost million approximately million consideration pay allocate purchase inprocess research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date result transaction relate purchase inprocess research development charge operate loss million acquisition important compound acquire opportunity provide create truvada coformulation viread emtriva single pill dose day note consolidated financial statement information triangle acquisition september gilead complete twoforone stock split effect form stock dividend stockholder record august accordingly share share amount period present restate reflect stock split addition certain prior year amount reclassify conform current year presentation management discussion analysis read conjunction consolidated financial statement note include report forwardlooke statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty risk factor discussion read conjunction consolidated financial statement note include report critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate estimate include related revenue recognition allowance doubtful account inventory clinical trial accrual tax provision base estimate historical experience marketspecific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure record estimate reduction revenue expect return expire product distributor fee government rebate program medicaid reimbursement customer incentive cash discount prompt payment estimate distributor fee base contractually determine fix percentage sale estimate government rebate program cash discount base contractual term historical utilization rate expectation future utilization rate program estimate product return include new product base ongoing analysis industry historical return pattern include monitor feedback receive sale force customer use satisfaction review inventory datum available wholesaler inventory management agreement assist monitor channel inventory level purchase thirdparty datum monitor prescription new product review long shelf life product sell similar channel monitor activity clinical trial key competitor assess potential impact future sale return expectation necessary expect return market drug generally low shelf life product range month truvada month ambisome viread united states condition competitive market serve drug circumstance change action increase product return estimate offer additional customer incentive result incremental reduction future revenue time return estimate change new incentive offer contract revenue research development record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize manufacturing obligation fulfil ratably development period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require allowance doubtful account balance percentage total account receivable materially change december december believe allowance doubtful account adequate cover anticipate loss current condition significant deterioration factor especially respect government funding reimbursement practice european market materially change expectation result increase allowance doubtful account inventory write inventory base historical review quantity bad batch experience manufacturing process expectation production inventory level perform quality control review individual raw material batch generally record inventory writeoff base estimate obsolescence risk competition primarily shelf life product long current assumption future production inventory level demand competition change actual market condition favorable project management inventory writedown require negatively impact product gross margin result operation clinical trial accrual record accrual estimate clinical preclinical study cost clinical preclinical study perform party contract research organization cro cost significant component research development expense incur million million million respectively cro cost accrue cost clinical study perform cro straightline basis term service period adjust estimate require base ongoing review level effort actually incur cro initially estimate work perform contract occur ratably period expect milestone event total contract completion date expect completion date estimate base term contract past experience similar contract estimate match actual service perform organization determine patient enrollment level measure activity specify contract result validate accrual quarterly write vendor confirmation detail review activity perform significant contract base result validation process assess appropriateness accrual adjustment deem necessary ensure expense reflect actual effort incur cro generally significant portion total cost associate start activity trial patient enrollment gilead extensively outsource clinical trial activity usually perform small portion startup activity inhouse result cro typically perform total startup activity trial include document preparation site identification screen preparation prestudy visit training program management budget basis cost typically total contract value actual basis percentage range significantly wider contract expand reduced scope compare original budget startup cost particular trial change significantly startup cost usually occur month contract establish milestone event drive nature remain activity relate cost patient monitor administration generally occur ratably life individual contract study contract negotiate fix unit price vary length month single dose phase study year complex phase study average length contract upper end range order provide long term safety efficacy datum support commercial launch viread truvada hepsera emtriva december difference actual estimate activity level particular study significant require material adjustment material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate management receive complete accurate information vendor underestimate activity level associate study give point time record additional potentially significant research development expense future period tax provision develop income tax provision include defer tax asset liability base significant management judgment evaluate realizibility defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination adjustment fourth quarter determine likely certain defer tax asset realized release related valuation allowance result income tax benefit approximately million million respectively similarly determine able realize defer tax asset valuation allowance increase valuation allowance period determination future effective income tax rate affect factor change tax law rate change interpretation law impact accounting employee stock option begin second half overall change future level earning research development capital spending management discuss development selection critical accounting policy audit committee gilead board director audit committee review disclosure present relate result operation total revenue total revenue billion million million include total revenue product sale royalty revenue contract revenue include revenue earn research development rd manufacturing collaboration product sale product sale consist follow thousand change change viread emtriva truvada total hiv product ambisome total product sale product sale increase compare compare primarily increase volume sale hiv product significant percentage product sale continue denominate foreign currency use forward contract hedge percentage forecast international sale primarily denominate euro reduce eliminate fluctuation sale change foreign currency exchange rate loss revenue hedge reduce increase product sale million million million fluctuation exchange rate product sale mainly viread ambisome benefit overall primarily increase exchange rate euro british pound comparison dollar million compare million compare prior experience significant fluctuation distribution channel inventory level speculative purchase major wholesaler result experience increase quarter quarter sale volatility purchase pattern order help alleviate fluctuation n july enter inventory management agreement imas amerisourcebergen drug corporation cardinal health inc mckesson corporation major pharmaceutical wholesaler distribute percent portfolio product sell united states agreement implement limit speculative buying help ensure wholesaler purchase consistent customer demand predictable agreement agree pay wholesalers fee exchange product distribution inventory management service market research information return good processing assistance counterfeit product detection service fee record reduction product sale consolidate statement operation additionally term agreement wholesaler agree exceed specify maximum level inventory hand end december believe major wholesaler inventory onhand gilead product month supply compliance contractually specify level viread emtriva truvada approve sale united states october july august respectively viread emtriva approve sale european union february october respectively sale viread total product sale respectively viread sale million sale increase versus million international sale increase versus viread sale million sale increase versus million international sale increase versus emtrivas introduction july sale increase significantly million million august truvada approve sale united states product sale total million december total hiv product sale million higher compare favorable european currency environment majority relate viread sale believe product sale mix change patient currently take viread andor emtriva switch truvada look hiv product sale collectively relevant basis periodoverperiod comparison sale hiv product percentage total product sale respectively expect sale hiv product billion billion year sale ambisome total product sale respectively hiv hbv product sale continue increase ambisome sale decrease percentage total product sale ambisome sale million sale decrease versus million international sale increase versus ambisome sale million sale decrease versus million international sale increase report ambisome sale million high favorable currency environment compare volume basis ambisome sale united states decrease sale volume europe increase slightly compare analyze decrease sale important note product sale decrease compare volume decrease discussion ambisome sale relate solely sale ambisome fujisawa record manufacturing cost great manufacturing efficiency unit manufacturing cost ambisome decrease decrease revenue report sale fujisawa royalty earn sale ambisome fujisawa discuss continue competition expect ambisome sale range million million royalty revenue record royalty revenue million compare million million year period significant source royalty revenue result sale tamiflu roche sale ambisome united states fujisawa copromotion arrangement royalty revenue earn sale tamiflu million million million respectively royalty revenue earn sale ambisome fujisawa million million million respectively difficult estimate party product sale record royalty revenue roche quarter arrear severe influenza epidemic united states late early royalty revenue increase substantially second quarter increase awareness discussion supply influenza treatment increase roche sale tamiflu consequently royaltie fourth quarter contract revenue total contract revenue million compare million million contract revenue consist primarily million research milestone revenue earn eyetech pharmaceutical include million net milestone payment earn file new drug application eyetech europe united states macugen pegaptanib sodium injection primary source contract revenue consist million license fee earn conjunction licensing agreement eyetech macugen contract revenue primarily consist million licensing selex process patent estate archemix collectibility concern recognize cash basis million milestone payment roche european prophylaxis treatment approval tamiflu december complete sale oncology asset osi term agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million million million respectively contract revenue manufacturing agreement cost good sell product gross margin follow table indicate cost good sell product gross margin thousand change change total product sale cost good sell gross margin percentage gross margin relatively flat positive impact improvement certain manufacturing process favorable foreign currency environment offset change product sale mix compare gross margin improve primarily change product mix viread high margin product contribute significantly net product sale change foreign currency exchange rate impact gross margin price product currency country product sell significant majority manufacturing cost dollar example increase value foreign currency relative dollar positively impact gross margin manufacturing cost remain approximately revenue translate dollar increase weaken dollar positively impact gross revenue gross margin effect foreign currency exchange rate moderate hedging program forecast international sale potential impact unpredictable uncontrollable change exchange rate relative dollar mix product sale hiv product hepsera ambisome expect gross margin consistent range research development expense follow table summarize research development expense major component thousand change change research clinical development pharmaceutical development total major category research development rd expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis prior clinical development consist clinical trial expense phase phase united states phase european clinical trial include sale general administrative sga order well reflect nature european phase clinical trial begin record clinical trial expense research development order consistent current year presentation million million expense reclassify sell general administrative research development expense year end december respectively million increase rd expense primarily attributable increase salary million largely high headcount increase contract research organization cost million associate increase clinical activity million research license fee pay relation hepatitis c collaboration agreement effective fourth quarter new collaboration enter achillion genelab require pay aggregate license fee million expense rd underlie technology alternative future use increase rd activity partially offset decrease spending discontinuation program gs gs focus development certain hiv investigational product important note rd expense include reimbursement gilead million settlement contractual dispute vendor million increase rd spending versus primarily attributable increase salary million largely high headcount increase clinical supply cost million increase clinical trial cost associate development emtriva truvada coformulation viread emtriva mention settle contractual dispute vendor result reimbursement million record research development expense expect rd expense approximately million million estimate increase expense level reflect increase spend internal research development effort cost associate postmarkete study support product exclude expense incur associate potential collaboration strategic acquisition include license milestone fee cost sharing arrangement impact accounting employee stock base compensation begin second half industry report indicate biopharmaceutical company generally take year average year research develop bring market new prescription medicine united states average generally consistent project undertake internally recent product development timeline slightly accelerate basis drug development united states process include step define fda process begin file ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase generally account average seven year drug total development time significant cost associate clinical development phase trial tend long large study conduct drug development process currently product development phase study successful development product highly uncertain completion date rd expense vary significantly product difficult predict successful development fda approval product undertake additional study try expand product label market potential complete discussion risk uncertainty associate complete development product risk factor affect gilead section item sell general administrative expense follow table highlight year year change sell general administrative expense thousand change change sell general administrative sga expense year end december million compare million year end december include reclassification phase iv clinical trial expense incur rd million significant increase expense compare primarily increase salary million largely high headcount increase consulting fee million relate sarbanesoxley compliance business strategy consulting increase cost million relate speaker program grant journal advertising remainder increase sga expense compare increase global marketing effort increase infrastructure require support growth business infrastructure investment implement reorganization sale marketing function newly create commercial division conjunction reorganization create fill new position executive vicepresident commercial operation responsibility global commercial operation strategy product portfolio increase expense compare include reclassification phase iv clinical trial expense rd million primarily increase salary million largely high headcount increase hedging cost million increase cost million relate marketing meeting grant increase general director officer insurance million remainder increase sga expense global sale marketing effort include expansion european sale force increase infrastructure require support growth business expect sga expense approximately million million primarily anticipated launch cost truvada european union ongoing investment global commercial organization hire promotional program exclude expense incur associate potential collaboration strategic acquisition impact apply new standard accounting employee stock base compensation begin second half purchase inprocess research development connection acquisition net asset triangle complete january record purchase inprocess research development expense million quarter charge triangle incomplete research development program reach technological feasibility alternative future use acquisition date value purchase inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market summary program acquisition date update subsequent development february follow estimate acquisition date fair value program description status development millions emtricitabine hiv nucleoside analogue phase study complete show prior acquisition date inhibitor hiv replication marketing approval receive patient fda july emtriva european union approval receive european commission october emtricitabinetenofovir df fixeddose acquisition date work fix dose combination coformulation tenofovir commence potential co hiv therapy emtricitabine formulation extent work emtricitabine single agent progress march application marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february amdoxovir hiv purine dioxolane program phase trial nucleoside offer acquisition date terminate advantage license agreement emory market nucleosides university university activity georgia research foundation inc drug resistant development discontinue virus exhibit patient hiv infection clevudine hbv pyrimidine nucleoside program phase trial analogue acquisition date august show inhibitor licensing agreement bukwang hbv replication patient pharm ind co ltd terminate chronically infect development discontinue hbv emtricitabine hbv inhibitor hbv phase trial complete replication patient december chronically infect hbv asset impairment record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment noncash charge drive decision december terminate liposomal research development activity san dimas discontinue daunoxome product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value longlive asset estimate fair value subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance generally accept accounting principle new cost basis impair asset adjust new fact circumstance gain loss marketable security pursuant agreement eyetech enter march receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust fair value warrant result gain million time fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share own realize gain approximately million include interest income net year end december july sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million year end december makewhole payment debt redemption october gilead call redemption outstanding convertible senior note december november convertible senior note call provisional redemption base market price gilead common stock exceed certain threshold aggregate principal outstanding note million convertible senior note redeemable redemption price equal principal note plus cash payment equal accrue unpaid interest redemption date cash makewhole payment equal principal value note interest actually pay accrue unpaid date issuance note redemption date interest convertible senior note cease accrue redemption date remain right holder receive redemption payment include accrue unpaid interest redemption date makewhole payment alternatively note holder elect convert note share gilead common stock price share share gilead common stock principal note holder substantially outstanding note convert note share gilead common stock prior november redemption date result conversion share common stock issue note holder connection redemption gilead pay aggregate makewhole payment million note holder interest income net record interest income million compare million million increase compare primarily attributable high cash balance yield past year decrease compare attributable significant decline interest rate low average cash balance acquisition net asset triangle purchase foster city campus partially offset positive cash flow operation interest income depend principally prevail interest rate level cash cash equivalent marketable security balance interest expense incur interest expense million compare million million decrease primarily conversion million convertible subordinated debt share common stock december outstanding debt consist million convertible senior debt issue december november convert convertible senior note significant increase year interest million convertible senior note issue december interest expense consist primarily interest million convertible subordinate note convert share common stock december expect interest expense decrease compare primarily conversion million convertible senior note november provision benefit income taxis provision benefit income taxis million million million respectively effective income tax rate differ federal statutory rate generally state taxis offset recognition previously unbenefitte net operating loss tax credit carryforward certain earning tax foreign tax rate jurisdiction low tax rate taxis provide earning plan permanently reinveste outside united states tax benefit include reversal valuation allowance certain defer tax asset december conclude likely realize portion benefit relate defer tax asset accordingly reduce valuation allowance asset record tax benefit million recognition defer tax asset impact cash flow partially offset tax benefit income tax expense associate income earn foreign subsidiary foreign loss benefit low tax rate nontax deductibility purchase inprocess research development significant net operating loss carryforward reduce tax liability exclude benefit relate reversal valuation allowance write purchase inprocess research development effective tax rate income tax expense primarily associate income earn foreign subsidiary significant net operating loss united states provision reduce change income tax law law allow net operating loss carryforward deduction offset alternative minimum taxable income result reduction income tax record previous year million october american jobs creation act ajca sign law ajca allow deduction certain foreign earning repatriate define ajca elect apply provision qualify earning repatriation fiscal start evaluation effect repatriation provision expect able complete evaluation congress treasury department provide additional clarify language key element provision expect complete evaluation effect repatriation provision reasonable period time follow publication additional clarify language range possible amount consider repatriation provision zero million maximum allowable define ajca currently relate potential range impact income taxis reasonably estimate liquidity capital resource cash cash equivalent marketable security total billion december million december increase million primarily net cash provide operation million proceed issuance stock employee stock plan million partially offset capital expenditure million cash decrease million primarily acquisition triangle net cash impact million purchase foster city campus million capital expenditure million partially offset proceed issuance stock employee stock plan million work capital december billion compare billion december significant change working capital include million decrease current defer tax asset offset million increase account receivable million increase inventory million decrease current defer tax asset primarily utilization net operating loss tax credit carryforward offset taxable income account receivable increase million primarily increase sale viread united states europe sale new product truvada launch united states half million increase inventory primarily increase purchase raw material production viread truvada inventory meet increase sale demand current liability increase million primarily follow million increase medicaid rebate obligation associate high sale viread million increase defer revenue primarily royalty receive roche million increase liability associate fair value forward currency contract dollar continue weaken european currency million increase account payable primarily increase raw material purchase support viread truvada sale growth million increase increase compensation cost employee benefit add headcount increase million distributor fee owe pay inventory management agreement enter july increase current liability partially offset million decrease accrue clinical preclinical expense result decrease activity associate clinical trial program viread hepsera end capital expenditure million compare million million expenditure primarily domestic international facility improvement include approximately million associate completion pilot plant foster city develop drug process prepare material supply clinical trial additional spending laboratory manufacturing equipment accommodate growth capital expenditure relate research development million spend million spend million spend expect capital spending million million increase infrastructure need high rd spending believe exist capital resource supplement cash generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance current future product progress scope research development effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire manufacturing capability additional office facility possibility acquire company new product establishment additional collaborative relationship company defense cost associate settlement adverse result litigation future require additional funding form proceed equity debt financing universal shelf registration statement file december potential issuance million security additional collaborative agreement corporate entity funding require assure available favorable term subsidiary establish variety subsidiary country purpose conduct business location subsidiary consolidate financial statement variable interest entity unconsolidate financial statement involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation contractual obligation form capital operating lease noncancelable raw material supply arrangement clinical research organization contract follow table summarize contractual obligation december thousands payment period contractual obligation total year year year year capital lease obligation operating lease obligation capital commitment inventory purchase obligation clinical trial total december firm capital project commitment approximately million relate facility improvement addition budget significant capital expenditure mainly anticipate increase infrastructure need high rd spending capital spend future year december firm commitment purchase active pharmaceutical ingredient amount disclose represent minimum purchase requirement actual purchase differ significantly amount december clinical study clinical trial phase significant expenditure contract research organization contract cancelable generally cancel contract amount reflect commitment base exist contract reflect future modification exist contract anticipate potential new contract recent accounting pronouncement december fasb issue sfas revise sharebased payment sfas r revision sfas sfas r supercede apb amends sfas statement cash flow sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value begin interim annual period june early adoption permit pro forma disclosure previously permit sfas long alternative financial statement recognition expect adopt sfas r quarter fiscal begin july sfas r determine appropriate fair value model value sharebase payment amortization method compensation cost transition method date adoption transition method include prospective retroactive adoption option retroactive option prior period restate begin year adoption period present prospective method require compensation expense record unvested stock option restrict stock begin quarter adoption sfas r retroactive method record compensation expense unvested stock option restrict stock begin period restate currently evaluate requirement sfas r option valuation methodology relate employee director stock option employee stock purchase plan determine method adoption effect adopt sfas r expect adoption sfas r material impact consolidate result operation earning share impact adoption sfas r predict time depend thing level sharebase payment grant future method adoption option valuation method sfas r require benefit tax deduction excess recognize compensation cost report finance cash flow operate cash flow require current literature requirement reduce net operating cash flow increase net financing cash flow period adoption estimate amount future depend thing employee director exercise stock option operate cash flow recognize prior period relate tax deduction million million million respectively current estimate option value blackschole method indicative result valuation methodology ultimately adopt gilead item quantitative qualitative disclosure market risk foreign currency exchange risk operation include manufacture sale activity united states sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate net monetary asset liabilitie significant percentage product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition prior hedge exposure impact fluctuate foreign exchange rate forecast sale january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency recent year weaken dollar foreign currency exchange fluctuation positively impact product sale gross margin impact favorable foreign currency environment moderated hedge contract enter follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value dollar thousand fair value currency notional average rate december british pound euro australian dollar total notional million fair value million open foreign exchange forward contract december compare total notional million fair value million open foreign exchange forward contract december significant increase outstanding contract primarily attribute project increase revenue forecast periods interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base duration industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate fixedrate interestbeare asset fixedrate liability december dollar thousand year e ndin g decem ber df eca eir v ba erl u e total asset availableforsale security average interest rate liability longterm obligation include current portion average interest rate longterm obligation consist capital lease operating lease net noncancelable sublease interest portion payment include international credit risk account receivable balance december million compare million december million december growth account receivable balance primarily high product sale viread united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase credit risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total approximately million approximately million day past date experience significant loss respect collection account receivable believe substantially account receivable balance collectible perform credit evaluation customer financial condition generally require collateral item financial statement supplementary datum financial statement require item set forth begin report incorporate reference item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness design operation disclosure control procedure define sec rule control procedure company design ensure information require disclose company report file securities exchange act exchange act record process summarize report require time period base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define security exchange act rule af internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include principal executive officer principal financial officer conduct evaluation effectiveness internal control financial reporting criterion set forth committee sponsor organization treadway commission coso internal control integrate framework base evaluation conclude internal control financial reporting effective december ernst young llp independent register public accounting firm audit consolidated financial statement include issue audit report assessment internal control financial reporting c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting item b information iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement headings nominee executive officer board director audit committee compliance section security exchange act gilead write code ethic apply director employee include executive officer code ethic available gilead website httpwwwinvestorsgileadcom change waiver code ethic disclose website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee report item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensation item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item exhibit financial statement schedule follow document file index list financial statement report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement schedule ii include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november agreement plan merger registrant simbolo acquisition sub inc wholly own subsidiary registrant triangle pharmaceutical inc date december amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc registration right agreement date december registrant goldman sach co amendment amend restate right agreement date october registrant mellon investor service llc form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april amend january amend january form nonqualified stock option issue certain executive officer director letter agreement date september registrant iocbrega exhibit certain confidential information omit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega registrant nonemployee director stock option plan amend january amend january development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit nexstar pharmaceutical incs incentive stock plan adopt february amend nexstar pharmaceutical inc director option plan adopt july vestar inc stock option plan lease date february registrant majestic mapa property llc lease date february registrant majestic mapa property llc assignment royalty agreement date december effective june vestar inc city hope national medical center agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date july registrant majestic realty co majesticmapa property llc amendment thereto date march license distribution agreement date september sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical co ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan licensing agreement date april gilead world market limited glaxo group limited employment agreement date july gilead sciences inc sharon surreybarbari triangle pharmaceuticals inc stock incentive plan option agreement triangle pharmaceuticals inc daniel g welch date august license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc compound amdoxovir dapd date march license agreement triangle pharmaceuticals inc emory university coviracil ftc date april exclusive license agreement triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university date settlement agreement triangle pharmaceuticals inc emory university dr david w barry glaxo wellcome plc glaxo wellcome inc glaxo group limited wellcome foundation limited date amendment license agreement triangle pharmaceuticals inc emory university date amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date july second amendment license agreement triangle pharmaceuticals inc emory university date july supply manufacturing agreement triangle pharmaceuticals inc abbott laboratories date july settlement exclusive license agreement triangle pharmaceuticals inc shire biochem inc shire pharmaceuticals group plc emory university university georgia research foundation date august second amendment license agreement triangle pharmaceuticals inc emory university university georgia research foundation inc date august manufacture supply agreement gilead world markets ltd ppgsipsy sas enter january gilead sciences inc severance plan adopt effective january amendment license agreement triangle pharmaceuticals inc emory university date lease agreement date june th registrant gra associates limited llc premise locate university drive durham north carolina master clinical commercial supply agreement date january gilead world markets ltd gilead sciences inc patheon inc toll manufacturing agreement date august gilead world markets ltd gilead sciences inc altana pharma oranienburg gmbh licensing agreement date march amend december april gilead sciences inc eyetech pharmaceuticals inc amendment licensing agreement date eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date december eyetech pharmaceuticals inc gilead sciences inc amendment licensing agreement date august eyetech pharmaceuticals inc gilead sciences inc amendment date license agreement date april glaxo group limited gilead world market limited amendment date january licensing agreement date april glaxo group limited gilead world market limited employment agreement date april gilead sciences inc mark l perry gilead sciences inc equity incentive plan amend july collaboration agreement gilead sciences inc gilead holdings llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date december th amendment license agreement triangle pharmaceuticals inc emory university date subsidiary registrant consent independent register public accounting firm power attorney reference signature section certification section certification section certification file exhibit registrant annual report fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc quarterly report form q quarter end june incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file march incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceutical inc registration statement form file incorporate reference file exhibit nexstar pharmaceutical inc form q quarterly period end september incorporate reference file exhibit nexstar pharmaceutical inc form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file january incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant quarterly report form q quarter end september incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant current report form k file december incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit registrant registration statement form file january incorporate reference file exhibit triangle pharmaceutical inc registration statement form amend incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit triangle pharmaceutical inc current report form k file september incorporate reference file exhibit triangle pharmaceutical inc quarterly report form q quarter end september incorporate reference file exhibit registrant current report form k file october incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant quarterly report form q quarter end march incorporate reference file exhibit registrant quarterly report form q quarter end june incorporate reference file exhibit registrant fiscal year end december incorporate reference file exhibit registrant fiscal year end december incorporate reference certain confidential portion exhibit omit mean mark portion asterisk mark exhibit file separately secretary sec mark pursuant registrant application request confidential treatment rule b securities exchange act gilead sciences inc consolidated financial statement year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states effectiveness gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date march express unqualified opinion thereon ernst young llp palo alto california march report independent register public accounting firm board director stockholder gilead sciences inc audit management assessment include accompany management annual report internal control financial reporting include item gilead sciences inc maintain effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission coso criterion gilead sciences incs management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment opinion effectiveness gilead sciences inc internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion management assessment gilead sciences inc maintain effective internal control financial reporting december fairly state material respect base coso criterion opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet gilead sciences inc december relate consolidated statement operation stockholder equity cash flow year period end december relate financial statement schedule report date march express unqualified opinion thereon ernst young llp palo alto california march gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security account receivable net allowance december december inventory defer tax asset prepay expense total current asset property plant equipment net noncurrent defer tax asset ther noncurrent asset liability stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue longterm obligation year convertible senior debt commitment contingency stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize share issue outstanding december respectively additional paidin capital accumulate comprehensive income loss defer stock compensation accumulate deficit otal stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale royalty revenue contract revenue total revenue cost expense cost good sell research development sell general administrative purchase inprocess research development asset impairment total cost expense income loss operation gain loss marketable security makewhole payment convertible debt redemption interest income net interest expense income loss provision benefit income taxis provision benefit income taxis net income loss net income loss sharebasic share share calculationbasic net income loss sharedilute share share calculationdilute accompany note gilead sciences inc consolidated statement stockholder equity thousand accumulate additional comprehensive total commo n stock paidin income defer stock accumulat ed stockholde rs share capital loss compensation deficit equity ba nla en tc ie n ot mde ec ember unrealize loss availableforsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income issuances employee stock purchase plan stock option exercise net tax benefit employee stock plan compensatory stock transaction balance ecember net loss unrealize loss availableforsale security net foreign currency translation adjustment unrealize loss sh flow hedge net comprehensive loss conversion convertible subordinate debt acquisition triangle pharmaceuticals inc issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock co mpensation compensatory stock transaction balance dec ember net income unrealize loss availableforsale security net foreign currency translation adjustment unrealize loss cash f low hedge net comprehensive income conversion convertible senior debt net debt issuance cost issuance employee stock purchase plan stock option exercise net tax benefit employee stock plan amortization defer stock co mpensation compensatory stock transaction b alance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash provide operating activity depreciation amortization purchase inprocess research development asset impairment loss disposal property plant equipment loss gain marketable security defer tax asset tax benefit employee stock plan noncash transaction change operate asset liability account receivable net inventory prepaid expense asset account payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale maturity marketable security acquisition triangle net asset net cash acquire acquisition real estate capital expenditure issuance note triangle net cash provide investing activity financing activity proceed issuance common stock repayment longterm debt proceed issuance convertible senior note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity common stock issue conversion debt reclassification defer debt issuance cost additional paidin capital conversion debt accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease multinational company revenue approve product marketing operation country focus research clinical program antiinfective currently market viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate treatment hiv infection hepsera adefovir dipivoxil treatment chronic hepatitis b infection ambisome amphotericin b liposome injection treatment fungal infection vistide cidofovir injection treatment cmv retinitis roche market tamiflu oseltamivir phosphate treatment influenza royalty pay collaborative agreement january eyetech start market macugen pegaptanib sodium injection united states treatment neovascular agerelate macular degeneration milestone royalty pay collaborative agreement accompany consolidated financial statement include account gilead whollyowne subsidiary significant intercompany transaction eliminate certain prior year amount reclassify consistent current year presentation research development expense stock split march september gilead complete twoforone stock split effect form stock dividend stockholder record february august respectively accordingly share share amount period present reflect stock split critical accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis management evaluate estimate include related revenue recognition allowance doubtful account inventory clinical trial accrual tax provision base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition recognize revenue product sale persuasive evidence arrangement exist delivery customer occur price fix determinable collectibility reasonably assure provide customer general right product return accept return products united states expire year expiration product gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue deem damage defective receive customer recognition revenue product sale provision estimate future return product expire government reimbursement certain distributor fee customer incentive cash discount prompt payment estimate government reimbursement cash discount base contractual term expectation utilization rate program estimate distributor fee base contractual term estimate product return include new product base ongoing analysis industry historical return pattern party datum assist monitor channel inventory level subsequent prescription contract revenue research development record performance occur earning process complete base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection reasonably assure revenue nonrefundable upfront license fee milestone payment continue involvement development collaboration obligation supply product recognize performance occur obligation complete accordance specific term gilead obligation type arrangement revenue recognize manufacturing obligation fulfil ratably development period revenue associate substantive atrisk milestone recognize base achievement milestone define respective agreement advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale hepsera tamiflu vistide recognize receive quarter follow quarter correspond sale occur shipping handle cost shipping handling cost incur inventory purchase product shipment record cost good sell consolidated statement operation research development expense major component research development rd expense consist personnel cost include salary benefit clinical study perform contract research organization cro material supply overhead allocation consist administrative facility relate cost rd activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase clinical trial pharmaceutical development cost consist product formulation chemical analysis gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue charge research development cost include clinical preclinical study cost expense incur consistent statement financial accounting standard sfas accounting research development cost cost significant component rd expense clinical preclinical study perform party cro accrue cost clinical study perform cro straightline basis service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro initially estimate work perform contract occur ratably service period expect milestone event total contract completion date expect completion date estimate base term contract past experience similar contract monitor level performance contract include extent patient enrollment activity communication cro adjust estimate require quarterly basis expense reflect actual effort expend cro material cro contract terminable write notice gilead generally liable actual effort expend cro point time contract regardless payment status amount pay advance service perform refunded contract terminate contract include additional termination payment payable gilead terminate contract additional termination payment record contract terminate order well reflect nature european phase clinical trial gilead begin recording cost rd expense amount previously classify sell general administrative expense consolidate statement operation order consistent current period presentation million million expense reclassify sell general administrative research development expense year end december respectively advertising expense expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation amend sfas accounting stockbase compensationtransition disclosure sfas elect continue follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price gilead employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize elect follow intrinsic value method prescribe apb evaluate approach accounting stock option light recent industry regulatory development gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue table present net income loss basic diluted net income loss share compensation cost gilead nexstar pharmaceuticals inc nexstar triangle stock option plan employee stock purchase plan espp determine base estimate fair value award plan grant purchase date accordance sfa thousand share amount year end december net income lossa report add stockbased employee compensation expense include report net income loss net relate tax effect deduct total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma net income loss net income loss share basica report basicpro forma diluteda report dilutedpro forma fair value award grant stock option plan espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility employee stock option characteristic significantly different trade option model develop future generate fair value differ calculate base blackschole calculate estimate fair value award multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue fourth quarter refine volatility assumption arrive fair value stock award purpose calculate expect volatility rate begin time period well reflect current stage development length time public company drug approval past year enable achieve positive cash flow operation believe estimate volatility rate well reflect expect volatility common stock future recent threeyear time period purpose calculate expect volatility twoyear time period derive weight average volatility fourth quarter weight average volatility quarter weight average estimate fair value espp share purchase earning loss share basic earning loss share calculate base weightedaverage number common share outstanding year dilute earning loss share calculate base weightedaverage number common share dilutive security dilutive potential common share result assume exercise outstanding stock option equivalent determine base treasury stock method dilutive potential common share result assumed conversion convertible note determine base ifconverted method follow table reconciliation numerator denominator calculation basic diluted earning loss share thousands year end december numerator net income loss calculation basic earning loss share interest expense makewhole payment convertible debt redemption net income loss calculation dilute earning loss share denominator weightedaverage common share outstanding calculation basic earning loss share effect dilutive security stock option equivalent convertible debt weightedaverage common share outstanding calculation dilute earning loss share gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue diluted net loss share exclude prorate effect million convertible subordinated note convert approximately million share effect million convertible senior note convert approximately million share outstanding stock option equivalent million share effect antidilutive diluted net income share exclude effect million convertible subordinated note convert approximately million share million convertible senior note convert approximately million share effect assume conversion antidilutive cash cash equivalent consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead eligible instrument investment policy include cash equivalent include commercial paper money market fund bank obligation marketable nonmarketable security determine appropriate classification marketable security consist solely debt security time purchase reevaluate designation balance sheet date marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss available forsale security exclude earning report separate component stockholder equity interest income net include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year result enter collaboration time time gilead hold stock nonpublic company record nonmarketable security cost noncurrent asset amount otherthantemporary impairment regularly review investment indicator impairment investment nonmarketable security material period present recognize otherthantemporary decline past year gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue concentration risk subject credit risk portfolio cash equivalent marketable security policy limit amount invest security duration industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale significant trade account receivable arise product sale viread united states europe certain country payment typically slow primarily greece italy portugal spain account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece italy portugal spain total approximately million approximately million day past base contractual term receivable december past receivables country million approximately million day past date experience significant loss respect collection account receivable believe past account receivable net allowance reflect consolidated balance sheet collectible perform credit evaluation customer financial condition generally require collateral material utilize operation facility example depend single supplier high quality amphotericin b distearoylphosphatidylcholine high quality cholesterol manufacture ambisome currently contract manufacturer qualified manufacture truvada tablet supply supplier interrupt reason unable ship viread ambisome hepsera emtriva vistide truvada supply product development clinical trial account receivable trade account receivable record net allowance cash discount prompt payment doubtful account government chargeback sale return estimate cash discount government chargeback sale return base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual obligation historical payment pattern customer individual customer circumstance analysis day sale outstanding customer geographic region review local economic environment potential impact government funding reimbursement practice historically level uncollectible account receivable write insignificant consistent management expectation gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straightline method land depreciate estimate useful life follow year description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement life relate lease office computer equipment include capitalize computer software capitalize software purchase internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term asset useful life amortization capitalize lease equipment include depreciation expense capitalize interest construction progress include property plant equipment interest capitalize insignificant intangible asset intangible asset definite life amortize estimate useful life review impairment fact circumstance suggest carry value asset recoverable inplace lease intangible asset amortize remain period relate lease term discuss note impairment longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset liability group low level identifiable cash flow largely independent cash flow generate group undiscounte future cash flow carry asset impairment loss measure excess carrying value asset estimate fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time foreign currency translation transaction contract adjustment result translate financial statement foreign subsidiary dollar exclude determination net income loss accumulate separate component stockholder equity net foreign exchange transaction gain loss report sell general administrative expense consolidate statement operation realize loss million million realize gain million hedge certain foreign currency exposure related outstanding trade account receivable forecast product sale foreign exchange forward contract general market risk contract offset correspond gain loss transaction hedge exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank limit risk loss enter contract provide net settlement maturity overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract ie contract positive fair value date default enter speculative foreign currency transaction write option presently hedge net investment foreign subsidiary accounting hedge net monetary asset liability record change fair value sell general administrative expense derivative instrument designate hedge sfas nos accounting derivative instrument hedge activity collectively refer sfas gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue selectively hedge anticipate currency exposure purchase forward contract hedge anticipate product sale year designate cash flow hedge sfas unrealized gain loss underlie forward contract record comprehensive income recognize earning forecast transaction occur december december net unrealized loss open foreign exchange forward contract million million respectively loss revenue hedge reduce product sale million million million notional amount forward exchange contract outstanding million december million december contract maturity year note discussion derivative financial instrument fair value financial instrument financial instrument consist principally cash cash equivalent marketable security account receivable certain non current asset forward foreign exchange contract account payable longterm obligation cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase forecast sale record fair value net relate deferred gain loss result report net balance zero gilead call convertible senior note redemption october convert million share gilead common stock november december fair value convertible senior note million carry value million gilead call convertible subordinate note redemption november convert million share gilead common stock december fair value convertible senior note december determine obtain quote market maker note believe remain financial instrument report consolidated balance sheet amount approximate current fair value recent accounting pronouncement december fasb issue sfas revise sharebased payment sfas r revision sfas sfas r supercede apb amends sfas statement cash flow sfas r require sharebase payment employee director include grant stock option recognize statement operation base fair value begin interim annual period june early adoption permit pro forma disclosure previously permit sfas long alternative financial statement recognition expect adopt sfas r quarter fiscal begin july sfas r determine appropriate fair value model value sharebase payment amortization method compensation cost transition method date adoption transition method include prospective retroactive adoption option retroactive option prior period restate begin year adoption period present prospective method require compensation expense record unvested stock option restrict stock begin quarter gilead sciences inc note consolidated financial statement continue december organization summary significant accounting policy continue adoption sfas r retroactive method record compensation expense unvested stock option restrict stock begin period restate currently evaluate requirement sfas r option valuation methodology relate employee director stock option employee stock purchase plan determine method adoption effect adopt sfas r expect adoption sfas r material impact consolidate result operation earning share impact adoption sfas r predict time depend thing level sharebase payment grant future method adoption option valuation method sfas r require benefit tax deduction excess recognize compensation cost report finance cash flow operate cash flow require current literature requirement reduce net operating cash flow increase net financing cash flow period adoption estimate amount future depend thing employee director exercise stock option operate cash flow recognize prior period relate tax deduction million million million respectively current estimate option value blackschole method indicative result valuation methodology ultimately adopt gilead derivative financial instrument derivative recognize asset liability measure fair value enter foreign currency forward contract hedge change fair value significant monetary asset liability denominate nonfunctional currency derivative designate meet definition fair value hedge change fair value derivative hedge item recognize earning enter foreign currency forward contract generally maturitie month hedge future cash flow relate forecasted product sale foreign denominate currency derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify hedge relate forecasted foreign currency product sale designate document inception respective hedge designate cash flow hedge evaluate effectiveness monthly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract estimate change fair value underlie hedged item effective component hedge record accumulate comprehensive income note substantially value report accumulate comprehensive loss december reclassify earning month residual change fair value instrument include result cancellation dedesignation hedge contract ineffectiveness recognize immediately sell general administrative expense impact ineffectiveness significant consolidated statement operation loss million million million hedging contract recognize consolidated statement operation respectively gilead sciences inc note consolidated financial statement continue december derivative financial instrument continue result enter collaboration arrangement gilead hold warrant purchase stock nonpublic company complete initial public offering january note warrant exercise february warrant net exercise feature pursuant sfas classify derivative instrument noncurrent asset december acquisition triangle pharmaceuticals inc january complete acquisition net asset triangle expand antiviral pipeline triangle development stage company particular focus potential therapy hiv include aids hepatitis b virus hbv triangle portfolio consist drug candidate clinical trial include emtriva emtricitabine treatment hiv infection emtricitabine treatment chronic hepatitis b amdoxovir treatment hiv infection clevudine treatment chronic hepatitis b july food drug administration fda grant marketing approval emtriva treatment hiv october european commission grant marketing authorisation emtriva member states european union triangle acquisition account acquisition asset business combination accordance criterion outline emerge issue task force triangle development stage company commence plan principal operation lack necessary element business complete product ability access customer result operation triangle january include consolidated financial statement primarily consist research development expense less extent sell general administrative expense december arrangement contemplate propose acquisition triangle gilead million loan extend triangle work capital corporate purpose triangle issue gilead unsecured convertible promissory note completion acquisition january loan eliminate consolidated financial statement aggregate purchase price million include cash pay million outstanding stock fair value stock option assume million direct transaction cost million employee relate cost million purchase establish workforce reduction plan assume obligation change control agreement acquisition date approximately million employee termination cost change control obligation record liability pay period approximately year december approximately remain liability gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue follow table summarize purchase price allocation january thousand net tangible asset assemble workforce defer compensation nprocess research development million net tangible asset include assume liability million million value assign assemble workforce amortize year estimate useful life asset defer compensation represent intrinsic value unvested stock option assume transaction amortize remain vest period option extend january reversal defer tax asset valuation allowance fourth quarter remain million assemble workforce asset eliminate note gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue approximately million purchase price allocate purchase inprocess research development represent fair value triangle incomplete research development program reach technological feasibility alternative future use acquisition date summary program acquisition date update subsequent development follow estimate acquisition date fair value program description status development millions emtricitab ine f nucleoside analogue phase study complete prior hiv show acquisition date marketing approval inhibitor hiv replication receive fda july patient emtriva european union approval receive european commission october emtricitabine fixeddose coformulation acquisition date work tenofovir df tenofovir emtricitabine commence potential coformulation fix dose extent work combination emtricitabine single agent hiv progress march application therapy marketing approval submit united states european union august marketing approval united states receive fda truvada fixeddose coformulation tenofovir emtricitabine marketing approval european union receive february amdoxovir purine dioxolane program phase trial hiv nucleoside offer acquisition date terminate advantage license agreement emory university market nucleoside university georgia research activity foundation inc development drug resistant discontinue virus exhibit patient hiv infection clevudine pyrimidine nucleoside program phase trial hbv analogue acquisition date august licensing show inhibitor agreement bukwang pharm ind co hbv replication patient ltd terminate development chronically infect hbv discontinue emtricitabine inhibitor hbv phase trial complete hbv replication patient december chronically infect hbv gilead sciences inc note consolidated financial statement continue december acquisition triangle pharmaceuticals inc continue value acquire inprocess research development determine estimate related future net cash flow present value risk adjust discount rate discount rate significant assumption base estimate weighted average cost capital adjust upward risk associate project acquire project cash flow acquire project base estimate revenue operate profit relate project consider stage development potential product acquire time resource need complete development approval product life potential commercialize product associate risk include inherent difficulty uncertaintie develop drug compound include obtain fda regulatory approval risk relate viability potential alternative treatment future target market acquisition real estate september complete purchase foster city california campus approximately million cash purchase include building total square foot office laboratory space accordance sfas business combination sfas goodwill intangible asset purchase price allocate land building exist inplace lease base estimate relative fair value land building record million million respectively fair value building depreciate remain economic life estimate year market approach value exist lease acquire record intangible asset approximately million amortize straightline basis net rental income approximately year remain term lease accumulate amortization intangible asset million million december december respectively net rental income generate lease amortization intangible asset include interest income net approximately million year end december million year end december future net rental income receive exist lease million million prior amortization inplace lease asset asset impairment fourth quarter record asset impairment charge million certain longlived asset primarily leasehold improvement manufacture laboratory equipment classify hold use noncash charge drive decision terminate liposomal research development activity san dimas discontinue daunoxome daunorubicin citrate liposome injection product line impairment base analysis undiscounte cash flow generate affected asset compare carry value carrying value exceed related estimate undiscounted cash flow write carry value longlive asset estimate fair value accordance sfas accounting impairment disposal longlive asset sfas estimate fair value derive expected cash flow approach gilead sciences inc note consolidated financial statement continue december asset impairment continue subsequent decision discontinue daunoxome product line receive unanticipated request europe ask gilead reconsider sell daunoxome result request management decide continue sell product certain country evaluate supply sale strategy respect daunoxome accordance sfas write asset continue daunoxome product line establish new cost basis asset adjust new fact circumstance gain loss marketable security eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc eyetech relate proprietary aptamer eye currently know macugen pegaptanib sodium injection pursuant agreement receive warrant purchase share eyetech series b convertible prefer stock exercisable price share january eyetech complete initial public offering common stock time adjust carry value warrant estimate fair value result gain million include consolidated statement operation year end december gain loss marketable security fair value warrant estimate blackschole valuation model volatility rate discount rate end quarter exercise warrant net basis share eyetech common stock consideration exercise price subsequently hold share eyetech common stock second quarter sell eyetech share hold realize gain approximately million include interest income net consolidated statement operation year end december osi pharmaceutical july gilead sell remain share osi common stock approximately million share partial consideration sale oncology asset osi december time record fair market value approximately million connection sale remain share recognize nonoperate loss approximately million reflect consolidated statement operation year end december gain loss marketable security gilead sciences inc note consolidated financial statement continue december availableforsale security follow summary availableforsale security record cash equivalent marketable security consolidate balance sheet estimate fair value availableforsale security base price obtain commercial pricing service thousand gross unrealize gross amortize unrealized estimate cost gain loss fair value december treasury security obligation government agency corporate debt security assetbacke security debt security total december treasury security obligation government agency corporate debt security assetbacke security debt security total debt security consist primarily money market fund december december security net unrealize gain loss approximately million million respectively follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december million portfolio marketable security exclude million assetbacked security contractual maturity year million portfolio contractual maturity great year year estimate maturity assetbacked security exceed year december marketable security continuous unrealized loss position year gilead sciences inc note consolidated financial statement continue december balance sheet detail thousand december inventory raw material work process finish good total property plant equipment net building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment c onstruction inprogress accumulate depreciation amortization subtotal land total accrue compensation employee benefit accrue bonus accrue compensation employee benefit total accrue liability accrue medicaid rebate fair value forward foreign currency contract value add taxis payable income taxis payable accrue royalty expense liability total joint venture bristolmyer squibb december enter collaboration bristolmyer squibb company bms develop commercialize fix dose combination gilead truvada bmss sustiva efavirenz united states structure joint venture gilead bms form limited liability company bristolmyers squibb gilead sciences llc term collaboration gilead bms grant royaltyfree sublicense joint venture use respective companyowne technology return grant license joint venture use intellectual property result collaboration ownership interest joint venture gilead bms gilead sciences inc note consolidated financial statement continue december joint venture bristolmyers squibb continue reflect respective economic interest base fraction estimate net selling price fixeddose combination product attributable truvada sustiva respectively adjust annual basis net selling price truvada change time relative net selling price sustiva gilead bmss respective economic interest joint venture vary annually gilead primary responsibility clinical development activity regulatory filing relate new product result collaboration bms gilead share marketing sale effort party provide equivalent sale force effort minimum number year daily operation joint venture govern primary joint committee gilead responsible accounting financial reporting product distribution joint venture party agree provide respective bulk active pharmaceutical ingredient joint venture approximate market value joint venture total equity investment risk expect sufficient allow finance operational activity ongoing funding gilead bms joint venture attribute believe result represent variable interest entity set forth fasb interpretation consolidation variable interest entity fin r expect consolidate result operation financial position joint venture conclude primary beneficiary party absorb majority joint venture expect loss primary beneficiary legal structure joint venture limit recourse creditor general credit asset gilead financial information consolidate operation joint venture begin december capital contribution gilead bms beginning expect consolidate joint venture record minority interest own bms significant intercompany transaction eliminate collaborative arrangement contract achillion pharmaceutical november enter exclusive license collaboration agreement achillion pharmaceuticals inc achillion agreement grant worldwide right research development commercialization certain small molecule hcv replication inhibitor involve hcv protease treatment infection hepatitis c virus hcv collaboration achillion obligate continue development compound accord mutually agree development plan completion proofofconcept clinical study hcvinfecte patient cost incur achieve proofofconcept share equally gilead achillion follow proofofconcept study gilead obligate assume responsibility incur cost associate development commercialization compound warrant development achillion option participate commercialization effort future product arise collaboration conjunction signing collaboration gilead pay million upfront license fee record research development expense gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue future alternative use license technology million investment purchase million share achillion convertible prefer stock record noncurrent asset additionally agree payment achillion achievement certain milestone outline agreement pay royalty future net sale product arise collaboration genelab technology september enter license research collaboration agreement genelabs technologies inc genelabs research develop commercialize certain genelab novel nucleoside inhibitor hcv polymerase treatment chronic infection cause hcv conjunction sign collaboration agreement pay million upfront license fee record research development expense future alternative use technology initially agree term year genelabs obligate lead research effort gilead option extend research term collaboration additional year gilead lead development commercialization activity agree provide annual funding time equivalent fte expect record research development expense obligate additional payment achievement certain milestone pay royalty future net sale select compound develop approve relation collaboration chiron corporation august enter nonexclusive licensing agreement chiron corporation chiron research development commercialization small molecule therapeutic select hcv drug target agreement gilead receive nonexclusive right use chiron hcv technology develop commercialize product treatment hcv term agreement pay chiron upfront license fee million record research development expense future alternative use license technology agree additional payment chiron certain clinical regulatory contractually determined milestone meet million payment chiron record research development expense additionally obligate royalty payment event product develop licensed technology japan tobacco inc july gilead enter licensing agreement japan tobacco inc japan tobacco japan tobacco commercialize product hiv product portfolio japan agreement include viread emtriva truvada term agreement receive upfront license fee million entitle receive additional cash payment achievement certain milestone japan tobacco pay royalty net sale product japan upfront fee record defer revenue amortize contract revenue period supply product japan tobacco approximately year december receive million milestone payment japan tobacco relate japanese regulatory approval marketing authorization viread amortize gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue remain period upfront license fee january japan tobacco submit marketing authorization application emtriva truvada japanese regulatory authority emory university april triangle obtain january acquire acquisition triangle exclusive worldwide license emory universitys emory right purify form emtricitabine use hiv hepatitis b field obligate certain milestone royalty payment emory include annual minimum royalty begin year fda registration grant antihiv product incorporate emtricitabine technology united states year registration grant antihepatitis b product incorporate emtricitabine technology certain major market country triangle begin pay license maintenance fee development milestone achieve launch emtriva begin pay royalty emory respect emtricitabine hiv indication pay royalty million million respectively net sale emtriva net sale truvada incorporate emtricitabine technology launch license agreement emory terminate late patent expiration expiration obligation pay royalty addition right terminate agreement entirety respect indication hiv hbv country prior expiration time day notice glaxosmithkline april gilead gsk enter licensing agreement provide gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territory agreement retain right hepsera united states canada eastern western europe australia new zealand turkey gsk receive exclusive right develop hepsera solely treatment chronic hepatitis b territory significant include china japan korea taiwan addition gsk pay upfront licensing fee million pay million achievement gsk certain regulatory development commercial milestone million million receive approval hepsera million receive canadian approval hepsera aggregate million receive commercial approval hepsera japan south korea taiwan gsk responsibility development commercialization hepsera territory upfront license fee approval milestone record defer revenue total million million million recognize contract revenue respectively million balance defer revenue december amortize contract revenue period supply hepsera gsk agreement approximately year addition gsk require pay gilead royalty net product sale gsk generate sale hepsera epivir hbvzeffix gsk hepatitis product gsk territory gilead begin receive royalty gsk sale hepsera quarter record million royalty revenue recognize royalty revenue gsk quarter follow quarter relate hepsera sale occur gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue osi pharmaceutical december complete sale oncology asset osi pharmaceutical osi term agreement entitle additional payment osi million cash combination cash osi stock osi reach certain development milestone nx advanced oncology product candidate sell osi relate manufacturing agreement produce nx gs l liposomal product include sale manufacturing facility san dimas california recognize million million million respectively contract revenue manufacturing agreement archemix october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million million require license agreement license equity holdings inc ulehi pay receipts ulehi recognize million million contract revenue respectively receive warrant purchase share archemix common stock value material require license agreement ulehi transfer warrant receipt transfer remainder warrant ulehi additional payment archemix agreement eyetech march enter agreement eyetech pharmaceuticals inc relate macugen macugen inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use macugen responsible research development cost receive million upfront license fee eyetech april recognize revenue ratably oneyear period provide clinical supply product eyetech entitle additional cash payment eyetech million eyetech reach certain macugen milestone royaltie worldwide net sale macugen december enter agreement eyetech supply macugen eyetech year record contract revenue million million respectively connection clinical supply provide eyetech milestone achieve eyetech recognize contact revenue million milestone payment eyetech second quarter file new drug application europe macugen january eyetech receive fda approval sale macugen united states agreement eyetech expire later year commercial sale product develop date patent expire agreement gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue additionally receive warrant purchase share eyetech series b convertible prefer stock exercisable price share price stock issue investor note discussion warrant fujisawa right market ambisome subject agreement gilead fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa gilead copromote ambisome united states fujisawa sole marketing right ambisome canada exclusive marketing right ambisome rest world provide pay royalty fujisawa connection sale significant asian market include china india japan korea taiwan connection sales fujisawa purchase ambisome gilead manufacturing cost sale canada fujisawa purchase ambisome manufacturing cost plus specify percentage fujisawa collect payment sale ambisome united states canada receive fujisawa gross profit sale ambisome united states gross profit include deduction cost good sell give current effective royalty rate approximately fujisawa net sale ambisome united states connection agreement record royalty revenue million million million sumitomo september gilead sumitomo enter agreement pursuant sumitomo agree develop market ambisome japan term agreement sumitomo pay initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment certain clinical commercial milestone meet pay royalty japanese ambisome sale agreement gilead obligate provide certain quantity ambisome sumitomo charge recognize payment receive revenue supply period ambisome approve marketing japan roche september gilead enter collaboration agreement hoffmannla roche roche develop commercialize therapy treat prevent viral influenza agreement roche receive exclusive worldwide right gilead proprietary influenza neuraminidase inhibitor recognize contract revenue million milestone payment european approval tamiflu treatment prophylaxis recognize contract revenue million milestone payment japanese approval tamiflu prophylaxis milestone receivable agreement addition roche require pay gilead royalty net product sale tamiflu subject reduction certain define manufacturing cost record total million million million tamiflu royalty respectively recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur gilead sciences inc note consolidated financial statement continue december collaborative arrangement contract continue iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide hepsera viread exclude tamiflu august agreement iocbrega amend include truvada future fixeddose combination product contain license technology gilead currently make quarterly payment iocbrega base percentage vistide hepsera viread truvada net sale pay royalty million million million iocbrega respectively december agreement iocbrega amend provide reduce royalty rate future sale hepsera viread return upfront payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december prepay royalty recognize royalty expense expect commercial life viread hepsera amortization million payment begin product launch date viread hepsera longterm obligation longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range total longterm obligation current portion longterm obligation year future minimum lease payment capital lease obligation follow thousand year end december represent interest total gilead sciences inc note consolidated financial statement continue december longterm obligation continue term agreement require comply certain financial operating covenant december compliance covenant convertible note december gilead issue million convertible senior note december note convertible total share gilead common stock share convertible senior note provisionally redeemable option gilead time june specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note gilead call convertible senior note redemption october issue share gilead common stock note holder conversion november redemption price equal principal note redeem plus accrue unpaid interest redemption date connection redemption gilead pay makewhole payment million note holder represent equivalent principal value note interest actually pay accrue unpaid date issuance note redemption date conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital december gilead issue million convertible subordinated note december convertible subordinate note convertible total share gilead common stock share convertible subordinate note redeemable option gilead time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance convertible subordinate note record noncurrent asset amortize interest expense straightline basis contractual term convertible subordinate note november gilead call convertible subordinate note redemption convert note share common stock december conversion million unamortized balance relate debt issuance cost reclassify additional paidin capital commitment contingency lease arrangement enter longterm noncancelable operating lease equipment facility facility lease foster city california san dimas california durham north carolina expire date foster city lease fiveyear renewal option addition gilead option purchase foster city property specify durham lease sevenyear renewal option operate lease sale marketing administrative facility europe australia term equipment lease include corporate airplane initial term year annual renewal option year gilead sciences inc note consolidated financial statement continue december commitment contingency continue lease expense operating lease total approximately million million million aggregate noncancelable future minimum rental payment operating lease follow thousand year end december operating lease legal proceeding complaint follow case allege large number defendant include gilead overcharge governmental entity name plaintiff pharmaceutical product furnish participant medicaid program general complaint assert claim federal state law alabama state action include state law claim seek treble damage attorney fee litigation preliminary stage possible predict outcome date gilead serve process case county westchester v abbott laboratories et al intend defend case vigorously outcome case predict time amount accrue county westchester v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend include approximately defendant january city new york v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit file gilead approximately defendant august amend approximately defendant january county rockland v abbott laboratories et al pende multidistrict litigation united states district court district massachusetts lawsuit originally gilead defendant amend include claim gilead approximately defendant january state alabama v abbott laboratories et al pending circuit court montgomery county alabama lawsuit file gilead approximately defendant january gilead sciences inc note consolidated financial statement continue december commitment contingency continue purport class action complaint file november united states district court northern district california gilead certain executive officer complaint allege defendant violate federal security law specifically section b securities exchange act rule b securities exchange commission make certain allege false misleading statement plaintiff seek unspecified damage behalf purport class purchaser gilead security period july october similar action subsequently file court issue order consolidate lawsuit single action december february court issue order appoint lead plaintiff consolidated action april lead plaintiff behalf purport class file consolidated amend complaint june gilead individual defendant file motion dismiss consolidated amend complaint january court grant defendant motion dismiss leave amend amount accrue date december purport shareholder derivative lawsuit file individual shareholder behalf gilead director certain executive officer superior court state california county san mateo allege thing defendant violate california corporations code breach fiduciary duty owe gilead gilead name nominal defendant plaintiff seek unspecified damage behalf gilead connection allege insider trading period july october defendant allege breach fiduciary duty abuse control waste mismanagement case consolidate single action january similar case file february later consolidate prior case plaintiff file consolidated complaint amend time recently november gilead demur consolidated complaint court grant demurrer december plaintiff file motion leave file consolidated amend complaint january court grant plaintiff motion render complaint operative complaint intend demur complaint trial schedule june outcome case predict time amount accrue party legal action arise ordinary course business believe legal action material adverse impact business result operation financial position commitment contingency normal course business subject contingency arise matter product liability claim legal proceeding shareholder suit tax matter accrue contingency accordance sfas accounting contingency normal course business enter firm minimum purchase commitment inventoryrelate material certain active pharmaceutical ingredient supplier december approximately million purchase commitment follow million million million million gilead sciences inc note consolidated financial statement continue december stockholder equity prefer stock gilead share authorize preferred stock issuable series board directors board authorize determine designation power preference right series reserve share prefer stock potential issuance preferred share purchase right plan prefer stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low market value date offer date purchase total million share common stock reserve issuance espp december million share total share reserve issue espp million share december stock option plan gileads stockholder approve gilead adopt equity incentive plan plan replacement stock option plan plan nonemployee director stock option plan director plan adoption plan include increase number share available issuance remain share available issuance plan director plan plan provide issuance type equity awards incentive stock option nonstatutory stock option stock appreciation right sar dividend equivalent right restrict stock performance unit performance share phantom share plan exercise purchase price incentive stock option shall fair value gilead common stock date grant case nonstatutory stock option sar share exercise price shall fair value gilead common stock date grant case type award exercise purchase price determine plan administrator incentive stock option typically vest year pursuant formula determine board expire year term award shall term state award agreement year date grant eligible participant include employee director consultant gilead employee eligible incentive stock option compensation committee delegate determine award grant vest term december share remain available future grant plan november gilead adopt plan issuance common stock employee consultant option issue plan discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year plan amend restate april extend term plan stockholder approve amendment plan increase gilead sciences inc note consolidated financial statement continue december stockholder equity continue total number authorize share plan remain share available future grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan november gilead adopt director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option grant january vest year date grant quarterly percent installment initial option grant january new director vest year date grant equal annual installment annual grant exist director vest year option expire year stockholder approve amendment director plan increase total number authorize share plan remain share available grant plan transfer plan additionally option grant plan expire terminate exercised share common stock reserve option available future grant plan stock plan assume gilead merger nexstar include stock option plan incentive stock plan director option plan collectively nexstar plan option pursuant nexstar plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan stock plan assume gilead acquisition net asset triangle include stock option plan separate plan chief executive officer triangle collectively triangle plan option pursuant plan issue outstanding january convert option purchase approximately million share gilead common stock result acquisition remain subject original term condition share available grant future option triangle plan gilead sciences inc note consolidated financial statement continue december stockholder equity continue follow table summarize activity gilead nexstar triangle stock option plan option grant present table exercise price fair value underlie stock grant date share thousand year end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant assume forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weighted weight remain average average exercise option contractual exercise option range exercise price outstanding life year price exercisable price total preferred share purchase right plan november adopt preferred share purchase right plan right plan right plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price gilead sciences inc note consolidated financial statement continue december stockholder equity continue purchase right purchase right voting privilege attach automatically trade gilead common stock october october board director approve amendment right plan amendment provide thing increase exercise price right plan extension term plan november october second amendment provide thing increase exercise price right plan extension term right plan october comprehensive income loss comprehensive income loss comprise net income certain change stockholder equity exclude net income exclude item comprehensive income loss include change fair value untriggered effective cash flow hedge change unrealize gain loss availableforsale security change cumulative foreign currency translation account comprehensive income loss year end december include consolidated statement stockholder equity component comprehensive income loss show net relate taxis underlie asset liability hold jurisdiction expect generate future tax benefit liability follow reclassification record connection net realize gain loss sale security cash flow hedge previously include comprehensive income loss thousands year end december net unrealize loss arise year availableforsale security net tax benefit respectively net unrealized gain loss arise year cash flow hedge reclassification adjustment net tax benefit provision respectively comprehensive loss balance accumulate comprehensive income loss net taxis report balance sheet consist follow component thousand december net unrealized loss availableforsale security net unrealize loss cash flow hedge net foreign currency translation gain accumulate comprehensive income loss gilead sciences inc note consolidated financial statement continue december disclosure segment enterprise related information gilead operate business segment primarily focus development commercialization human therapeutic infectious disease product include segment major product viread tenofovir disoproxil fumarate emtriva emtricitabine truvada emtricitabine tenofovir disoproxil fumarate collectively hiv product ambisome amphotericin b liposome injection account product sale year end december respectively similar economic characteristic include nature product production process type customer distribution method regulatory environment product sale consist follow thousands year end december hiv product viread emtriva truvada total hiv product ambisome hepsera vistide daunoxome total product revenue follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states france spain united kingdom italy germany switzerland european country country total revenue gilead sciences inc note consolidated financial statement continue december disclosure segment enterprise relate information continue december net book value property plant equipment million approximately asset locate united states december net book value property plant equipment million approximately asset locate united states follow table summarize revenue large customer distribute drug primarily united states total revenue year end december cardinal health inc amerisourcebergen corp mckesson corp income taxis provision benefit income taxis consist follow thousands year end december federal current deferred state current defer foreign current defer foreign pretax income loss million million million gilead foreign subsidiary generate operating loss reflect cost build commercial infrastructure europe foreign subsidiary investment research development effort unremitte foreign earning consider permanently invest outside united states taxis provide approximately million december residual tax liability amount remit approximately million gilead sciences inc note consolidated financial statement continue december income taxis continue difference provision benefit taxis income compute apply federal statutory income tax rate income loss provision benefit income taxis explain thousands year end december income loss provision benefit income taxis tax federal statutory rate state taxis net federal benefit benefit loss change valuation allowance foreign earning different rate research experimentation credit inprocess research development charge foreign loss different rate provision benefit income taxis tax benefit associate stock option exercise employee stock purchase plan result tax benefit million year end december benefit credit additional paidin capital realize gilead sciences inc note consolidated financial statement continue december income taxis continue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability december follow thousand december defer tax asset net operating loss carryforward research tax credit carryforward reserve accrual currently deductible depreciation relate capitalize research development expense ther net valuation allowance total defer tax asset defer tax liability unremitte foreign earning total defer tax liability net defer tax asset valuation allowance decrease million million year end december respectively valuation allowance million million december respectively conclude base standard set forth sfas accounting income taxis likely realize benefit relate deferred tax asset assess need valuation allowance quarter end base available evidence approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize december federal net operating loss carryforward approximately million federal net operating loss carryforward expire date utilize addition federal state tax credit carryforward approximately million million respectively expire date utilize utilization net operating loss tax credit carryforward subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization october american jobs creation act ajca sign law ajca include deduction certain foreign earning repatriate define ajca elect apply provision qualify earning repatriation fiscal start gilead sciences inc note consolidated financial statement continue december income taxis continue evaluation effect repatriation provision expect able complete evaluation congress treasury department provide additional clarify language key element ajca expect complete evaluation potential effect repatriation provision reasonable period time follow publication additional clarify language range possible amount consider repatriation ajca zero million maximum allowable company define ajca relate potential range income tax reasonably estimate december defer compensation plan gilead maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead plan gilead plan employee contribute eligible annual compensation gilead make matching contribution gilead plan contribute employee contribution annual maximum match total matching contribution expense gilead plan million million million gilead maintain defer compensation plan director officer defer compensation income tax purpose internal revenue code plan officer contribute annual salary annual management bonus director contribute annual retainer fee amount defer participant deposit rabbi trust record noncurrent asset consolidate balance sheet begin director elect receive portion annual cash retainer phantom share december issue phantom share participant elect distribution date available plan receive defer compensation payment gilead sciences inc note consolidated financial statement continue december quarterly result operation unaudite follow table thousand share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income net income sharebasic net income sharedilute st quarter nd quarter rd quarter th quarter total revenue gross profit product sale total cost expense net income loss net income loss sharebasic net income loss sharedilute quarter gilead record pretax gain million relate warrant eyetech complete initial public offering fourth quarter gilead record expense million connection makewhole payment convertible senior debt holder relation redemption conversion convertible senior debt quarter gilead complete acquisition net asset triangle record charge million purchase inprocess research development quarter gilead reimburse million research development expense result settlement contractual dispute vendor fourth quarter gilead record noncash impairment charge certain longlive asset million addition record income tax benefit million relate reduction valuation allowance certain net defer tax asset september gilead implement twoforone stock split form stock dividend share share amount period present restate reflect stock split gilead sciences inc schedule ii valuation qualifying account balance addition balance begin charge charge end period expense deduction period year end december account receivable allowance inventory reserve valuation allowance defer tax asset year end december account receivable allowance inventory reserve valuation allowance defer tax asset year end december account receivable allowance inventory reserve valuation allowance defer tax asset allowance doubtful account sale return cash discount chargeback signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize gilead sciences inc john c martin john c martin president chief executive officer power attorney know person present person signature appear constitute appoint john c martin mark l perry true lawful attorneysinfact agent power substitution resubstitution place stead capacity sign amendment report file exhibit thereto document connection therewith securities exchange commission grant unto say attorneysinfact agent power authority perform act thing requisite necessary connection therewith fully intent purpose person ratify confirming say attorneysinfact agent substitute substitute lawfully cause virtue hereof pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date john c martin president chief executive officer director march john c martin principal executive officer john f milligan executive vice president chief financial officer march john f milligan principal financial accounting officer james denny c hairman board director march james denny paul berg irector march paul berg etienne f davignon irector march etienne f davignon gordon e moore irector march gordon e moore nicholas g moore irector march nicholas g moore george p shultz irector march george p shultz gayle e wilson irector march gayle e wilson exhibit southern california chapter society industrial office realtor inc industrial real estate lease singletenant facility article basic term article contain basic term lease landlord tenant name article section paragraph lease refer article explain define basic term read conjunction basic term section date lease february section landlord include legal entity majesticmapa properites llc california limited liabil ity company ddress landlord crossroad parkway north th floor city industry section ant include legal entity gilead sciences inc delaware corporation ddress tenant lakeside drive foster city section property include street address approximate square footage description approximately square foot building commonly know covina boulevard san dimas california outline red exhibit subject nonexclusive use area outline green section lease term year month begin december date specify lease end november section permit use article general office laboratory warehousing manufacture pharmaceutical product section tenant guarantor state section b roker article fourteen state landlord broker majestic realty co tenant broker section commission payable landlords broker article fourteen separate agreement section initial security deposit section section vehicle parking space allocate tenant exhibit section rent charge payable tenant base rent fiftyeight thousand dollar month month provide section shall increase day sixtyfirst st month commencement date sixtyfour thousand dollar b periodic payment real property taxis section ii utility section iii insurance premium section iv impound insurance premium property taxis section v maintenance repair alteration article section landlord share profit assignment sublease section percent profit landlord share southern california chapter society industrial nd office realtor inc singletenant net form gilead sciences inc covina blvd san dimas casection rider follow rider attach lease state addendum page exhibit b c article lease term section lease property lease term landlord lease property tenant tenant lease property landlord lease term lease term period state section shall begin end date specify section begin end lease term change provision lease commencement date shall date specify section begin lease term advanced delay provision lease section intentionally delete section intentionally delete section hold tenant shall vacate property expiration early termination lease tenant shall reimburse landlord indemnify landlord damage landlord incur tenant delay vacate property tenant vacate property expiration early termination lease landlord accept rent tenant tenant occupancy property shall monthtomonth tenancy subject term lease applicable monthto month tenancy base rent effect shall increase twentyfive percent section addendum article base rent section time manner payment execution lease tenant shall pay landlord base rent state paragraph month lease term day second month lease term month tenant shall pay landlord base rent advance offset deduction prior demand base rent shall payable landlord address place landlord designate writing section intentionally delete section security deposit increase execution lease tenant shall deposit landlord cash security deposit set forth section landlord apply security deposit unpaid rent charge tenant cure default tenant landlord use security deposit tenant shall restore security deposit day landlord write request tenant failure shall material default lease interest shall pay security deposit landlord shall require security deposit separate account trust relationship create respect security deposit b time base rent increase tenant shall deposit additional fund landlord sufficient increase security deposit bear relationship adjust base rent initial security deposit bore initial base rent section termination advance payment termination lease article seven damage destruction article condemnation termination result tenant default tenant vacate property manner require lease landlord shall day tenant deliver exclusive possession property landlord refund tenant tenant successor unused portion security deposit advance rent advance payment tenant landlord amount pay real property taxis reserve apply time period termination lease article charge payable tenant section additional rent charge payable tenant base rent call additional rent lease provide tenant shall pay additional rent monthly installment base rent term rent shall mean base rent additional rent section property taxis real property taxis tenant shall pay real property taxis property include fee taxis assessment result tenant improvement instal property benefit tenant lease term subject paragraph c section payment shall day prior delinquency date taxis day period tenant shall furnish landlord satisfactory evidence real property taxis pay landlord shall reimburse tenant real property taxis pay tenant cover period time prior lease term tenant fail pay real property taxis landlord pay taxis tenant shall reimburse landlord tax payment additional rent b definition real property tax real property tax mean fee license fee license tax business license fee commercial rental tax levy charge assessment penalty extent cause tenant act omission tax impose tax authority property ii tax landlord right receive receipt rent income property landlord business leasing property iii tax charge fire protection street sidewalk road maintenance refuse service provide property governmental agency iv tax impose transaction base reassessment property change ownership define applicable law transfer landlord interest property v charge fee replace tax previously include definition real property tax real property tax include landlord federal state income franchise inheritance estate taxis c joint assessment property separately assess landlord shall reasonably determine tenant share real property tax payable tenant paragraph assessor worksheet reasonably available information tenant shall pay share landlord day receipt landlord write statement personal property taxis tenant shall pay taxis charge trade fixture furnishing equipment personal property belong tenant tenant shall try personal property tax separately property ii tenant personal property tax property tenant shall pay landlord taxis personal property day tenant receive write statement landlord personal property taxis e tenant right contest taxis tenant attempt assess valuation property reduce initiate proceeding contest real property taxis require law landlord shall join proceeding bring tenant tenant shall pay cost proceeding include cost fee incur landlord final determination proceeding contest tenant shall immediately pay real property taxis cost charge interest penalty incidental proceeding tenant pay real property taxis contest taxis tenant shall default lease nonpayment taxis tenant deposit fund landlord open interestbeare account reasonably acceptable landlord joint name landlord tenant deposit shall sufficient pay real property taxis plus reasonable estimate interest cost charge penalty accrue tenant action unsuccessful applicable tax impound previously pay tenant landlord deposit shall apply real property taxis determine proceeding real property taxis shall pay protest deposit payment protest necessary prevent property sell tax sale similar enforcement proceeding section utility tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utility service supply property service utility jointly meter property landlord shall reasonable determination tenant proportionate share cost utility service tenant shall pay share landlord day receipt landlord write statement section insurance policy liability insurance lease term tenant shall maintain policy commercial general liability insurance know broad form comprehensive general liability insurance insure tenant liability bodily injury property damage include loss use property personal injury arise operation use occupancy property tenant shall landlord additional insure policy initial insurance shall million dollar occurrence shall subject periodic increase base industry standard similar facility liability insurance obtain tenant paragraph shall primary noncontributing ii contain crossliability endorsement iii insure landlord tenant performance section matter give rise indemnity section result negligence tenant coverage insurance shall limit tenant liability relieve tenant obligation lease landlord obtain comprehensive public liability insurance coverage determine landlord insure landlord liability arise ownership operation use occupancy property policy obtain landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policy insurance cover loss damage property replacement value policy shall provide protection loss damage fire casualty cover classification fire standard extend coverage vandalism malicious mischief sprinkler leakage peril landlord deem reasonably necessary landlord shall right obtain terrorism flood earthquake insurance form insurance require lender hold security interest property landlord shall obtain insurance tenant fixture equipment building improvement instal tenant property lease term landlord shall maintain rental income insurance policy loss payable landlord equal year base rent plus estimate real property taxis insurance premium tenant shall liable payment deductible landlord tenant insurance policy maintain pursuant section provide landlord insurance deductible shall exceed thousand dollar tenant shall permit invalidate insurance policy tenant request landlord shall provide tenant certificate evidence insurance c payment premium subject section tenant shall pay premium insurance policy describe paragraph b obtain landlord tenant day tenant receipt copy premium statement evidence landlord shall pay premium nonprimary comprehensive public liability insurance landlord elect obtain provide paragraph insurance policy maintain landlord cover improvement real property property landlord shall deliver tenant statement premium applicable property show reasonable detail tenant share premium compute lease term expire expiration insurance policy maintain landlord tenant shall liable tenant prorate share insurance premium commencement date tenant shall deliver landlord copy policy insurance tenant require maintain section thirty day prior expiration policy tenant shall deliver landlord renewal policy alternative provide policy insurance tenant shall right provide landlord certificate insurance execute authorized officer insurance company show insurance tenant require maintain section force effect contain information landlord reasonably require general insurance provision insurance tenant require maintain lease shall include provision require insurance carrier landlord thirty day write notice prior cancellation modification coverage ii tenant fail deliver policy certificate renewal landlord require lease prescribed time period policy cancel modify lease term landlord consent landlord obtain insurance case tenant shall reimburse landlord cost insurance day receipt statement indicate cost insurance iii landlord tenant shall maintain insurance require lease company hold general policy rating well set forth current issue good key rating guide landlord tenant acknowledge insurance market rapidly change insurance form amount describe section available future tenant acknowledge insurance describe section primary benefit landlord time lease term tenant landlord unable maintain insurance require lease landlord tenant shall maintain insurance coverage customary commercially reasonable insurance industry tenant type business coverage change time time landlord make representation adequacy insurance protect landlord tenant interest tenant shall obtain additional property liability insurance tenant deem necessary protect landlord tenant iv landlord tenant waive right recovery officer employee agent representative loss damage property property control loss damage cover insurance policy force describe lease time loss damage obtain require policy insurance landlord tenant shall notice insurance carrier mutual waiver subrogation landlord tenant insurance policy describe section shall contain provision waive carrier right subrogation section late charge tenant failure pay rent promptly cause landlord incur unanticipated cost exact cost impractical extremely difficult ascertain cost include limited processing accounting charge late charge impose landlord ground lease mortgage trust deed encumber property landlord receive rent payment day provide landlord give tenant fortheight hour write notice tenant fail pay base rent fortyeight shall run concurrently day period tenant shall pay landlord late charge equal percent overdue party agree late charge represent fair reasonable estimate cost landlord incur reason late payment section interest past obligation owe party hereunder pay shall bear interest rate percent annum date interest shall payable late charge pay tenant lease payment interest amount shall excuse cure default lease interest rate specify lease high rate permit law interest rate decrease maximum legal interest rate permit law section impound insurance premium real property taxis tenant day late payment base rent twice consecutive month period tenant shall pay landlord sum equal onetwelfth annual real property taxis insurance premium payable tenant lease payment base rent landlord shall hold payment noninterest bear impound account unknown landlord shall reasonably estimate real property taxis insurance premium tenant shall pay deficiency fund impound account landlord write request tenant default lease landlord apply fund impound account obligation lease section addendum article use property section permit use tenant use property permit use set forth section section manner use tenant shall cause permit property way constitute violation law ordinance governmental regulation order annoy interfere right tenant landlord constitute nuisance waste tenant shall obtain pay permit include certificate occupancy require tenant occupancy property shall promptly action necessary comply applicable statute ordinance rule regulation order requirement regulate use tenant property include occupational safety health act addendum section addendum section section sign auction tenant shall place sign property landlord prior write consent tenant shall conduct permit auction sheriff sale property addendum section section indemnity tenant shall indemnify landlord hold landlord harmless cost claim liability arise tenant use property b conduct tenant business permit tenant property c breach default performance tenant obligation lease misrepresentation breach warranty tenant lease e act omission tenant tenant shall defend landlord cost claim liability tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost incur landlord connection claim material consideration landlord tenant assume risk damage property injury person property arising cause tenant waif claim respect thereof landlord claim arise landlord landlord employee agent contractor active negligence willful misconduct section term tenant shall include tenant employee agent contractor invite applicable addendum section section landlord access landlord agent enter property reasonable time property potential buyer investor tenant party act inspect conduct test order monitor tenant compliance applicable environmental law law govern presence use hazardous material purpose landlord deem necessary landlord shall tenant hour prior notice entry case emergency landlord agree allow representative tenant accompany landlord agree comply tenant reasonable security measure landlord place customary sale lease sign property section quiet possession tenant pay rent complie term lease tenant occupy enjoy property lease term subject provision lease article condition property maintenance repair alteration section exist condition subject provision lease tenant accept property condition execution lease subject record matter law ordinance governmental regulation order provide tenant acknowledge landlord agent landlord representation condition property suitability property tenant intend use tenant represent warrant tenant inspection inquiry condition property rely representation landlord broker respect thereto landlord landlords broker provide property information sheet disclosure statement property copy attach exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom good ware merchandise property tenant tenant employee invite customer person property damage injury cause result fire steam electricity water gas rain b breakage leakage obstruction defect pipe sprinkler wire appliance plumb air conditioning lighting fixture cause c condition arise property source place act omission tenant landlord landlord shall liable damage injury cause mean repair damage injury accessible tenant provision section shall exempt landlord liability landlord landlord employee agent contractor active negligence willful misconduct section landlord obligation addendum section section tenant obligation provide section article seven damage destruction article condemnation tenant shall portion property include structural nonstructural interior exterior landscape area portion system equipment good order condition repair include interior repainting refinish need portion property system equipment property tenant obligate repair fully repair restore tenant shall promptly replace portion property system equipment property regardless benefit replacement extend lease term benefit useful life replacement extend lease term term extend exercise option useful life replacement shall prorate remaining portion lease term extend tenant shall liable portion cost applicable lease term extend tenant shall maintain preventive maintenance contract provide regular inspection maintenance heating air conditioning system license heating air conditioning contractor subject provision section div property damage act omission tenant tenant shall pay landlord cost repair replace damage property landlord obligate pay cost maintaining repair property intention landlord tenant times tenant shall maintain portion property tenant obligate maintain attractive firstclass fully operative condition b tenant shall fulfill tenant obligation section tenant sole expense tenant fails maintain repair replace property require section reasonable effort landlord day prior notice tenant notice shall require case emergency enter property perform maintenance repair include replacement need behalf tenant case tenant shall reimburse landlord cost incur perform maintenance repair immediately demand section alteration addition improvement tenant shall alteration addition improvement property landlord prior write consent shall unreasonably withhold nonstructural alteration exceed thousand dollar cost project visible outside build property landlord require tenant provide demolition andor lien completion bond form satisfactory landlord tenant shall promptly remove alteration addition improvement construct violation paragraph landlord write request alteration addition improvement shall good workmanlike manner conformity applicable law regulation contractor approve landlord shall unreasonably withhold completion work tenant shall provide landlord build plan copy construction contract proof payment labor materials b tenant shall pay claim labor material furnish tenant group property tenant shall landlord day prior write notice commencement work property regardless landlord consent work require landlord elect record post notice nonresponsibility property section condition termination termination lease tenant shall surrender property landlord broom clean condition receive ordinary wear tear tenant obligate remedy provision lease tenant shall obligate repair damage landlord require repair accordance lease addition landlord require tenant remove alteration addition improvement landlord consent prior expiration lease restore property prior condition tenant expense alteration addition improvement landlord require tenant remove shall landlord property shall surrender landlord expiration early termination lease tenant remove tenant trade fixture machinery equipment remove material damage property tenant shall repair tenant expense damage property cause removal trade fixture machinery equipment event shall tenant remove follow material equipment shall deem landlord property landlord prior write consent power wiring power panel light lighting fixture wall covering drape blind window covering carpet floor covering heater air conditioner heat air conditioning equipment fence security gate similar building operating equipment decoration addendum section article seven damage destruction section partial damage property tenant shall notify landlord write immediately occurrence damage property property partially damage ie percent property untenantable result damage percent tenant operation materially impair proceed receive landlord insurance policy describe paragraph b sufficient pay necessary repair lease shall remain effect landlord shall repair damage soon reasonably possible landlord elect require repair damage tenant fixture equipment improvement b landlord maintain insurance require maintain paragraph b insurance proceed receive landlord sufficient pay entire cost repair ii cause damage cover insurance policy iii holder mortgage property shall require insurance proceed portion thereof retire mortgage debt landlord elect repair damage soon reasonably possible case lease shall remain force effect ii terminate lease date damage occur landlord shall notify tenant thirty day receipt notice occurrence damage landlord elect repair damage terminate lease landlord elect repair damage tenant shall pay landlord deductible landlord insurance policy damage act omission tenant tenant employee agent contractor invite difference actual cost repair insurance proceed receive landlord landlord elect terminate lease tenant elect continue lease force effect case tenant shall repair damage property building property locate tenant shall pay cost repair satisfactory completion repair landlord shall deliver tenant insurance proceed receive landlord damage repair tenant tenant shall landlord write notice election day receive landlord termination notice c damage property occur month lease term damage require thirty day repair landlord tenant elect terminate lease date damage occur regardless sufficiency insurance proceed party elect terminate lease shall write notification party election thirty day tenant notice landlord occurrence damage section substantial total destruction property substantially totally destroy cause whatsoever ie damage property great partial damage describe section regardless landlord receive insurance proceed lease shall terminate later date destruction occur ii date tenant cease business property notwithstanding precede sentence property rebuild month date destruction landlord elect rebuild property landlord expense case lease shall remain force effect landlord shall notify tenant election thirty day tenant notice occurrence total substantial destruction landlord elect landlord shall rebuild property landlord sole expense destruction cause act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceed receive landlord section temporary reduction rent property destroy damage landlord tenant repair restore property pursuant provision article seven rent payable period damage repair andor restoration shall reduce according degree tenant use property impair possible reduction base rent insurance premium real property taxis tenant shall entitled compensation reduction reimbursement landlord result damage destruction repair restoration property section waiver tenant waif protection statute code judicial decision grant tenant right terminate lease event substantial total destruction lease property tenant agree provision section shall govern right obligation landlord tenant event substantial total destruction property article condemnation portion property take power eminent domain sell threat power call condemnation lease shall terminate take sell date condemn authority take title possession whichever occur percent floor area build property locate locate property take landlord tenant terminate lease date condemn authority take title possession deliver write notice day receipt write notice take absence notice day condemn authority take title possession landlord tenant terminate lease lease shall remain effect portion property take base rent additional rent shall reduce proportion reduction floor area property condemnation award payment shall distribute follow order ground lessor mortgagee beneficiary dee trust encumber property interest property b second tenant award specifically designate loss damage tenant trade fixture removable personal property c landlord remainder award compensation reduction value leasehold taking fee lease terminate landlord shall repair damage property cause condemnation landlord shall obligate repair damage tenant reimburse condemn authority severance damage receive landlord sufficient pay repair landlord shall right terminate lease repair landlord expense article assignment subletting section landlord consent require portion property tenant interest lease acquire person entity sale assignment mortgage sublease transfer operation law act tenant landlord prior write consent provide section landlord right grant withhold consent provide section attempt transfer consent shall void shall constitute noncurable breach lease section tenant affiliate addendum section section release tenant transfer permit article landlord consent shall release tenant change tenant primary liability pay rent perform obligation tenant lease landlords acceptance rent person waiver provision article consent transfer consent subsequent transfer tenant transferee defaults lease landlord proceed directly tenant pursue remedy transferee landlord consent subsequent assignment modification lease tenant transferee notify tenant obtain consent action shall relieve tenant liability lease section offer terminate tenant desire assign lease sublease property landlord elect write terminate lease pursuant section lease shall terminate commencement date new lease landlord propose assignee subtenant term provision lease govern termination shall apply landlord elect lease shall continue effect terminate provision section respect propose transfer shall continue apply section landlord consent tenant request consent transfer describe section shall set forth write detail propose transfer include business financial condition prospective transferee financial detail propose transfer eg term rent security deposit payable propose assignment sublease information landlord reasonably deem relevant landlord shall right elect terminate lease withhold consent reasonable grant consent base follow factor business propose assignee subtenant propose use property ii net worth financial reputation propose assignee subtenant iii tenant compliance obligation lease landlord object propose assignment solely net worth andor financial reputation propose assignee tenant nonetheless sublease assign portion property propose transferee term propose transfer b tenant assign sublease follow shall apply tenant assign sublease seventy percent build locate property aggregate tenant shall pay landlord additional rent lease landlord share state section profit define transaction receive tenant landlord give write notice tenant assignee subtenant landlord share shall pay assignee subtenant landlord directly profit mean amount pay tenant assignment sublease include key money monthly rent excess monthly rent payable lease fee consideration pay assignment sublease include fee collateral agreement b cost expense directly incur tenant connection execution performance assignment sublease real estate broker commission cost renovation construction assignment sublease real estate broker commission cost renovation construction tenant improvement require assignment sublease tenant entitle recover cost expense tenant obligate pay landlord share landlord profit case sublease property rent allocable sublease space percentage square footage basis ii tenant shall provide landlord write statement certify amount pay assignment sublease property thirty day transaction documentation sign landlord inspect tenant relevant book record verify accuracy statement write request tenant shall promptly furnish landlord copy transaction documentation shall certify tenant complete true correct landlord receipt landlord share shall consent assignment sublet breach tenant obligation paragraph b shall material default lease section merger merger shall result tenant sublease property article tenant surrender lease termination lease manner event landlord terminate subtenancie succeed interest tenant sublandlord subtenancie article default remedy section covenant condition tenant landlord performance obligation lease condition covenant tenant right continue possession property condition tenant performance time essence performance covenant condition section default tenant shall material default lease tenant fail pay rent abandon property tenant vacation property result cancellation insurance describe section b tenant fail pay rent charge day receipt bill statement landlord c tenant fails perform tenant nonmonetary obligation lease period thirty day write notice landlord provide thirty day require complete performance tenant shall default tenant commence performance thirty day period diligently pursue completion notice require paragraph intended satisfy notice requirement impose law landlord addition requirement tenant make general assignment general arrangement benefit creditor ii petition adjudication bankruptcy reorganization rearrangement file tenant dismiss thirty day iii trustee receiver appoint possession substantially tenant asset locate property tenant interest lease possession restore tenant thirty day iv substantially tenant asset locate property tenant interest lease subject attachment execution judicial seizure discharge thirty day court competent jurisdiction determines act describe subparagraph default lease trustee appoint possession tenant remain debtor possession trustee tenant transfer tenant interest hereunder landlord shall receive additional rent excess rent consideration pay connection assignment sublease rent payable tenant lease e guarantor lease revoke terminate purport revoke terminate guaranty potion tenant obligation lease expressly provide guaranty lease revocable section remedy occurrence material default tenant landlord time follow day write notice demand form day notice pay rent quit time run concurrently therewith limit landlord exercise right remedy landlord terminate tenant right possession property lawful mean case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall serve demand payment past rent charge payment render cure default tenant shall cashier check event landlord shall entitle recover tenant damage incur landlord reason tenant default include worth time award unpaid base rent additional rent charge landlord earn time termination ii worth time award unpaid base rent additional rent charge landlord earn termination time award exceed rental loss tenant prove landlord reasonably avoid iii worth time award unpaid base rent additional rent charge tenant pay balance lease term time award exceed rental loss tenant prove landlord reasonably avoid iv necessary compensate landlord detriment proximately cause tenant failure perform obligation lease ordinary course thing likely result therefrom include limited cost expense landlord incur maintain preserve property default cost recover possession property expense relette include necessary renovation alteration property landlord reasonable attorney fee incur connection therewith real estate commission pay payable subpart ii worth time award compute allow interest unpaid amount rate percent annum less maximum lawful rate subpart iii worth time award compute discount discount rate federal reserve bank san francisco time award plus percent tenant abandon property landlord shall option retake possession property recover tenant specify paragraph andor ii proceeding paragraph b b maintain tenant right possession case lease shall continue effect tenant abandon property event landlord shall entitle enforce landlord right remedy lease include right recover rent landlord shall remedy describe california civil code section lessor continue lease effect lessee breach abandonment recover rent lessee right sublet assign subject reasonable limitation c pursue remedy available landlord law judicial decision state property locate section intentionally delete section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirm landlords intention terminate lease provide section hereof include file unlawful detainer action tenant termination landlord damage default shall include cost fee include reasonably attorney fee landlord incur connection filing commencement pursue andor defend action bankruptcy court court respect lease obtain relief stay bankruptcy restrain action evict tenant pursue action respect landlord right possession property damage suffer apart base rent rent payable hereunder shall constitute pecuniary damage reimburse landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedy landlord exercise right remedy shall prevent exercise right remedy article protection lender section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumber property advance security thereof renewal modification consolidation replacement extension thereof recorded tenant shall cooperate landlord lender acquire security interest property lease tenant shall execute document assurance lender require form attach hereto exhibit b form require landlord lender provide agreement contain nondisturbance agreement favor tenant provide tenant obligation lease shall increase material way performance ministerial act shall deem material tenant shall deprive right lease tenant right quiet possession property lease term shall disturb tenant pay rent perform tenant obligation lease default ground lessor beneficiary mortgagee elect lease prior lien ground lease deed trust mortgage give write notice thereof tenant lease shall deem prior ground lease deed trust mortgage lease date prior subsequent date say ground lease deed trust mortgage date recording thereof addendum section section attornment landlord interest property acquire ground lessor beneficiary dee trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waive protection current future statute rule law give purport tenant right terminate lease surrender possession property transfer landlord interest section sign document tenant shall sign deliver instrument document necessary appropriate evidence attornment subordination agreement provide agreement include nondisturbance provision favor tenant tenant fail day write request tenant make constitute irrevocably appoint landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complie provision article section estoppel certificate landlord write request tenant shall execute acknowledge deliver landlord write statement form attach hereto exhibit c form require landlord lender certify term provision lease change change state change ii lease cancel terminate iii date payment base rent charge time period cover payment iv landlord default lease landlord claim default state v representation information respect tenant lease landlord reasonably request prospective purchaser encumbrancer property require tenant shall deliver statement landlord day landlord request landlord statement tenant prospective purchaser encumbrancer property purchaser encumbrancer rely conclusively statement true correct b tenant deliver statement landlord day period landlord prospective purchaser encumbrancer conclusively presume rely follow fact term provision lease change represent landlord ii lease cancel terminate represent landlord iii month base rent charge pay advance iv landlord default lease event tenant shall estop deny truth fact section c addendum section tenant financial condition day write request landlord tenant shall deliver landlord tenant exist financial statement verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designate landlord financial statement require lender facilitate financing refinance property tenant represent warrant landlord financial statement true accurate statement date statement al financial statement shall confidential shall purpose set forth lease addendum section article legal cost section legal proceeding tenant landlord shall breach default lease party default party shall reimburse party nondefaulte party demand cost expense nondefaulte party incur connection breach default default party lease suit commence judgment enter cost shall include legal fee cost incur negotiation settlement enforcement right furthermore action breach enforce provision lease commenced court action shall award party favor judgment enter reasonable sum attorney fee cost lose party action shall pay attorney fee cost tenant shall indemnify landlord hold landlord harmless cost expense demand liability landlord incur landlord party claim action institute tenant party party tenant person hold interest property license agreement tenant b foreclosure lien labor material furnish tenant group c arise result act transaction tenant group necessary protect landlord interest lease bankruptcy proceeding proceeding title united states code amend tenant shall defend landlord claim action tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost landlord reasonably incur claim action section landlord consent tenant shall pay landlord reasonable attorney fee incur connection tenant request landlord consent article assignment sublet connection act tenant propose require landlord consent article thirteen miscellaneous provision section nondiscrimination tenant promise condition continuance lease discrimination segregation person group person basis race color sex creed national origin ancestry lease sublease transfer occupancy tenure use property portion thereof section landlord liability certain duty lease term landlord mean current owner owner fee title property leasehold estate ground lease property time question landlord obligate perform obligation landlord lease time landlord own interest title landlord transfer title interest relieve al liability respect obligation landlord lease perform date transfer provide transferee assume landlord obligation date transfer landlord shall deliver transferee fund tenant previously pay fund apply term lease b tenant shall write notice failure landlord perform obligation lease landlord ground lessor mortgagee beneficiary dee trust encumber property address furnish tenant write landlord shall default lease landlord ground lessor mortgagee beneficiary fail cure nonperformance thirty day receipt tenant notice nonperformance reasonably require thirty day cure landlord shall default cure commence thirty day period diligently pursue completion c notwithstanding term provision contrary liability landlord performance duty obligation lease limited landlord interest property landlord partner shareholder officer principal shall personal liability lease section severability determination court competent jurisdiction provision lease thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain force effect section interpretation caption article section lease assist party read lease term provision lease require context lease singular shall include plural plural shall include singular masculine feminine neuter gender shall include provision relate conduct act omission tenant term tenant shall include tenant agent employee contractor invite successor property tenant express imply permission section incorporation prior agreement modification lease agreement party pertain lease property agreement effective amendment lease shall write singe party attempt amendment shall void section notice notice require permit lease shall writing shall personally deliver send national overnight carrier certify mail return receipt request postage prepay notice tenant shall deliver address specify section notice landlord shall deliver address specify section notice shall effective delivery party change notice address write notice party section waiver waiver write sign waive party landlord failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforce provision provision lease future statement payment check tenant letter accompany payment check shall bind landlord landlord notice tenant negotiate check bind condition statement section recordation tenant shall record lease prior write consent landlord landlord tenant require short form memorandum lease execute party record party require recording shall pay transfer taxis recording fee section bind effect choice law lease bind party legally acquire right interest lease landlord tenant landlord shall obligation tenant successor right interest tenant successor acquire accordance term lease law state property locate shall govern lease section corporate authority partnership authority tenant corporation corporation represent warrant person sign lease behalf tenant authority lease bind corporation thirty day lease sign tenant shall deliver landlord certify copy resolution tenant board director authorize execution lease evidence authority reasonably acceptable landlord tenant partnership person entity sign lease tenant represent warrant general partner partnership authority sign partnership lease bind partnership general partner partnership tenant shall write notice landlord general partner withdrawal addition thirty day lease sign tenant shall deliver landlord copy tenant record statement partnership certificate limited partnership section joint liability intentionally delete section addendum section section execution lease lease execute counterpart counterpart document execute counterpart shall constitute single bind instrument landlord delivery lease tenant shall deem offer lease shall bind party execute deliver party section survival representation warranty landlord tenant shall survive termination lease article fourteen broker section broker fee lease signed deliver landlord tenant landlord shall pay real estate commission landlords broker name section provide write agreement landlord landlords broker sum state section service render landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercise option extend lease term buy property similar option right landlord grant tenant landlord broker procure cause lease sale enter landlord tenant cover property commission shall set forth landlord broker commission schedule effect execution lease tenant broker name section landlords broker shall pay appropriate portion commission tenant broker provide agreement landlord broker tenant broker contain lease shall impose obligation landlord pay commission fee party landlords broker section protection broker landlord sell property assign landlord interest lease buyer assignee shall accept conveyance property assignment lease conclusively deem agree payment landlord broker require landlord article fourteen landlord broker shall right bring legal action enforce declare right provision prevail party action shall entitle reasonably attorney fee pay lose party attorney fee shall fix court action paragraph include lease benefit landlords broker section broker disclosure agency landlords broker disclose landlord tenant landlord tenant consent landlords broker act transaction agent check cid landlord exclusively cid landlord tenant section broker tenant represent warrant landlord broker name section agent broker finder party tenant deal entitle commission fee respect lease property additional provision set forth rider rider attach hereto blank space additional provision insert draw line space landlord tenant sign lease place date specify adjacent signature initial rider attach incorporate reference lease landlord majesticmapa property llc sign california limited liability company majestic realty co california corporation manager david wheeler president jay h bradford executive vice president chief financial officer tenant sign gilead sciences inc delaware corporation anthony caracciolo mark l perry executive vice president operation real estate transaction recommend consult professional civil engineer industrial hygienist person experience evaluate condition property include possible presence asbestos hazardous material underground storage tank print form lease draft legal counsel direction southern california chapter society industrial office realtor inc representation recommendation southern california chapter society industrial office realtor inc legal counsel real estate broker name employee agent legal sufficiency legal effect tax consequence lease transaction landlord tenant retain legal counsel advise matter rely advice legal counsel exhibit southern california chapter society industrial office realtor inc industrial real estate lease singletenant facility article basic term article contain basic term lease landlord tenant name article section paragraph lease refer article explain define basic term read conjunction basic term section date lease february section landlord include legal entity majesticmapa property llc california limited liability company address landlord crossroad parkway north th floor city industry section tenant include legal entity gilead sciences inc delaware corporation address tenant lakeside drive foster city section property include street address approximate square footage description approximately square foot building commonly know cliffside drive san dimas california outline red exhibit subject nonexclusive use area outline green section lease term year month begin june date specify lease end november section permit use article general office laboratory warehousing manufacture pharmaceutical product section tenant guarantor state section broker article fourteen state landlord broker majestic realty co tenant broker section commission payable landlords broker article fourteen separate agreement section initial security deposit section section vehicle parking space allocate tenant exhibit section rent charge payable tenant southern california chapter society industrial nd office realtor inc singletenant net form gilead sciences inc cliffside san dimas base rent fiftynine thousand twentyfive dollar month month provide section shall increase day sixtyfirst st month commencement date sixtyfive thousand fortyseven dollar b periodic payment real property taxis section ii utility section iii insurance premium section iv impound insurance premium property taxis section v maintenance repair alteration article section landlord share profit assignment sublease section percent profit landlord share section rider follow rider attach lease state addendum page exhibit b c article lease term section lease property lease term landlord lease property tenant tenant lease property landlord lease term lease term period state section shall begin end date specify section begin end lease term change provision lease commencement date shall date specify section begin lease term advanced delay provision lease section addendum section section intentionally delete section hold tenant shall vacate property expiration early termination lease tenant shall reimburse landlord indemnify landlord damage landlord incur tenant delay vacate property tenant vacate property expiration early termination lease landlord accept rent tenant tenant occupancy property shall monthtomonth tenancy subject term lease applicable monthto month tenancy base rent effect shall increase twentyfive percent section addendum article base rent section time manner payment execution lease tenant shall pay landlord base rent state paragraph month lease term day second month lease term month tenant shall pay landlord base rent advance offset deduction prior demand base rent shall payable landlord address place landlord designate writing section intentionally delete section security deposit increase execution lease tenant shall deposit landlord cash security deposit set forth section landlord apply security deposit unpaid rent charge tenant cure default tenant landlord use security deposit tenant shall restore security deposit day landlord write request tenant failure shall material default lease interest shall pay security deposit landlord shall require security deposit separate account trust relationship create respect security deposit b time base rent increase tenant shall deposit additional fund landlord sufficient increase security deposit bear relationship adjust base rent initial security deposit bore initial base rent section termination advance payment termination lease article seven damage destruction article condemnation termination result tenant default tenant vacate property manner require lease landlord shall day tenant deliver exclusive possession property landlord refund tenant tenant successor unused portion security deposit advance rent advance payment tenant landlord amount pay real property taxis reserve apply time period termination lease article charge payable tenant section additional rent charge payable tenant base rent call additional rent lease provide tenant shall pay additional rent monthly installment base rent term rent shall mean base rent additional rent section property taxis real property taxis tenant shall pay real property taxis property include fee taxis assessment result tenant improvement instal property benefit tenant lease term subject paragraph c section payment shall day prior delinquency date taxis day period tenant shall furnish landlord satisfactory evidence real property taxis pay landlord shall reimburse tenant real property taxis pay tenant cover period time prior lease term tenant fail pay real property taxis landlord pay taxis tenant shall reimburse landlord tax payment additional rent b definition real property tax real property tax mean fee license fee license tax business license fee commercial rental tax levy charge assessment penalty extent cause tenant act omission tax impose tax authority property ii tax landlord right receive receipt rent income property landlord business leasing property iii tax charge fire protection street sidewalk road maintenance refuse service provide property governmental agency iv tax impose transaction base reassessment property change ownership define applicable law transfer landlord interest property v charge fee replace tax previously include definition real property tax real property tax include landlord federal state income franchise inheritance estate taxis c joint assessment property separately assess landlord shall reasonably determine tenant share real property tax payable tenant paragraph assessor worksheet reasonably available information tenant shall pay share landlord day receipt landlord write statement personal property taxis tenant shall pay taxis charge trade fixture furnishing equipment personal property belong tenant tenant shall try personal property tax separately property ii tenant personal property tax property tenant shall pay landlord taxis personal property day tenant receive write statement landlord personal property taxis e tenant right contest taxis tenant attempt assess valuation property reduce initiate proceeding contest real property taxis require law landlord shall join proceeding bring tenant tenant shall pay cost proceeding include cost fee incur landlord final determination proceeding contest tenant shall immediately pay real property taxis cost charge interest penalty incidental proceeding tenant pay real property taxis contest taxis tenant shall default lease nonpayment taxis tenant deposit fund landlord open interestbeare account reasonably acceptable landlord joint name landlord tenant deposit shall sufficient pay real property taxis plus reasonable estimate interest cost charge penalty accrue tenant action unsuccessful applicable tax impound previously pay tenant landlord deposit shall apply real property taxis determine proceeding real property taxis shall pay protest deposit payment protest necessary prevent property sell tax sale similar enforcement proceeding section utility tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utility service supply property service utility jointly meter property landlord shall reasonable determination tenant proportionate share cost utility service tenant shall pay share landlord day receipt landlord write statement section insurance policy liability insurance lease term tenant shall maintain policy commercial general liability insurance know broad form comprehensive general liability insurance insure tenant liability bodily injury property damage include loss use property personal injury arise operation use occupancy property tenant shall landlord additional insure policy initial insurance shall million dollar occurrence shall subject periodic increase base industry standard similar facility liability insurance obtain tenant paragraph shall primary noncontributing ii contain crossliability endorsement iii insure landlord tenant performance section matter give rise indemnity section result negligence tenant coverage insurance shall limit tenant liability relieve tenant obligation lease landlord obtain comprehensive public liability insurance coverage determine landlord insure landlord liability arise ownership operation use occupancy property policy obtain landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policy insurance cover loss damage property replacement value policy shall provide protection loss damage fire casualty cover classification fire standard extend coverage vandalism malicious mischief sprinkler leakage peril landlord deem reasonably necessary landlord shall right obtain terrorism flood earthquake insurance form insurance require lender hold security interest property landlord shall obtain insurance tenant fixture equipment building improvement instal tenant property lease term landlord shall maintain rental income insurance policy loss payable landlord equal year base rent plus estimate real property taxis insurance premium tenant shall liable payment deductible landlord tenant insurance policy maintain pursuant section provide landlord insurance deductible shall exceed thousand dollar tenant shall permit invalidate insurance policy tenant request landlord shall provide tenant certificate evidence insurance c payment premium subject section tenant shall pay premium insurance policy describe paragraph b obtain landlord tenant day tenant receipt copy premium statement evidence landlord shall pay premium nonprimary comprehensive public liability insurance landlord elect obtain provide paragraph insurance policy maintain landlord cover improvement real property property landlord shall deliver tenant statement premium applicable property show reasonable detail tenant share premium compute lease term expire expiration insurance policy maintain landlord tenant shall liable tenant prorate share insurance premium commencement date tenant shall deliver landlord copy policy insurance tenant require maintain section thirty day prior expiration policy tenant shall deliver landlord renewal policy alternative provide policy insurance tenant shall right provide landlord certificate insurance execute authorized officer insurance company show insurance tenant require maintain section force effect contain information landlord reasonably require general insurance provision insurance tenant require maintain lease shall include provision require insurance carrier landlord thirty day write notice prior cancellation modification coverage ii tenant fail deliver policy certificate renewal landlord require lease prescribed time period policy cancel modify lease term landlord consent landlord obtain insurance case tenant shall reimburse landlord cost insurance day receipt statement indicate cost insurance iii landlord tenant shall maintain insurance require lease company hold general policy rating well set forth current issue good key rating guide landlord tenant acknowledge insurance market rapidly change insurance form amount describe section available future tenant acknowledge insurance describe section primary benefit landlord time lease term tenant landlord unable maintain insurance require lease landlord tenant shall maintain insurance coverage customary commercially reasonable insurance industry tenant type business coverage change time time landlord make representation adequacy insurance protect landlord tenant interest tenant shall obtain additional property liability insurance tenant deem necessary protect landlord tenant iv landlord tenant waive right recovery officer employee agent representative loss damage property property control loss damage cover insurance policy force describe lease time loss damage obtain require policy insurance landlord tenant shall notice insurance carrier mutual waiver subrogation landlord tenant insurance policy describe section shall contain provision waive carrier right subrogation section late charge tenant failure pay rent promptly cause landlord incur unanticipated cost exact cost impractical extremely difficult ascertain cost include limited processing accounting charge late charge impose landlord ground lease mortgage trust deed encumber property landlord receive rent payment day provide landlord give tenant fortyeight hour write notice tenant fail pay base rent fortyeight shall run concurrently day period tenant shall pay landlord late charge equal percent overdue party agree late charge represent fair reasonable estimate cost landlord incur reason late payment section interest past obligation owe party hereunder pay shall bear interest rate percent annum date interest shall payable late charge pay tenant lease payment interest amount shall excuse cure default lease interest rate specify lease high rate permit law interest rate decrease maximum legal interest rate permit law section impound insurance premium real property taxis tenant day late payment base rent twice consecutive month period tenant shall pay landlord sum equal onetwelfth annual real property taxis insurance premium payable tenant lease payment base rent landlord shall hold payment noninterest bear impound account unknown landlord shall reasonably estimate real property taxis insurance premium tenant shall pay deficiency fund impound account landlord write request tenant default lease landlord apply fund impound account obligation lease section addendum article use property section permit use tenant use property permit use set forth section section manner use tenant shall cause permit property way constitute violation law ordinance governmental regulation order annoy interfere right tenant landlord constitute nuisance waste tenant shall obtain pay permit include certificate occupancy require tenant occupancy property shall promptly action necessary comply applicable statute ordinance rule regulation order requirement regulate use tenant property include occupational safety health act addendum section section addendum section section sign auction tenant shall place sign property landlord prior write consent tenant shall conduct permit auction sheriff sale property addendum section section indemnity tenant shall indemnify landlord hold landlord harmless cost claim liability arise tenant use property b conduct tenant business permit tenant property c breach default performance tenant obligation lease misrepresentation breach warranty tenant lease e act omission tenant tenant shall defend landlord cost claim liability tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost incur landlord connection claim material consideration landlord tenant assume risk damage property injury person property arising cause tenant waif claim respect thereof landlord claim arise landlord landlord employee agent contractor active negligence willful misconduct section term tenant shall include tenant employee agent contractor invite applicable addendum section section landlord access landlord agent enter property reasonable time property potential buyer investor tenant party act inspect conduct test order monitor tenant compliance applicable environmental law law govern presence use hazardous material purpose landlord deem necessary landlord shall tenant hour prior notice entry case emergency landlord agree allow representative tenant accompany landlord agree comply tenant reasonable security measure landlord place customary sale lease sign property section quiet possession tenant pay rent complie term lease tenant occupy enjoy property lease term subject provision lease article condition property maintenance repair alteration section exist condition subject provision lease tenant accept property condition execution lease subject record matter law ordinance governmental regulation order provide tenant acknowledge landlord agent landlord representation condition property suitability property tenant intend use tenant represent warrant tenant inspection inquiry condition property rely representation landlord broker respect thereto landlord landlords broker provide property information sheet disclosure statement property copy attach exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom good ware merchandise property tenant tenant employee invite customer person property damage injury cause result fire steam electricity water gas rain b breakage leakage obstruction defect pipe sprinkler wire appliance plumb air conditioning lighting fixture cause c condition arise property source place act omission tenant landlord landlord shall liable damage injury cause mean repair damage injury accessible tenant provision section shall exempt landlord liability landlord landlord employee agent contractor active negligence willful misconduct section landlord obligation addendum section section tenant obligation provide section article seven damage destruction article condemnation tenant shall portion property include structural nonstructural interior exterior landscape area portion system equipment good order condition repair include interior repainting refinish need portion property system equipment property tenant obligate repair fully repair restore tenant shall promptly replace portion property system equipment property regardless benefit replacement extend lease term benefit useful life replacement extend lease term term extend exercise option useful life replacement shall prorate remaining portion lease term extend tenant shall liable portion cost applicable lease term extend tenant shall maintain preventive maintenance contract provide regular inspection maintenance heating air conditioning system license heating air conditioning contractor subject provision section div property damage act omission tenant tenant shall pay landlord cost repair replace damage property landlord obligate pay cost maintaining repair property intention landlord tenant times tenant shall maintain portion property tenant obligate maintain attractive firstclass fully operative condition b tenant shall fulfill tenant obligation section tenant sole expense tenant fails maintain repair replace property require section reasonable effort landlord day prior notice tenant notice shall require case emergency enter property perform maintenance repair include replacement need behalf tenant case tenant shall reimburse landlord cost incur perform maintenance repair immediately demand section alteration addition improvement tenant shall alteration addition improvement property landlord prior write consent shall unreasonably withhold nonstructural alteration exceed thousand dollar cost project visible outside build property landlord require tenant provide demolition andor lien completion bond form satisfactory landlord tenant shall promptly remove alteration addition improvement construct violation paragraph landlord write request alteration addition improvement shall good workmanlike manner conformity applicable law regulation contractor approve landlord shall unreasonably withhold completion work tenant shall provide landlord build plan copy construction contract proof payment labor materials b tenant shall pay claim labor material furnish tenant group property tenant shall landlord day prior write notice commencement work property regardless landlord consent work require landlord elect record post notice nonresponsibility property section condition termination termination lease tenant shall surrender property landlord broom clean condition receive ordinary wear tear tenant obligate remedy provision lease tenant shall obligate repair damage landlord require repair accordance lease addition landlord require tenant remove alteration addition improvement landlord consent prior expiration lease restore property prior condition tenant expense alteration addition improvement landlord require tenant remove shall landlord property shall surrender landlord expiration early termination lease tenant remove tenant trade fixture machinery equipment remove material damage property tenant shall repair tenant expense damage property cause removal trade fixture machinery equipment event shall tenant remove follow material equipment shall deem landlord property landlord prior write consent power writing power panel light lighting fixture wall covering drape blind window covering carpet floor covering heater air conditioner heat air conditioning equipment fence security gate similar building operating equipment decoration addendum section article seven damage destruction section partial damage property tenant shall notify landlord write immediately occurrence damage property property partially damage ie percent property untenantable result damage percent tenant operation materially impair proceed receive landlord insurance policy describe paragraph b sufficient pay necessary repair lease shall remain effect landlord shall repair damage soon reasonably possible landlord elect require repair damage tenant fixture equipment improvement b landlord maintain insurance require maintain paragraph b insurance proceed receive landlord sufficient pay entire cost repair ii cause damage cover insurance policy iii holder mortgage property shall require insurance proceed portion thereof retire mortgage debt landlord elect repair damage soon reasonably possible case lease shall remain force effect ii terminate lease date damage occur landlord shall notify tenant thirty day receipt notice occurrence damage landlord elect repair damage terminate lease landlord elect repair damage tenant shall pay landlord deductible landlord insurance policy damage act omission tenant tenant employee agent contractor invite difference actual cost repair insurance proceed receive landlord landlord elect terminate lease tenant elect continue lease force effect case tenant shall repair damage property building property locate tenant shall pay cost repair satisfactory completion repair landlord shall deliver tenant insurance proceed receive landlord damage repair tenant tenant shall landlord write notice election day receive landlord termination notice c damage property occur month lease term damage require thirty day repair landlord tenant elect terminate lease date damage occur regardless sufficiency insurance proceed party elect terminate lease shall write notification party election thirty day tenant notice landlord occurrence damage section substantial total destruction property substantially totally destroy cause whatsoever ie damage property great partial damage describe section regardless landlord receive insurance proceed lease shall terminate later date destruction occur ii date tenant cease business property notwithstanding precede sentence property rebuild month date destruction landlord elect rebuild property landlord expense case lease shall remain force effect landlord shall notify tenant election thirty day tenant notice occurrence total substantial destruction landlord elect landlord shall rebuild property landlord sole expense destruction cause act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceed receive landlord section temporary reduction rent property destroy damage landlord tenant repair restore property pursuant provision article seven rent payable period damage repair andor restoration shall reduce according degree tenant use property impair possible reduction base rent insurance premium real property taxis tenant shall entitled compensation reduction reimbursement landlord result damage repair restoration property section waiver tenant waif protection statute code judicial decision grant tenant right terminate lease event substantial total destruction lease property tenant agree provision section shall govern right obligation landlord tenant event substantial total destruction property article condemnation portion property take power eminent domain sell threat power call condemnation lease shall terminate take sell date condemn authority take title possession whichever occur percent floor area build property locate locate property take landlord tenant terminate lease date condemn authority take title possession deliver write notice day receipt write notice take absence notice day condemn authority take title possession landlord tenant terminate lease lease shall remain effect portion property take base rent additional rent shall reduce proportion reduction floor area property condemnation award payment shall distribute follow order ground lessor mortgagee beneficiary dee trust encumber property interest property b second tenant award specifically designate loss damage tenant trade fixture removable personal property c landlord remainder award compensation reduction value leasehold taking fee lease terminate landlord shall repair damage tenant reimburse condemn authority severance damage receive landlord sufficient pay repair landlord shall right terminate lease repair landlord expense article assignment subletting section landlord consent require portion property tenant interest lease acquire person entity sale assignment mortgage sublease transfer operation law act tenant landlord prior write consent provide section landlord right grant withhold consent provide section attempt transfer consent shall void shall constitute noncurable breach lease section tenant affiliate addendum section section release tenant transfer permit article landlord consent shall release tenant change tenant primary liability pay rent perform obligation tenant lease landlords acceptance rent person waiver provision article consent transfer consent subsequent transfer tenant transferee defaults lease landlord proceed directly tenant pursue remedy transferee landlord consent subsequent assignment modification lease tenant transferee notify tenant obtain consent action shall relieve tenant liability lease section offer terminate tenant desire assign lease sublease property landlord elect terminate lease pursuant section lease shall terminate commencement date new lease landlord propose assignee subtenant term provision lease govern termination shall apply landlord elect lease shall continue effect terminate provision section respect propose transfer shall continue apply section landlord consent tenant request consent transfer describe section shall set forth write detail propose transfer include business financial condition prospective transferee financial detail propose transfer eg term rent security deposit payable propose assignment sublease information landlord reasonably deem relevant landlord shall right elect terminate lease withhold consent reasonable grant consent base follow factor business propose assignee subtenant propose use property ii net worth financial reputation propose assignee subtenant iii tenant compliance obligation lease landlord object propose assignment solely net worth andor financial reputation propose assignee tenant nonetheless sublease assign portion property propose transferee term propose transfer b tenant assign sublease follow shall apply tenant assign sublease seventy percent build locate property aggregate tenant shall pay landlord additional rent lease landlord share state section profit define transaction receive tenant landlord give write notice tenant assignee subtenant landlord share shall pay assignee subtenant landlord directly profit mean amount pay tenant assignment sublease include key money monthly rent excess monthly rent payable lease fee consideration pay assignment sublease include fee collateral agreement b cost expense directly incur tenant connection execution performance assignment sublease real estate broker commission cost renovation construction tenant improvement require assignment sublease tenant entitle recover cost expense tenant obligate pay landlord share landlord profit case sublease property rent allocable sublease space percentage square footage basis ii tenant shall provide landlord write statement certify amount pay assignment sublease property thirty day transaction documentation sign landlord inspect tenant relevant book record verify accuracy statement write request tenant shall promptly furnish landlord copy transaction documentation shall certify tenant complete true correct landlord receipt landlord share shall consent assignment sublet breach tenant obligation paragraph b shall material default lease section merger merger shall result tenant sublease property article tenant surrender lease termination lease manner event landlord terminate subtenancie succeed interest tenant sublandlord subtenancie article default remedy section covenant condition tenant landlord performance obligation lease condition covenant tenant right continue possession property condition tenant performance time essence performance covenant condition section default tenant shall material default lease tenant fail pay rent abandon property tenant vacation property result cancellation insurance describe section b tenant fail pay rent charge day receipt bill statement landlord c tenant fails perform tenant nonmonetary obligation lease period thirty day write notice landlord provide thirty day require complete performance tenant shall default tenant commence performance thirty day period diligently pursue completion notice require paragraph intended satisfy notice requirement impose law landlord addition requirement tenant make general assignment general arrangement benefit creditor ii petition adjudication bankruptcy reorganization rearrangement file tenant dismiss thirty day iii trustee receiver appoint possession substantially tenant asset locate property tenant interest lease possession restore tenant thirty day iv substantially tenant asset locate property tenant interest lease subject attachment execution judicial seizure discharge thirty day court competent jurisdiction determines act describe subparagraph default lease trustee appoint possession tenant remain debtor possession trustee tenant transfer tenant interest hereunder landlord shall receive additional rent excess rent consideration pay connection assignment sublease rent payable tenant lease e guarantor lease revoke terminate purport revoke terminate guaranty portion tenant obligation lease expressly provide guaranty lease revocable section remedy occurrence material default tenant landlord time follow day write notice demand form day notice pay rent quit time run concurrently therewith limit landlord exercise right remedy landlord terminate tenant right possession property lawful mean case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall serve demand payment past rent charge payment render cure default tenant shall cashier check event landlord shall entitle recover tenant damage incur landlord reason tenant default include worth time award unpaid base rent additional rent charge landlord earn time termination ii worth time award unpaid base rent additional rent charge landlord earn termination time award exceed rental loss tenant prove landlord reasonably avoid iii worth time award unpaid base rent additional rent charge tenant pay balance lease term time award exceed rental loss tenant prove landlord reasonably avoid iv necessary compensate landlord detriment proximately cause tenant failure perform obligation lease ordinary course thing likely result therefrom include limited cost expense landlord incur maintain preserve property default cost recover possession property expense relette include necessary renovation alteration property landlord reasonable attorney fee incur connection therewith real estate commission pay payable subpart ii worth time award compute allow interest unpaid amount rate percent annum less maximum lawful rate subpart iii worth time award compute discount discount rate federal reserve bank san francisco time award plus percent tenant abandon property landlord shall option retake possession property recover tenant specify paragraph andor ii proceeding paragraph b b maintain tenant right possession case lease shall continue effect tenant abandon property event landlord shall entitle enforce landlord right remedy lease include right recover rent landlord shall remedy describe california civil code section lessor continue lease effect lessee breach abandonment recover rent lessee right sublet assign subject reasonable limitation c pursue remedy available landlord law judicial decision state property locate section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirm landlords intention terminate lease provide section hereof include file unlawful detainer action tenant termination landlord damage default shall include cost fee include reasonable attorney fee landlord incur connection filing commencement pursue andor defend action bankruptcy court court respect lease obtain relief stay bankruptcy restrain action evict tenant pursue action respect landlord right possession property damage suffer apart base rent rent payable hereunder shall constitute pecuniary damage reimburse landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedy landlord exercise right remedy shall prevent exercise right remedy section addendum article protection lender section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumber property advance security thereof renewal modification consolidation replacement extension thereof recorded tenant shall cooperate landlord lender acquire security interest property lease tenant shall execute document assurance lender require form attach hereto exhibit b form require landlord lender provide agreement contain nondisturbance agreement favor tenant provide tenant obligation lease shall increase material way performance ministerial act shall deem material tenant shall deprive right lease tenant right quiet possession property lease term shall disturb tenant pay rent perform tenant obligation lease default ground lessor beneficiary mortgagee elect lease prior lien ground lease deed trust mortgage give write notice thereof tenant lease shall deem prior ground lease deed trust mortgage lease date prior subsequent date say ground lease deed trust mortgage date recording thereof addendum section section attornment landlord interest property acquire ground lessor beneficiary dee trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waive protection current future statute rule law give purport tenant right terminate lease surrender possession property transfer landlord interest section sign document tenant shall sign deliver instrument document necessary appropriate evidence attornment subordination agreement provide agreement include nondisturbance provision favor tenant tenant fail day write request tenant make constitute irrevocably appoint landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complie provision article section estoppel certificate landlord write request tenant shall execute acknowledge deliver landlord write statement form attach hereto exhibit c form require landlord lender certify term provision lease change change state change ii lease cancel terminate iii date payment base rent charge time period cover payment iv landlord default lease landlord claim default state v representation information respect tenant lease landlord reasonably request prospective purchaser encumbrancer property require tenant shall deliver statement landlord day landlord request landlord statement tenant prospective purchaser encumbrancer property purchaser encumbrancer rely conclusively statement true correct b tenant deliver statement landlord day period landlord prospective purchaser encumbrancer conclusively presume rely follow fact term provision lease change represent landlord ii lease cancel terminate represent landlord iii month base rent charge pay advance iv landlord default lease event tenant shall estop deny truth fact c addendum section tenant financial condition day write request landlord tenant shall deliver landlord tenant exist financial statement verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designate landlord financial statement require lender facilitate financing refinance property tenant represent warrant landlord financial statement true accurate statement date statement financial statement shall confidential shall purpose set forth lease addendum section article legal cost section legal proceeding tenant landlord shall breach default lease party default party shall reimburse party nondefaulte party demand cost expense nondefaulte party incur connection breach default default party lease suit commence judgment enter cost shall include legal fee cost incur negotiation settlement enforcement right furthermore action breach enforce provision lease commenced court action shall award party favor judgment enter reasonable sum attorney fee cost lose party action shall pay attorney fee cost tenant shall indemnify landlord hold landlord harmless cost expense demand liability landlord incur landlord party claim action institute tenant party party tenant person hold interest property license agreement tenant b foreclosure lien labor material furnish tenant group c arise result act transaction tenant group necessary protect landlord interest lease bankruptcy proceeding proceeding title united states code amend tenant shall defend landlord claim action tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost landlord reasonably incur claim action section landlord consent tenant shall pay landlord reasonable attorney fee incur connection tenant request landlord consent article assignment sublet connection act tenant propose require landlord consent article thirteen miscellaneous provision section nondiscrimination tenant promise condition continuance lease discrimination segregation person group person basis race color sex creed national origin ancestry lease sublease transfer occupancy tenure use property portion thereof section landlord liability certain duty lease term landlord mean current owner owner fee title property leasehold estate ground lease property time question landlord obligate perform obligation landlord lease time landlord own interest title landlord transfer title interest relieve liability respect obligation landlord lease perform date transfer provide transferee assume landlord obligation date transfer landlord shall deliver transferee fund tenant previously pay fund apply term lease b tenant shall write notice failure landlord perform obligation lease landlord ground lessor mortgage beneficiary dee trust encumber property address furnish tenant write landlord shall default lease landlord ground lessor mortgagee beneficiary fail cure nonperformance thirty day receipt tenant notice nonperformance reasonably require thirty day cure landlord shall default cure commence thirty day period diligently pursue completion c notwithstanding term provision contrary liability landlord performance duty obligation lease limited landlord interest property landlord partner shareholder officer principal shall personal liability lease section severability determination court competent jurisdiction provision lease thereof illegal unenforceable shall cancel invalidate remainder provision lease thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain force effect section interpretation caption article section lease assist party read lease term provision lease require context lease singular shall include plural plural shall include singular masculine feminine neuter gender shall include provision relate conduct act omission tenant term tenant shall include tenant agent employee contractor invite successor property tenant express imply permission section incorporation prior agreement modification lease agreement party pertain lease property agreement effective amendment lease shall write sign party attempt amendment shall void section notice notice require permit lease shall writing shall personally deliver send national overnight carrier certify mail return receipt request postage prepay notice tenant shall deliver address specify section notice landlord shall deliver address specify section notice shall effective delivery party change notice address write notice party section waiver waiver write sign waive party landlord failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforce provision provision lease future statement payment check tenant letter accompany payment check shall bind landlord landlord notice tenant negotiate check bind condition statement section recordation tenant shall record lease prior write consent landlord landlord tenant require short form memorandum lease execute party record party require recording shall pay transfer taxis recording fee section bind effect choice law lease bind party legally acquire right interest lease landlord tenant landlord shall obligation tenant successor right interest tenant successor acquire accordance term lease law state property locate shall govern lease section corporate authority partnership authority tenant corporation corporation represent warrant person sign lease behalf tenant authority lease bind corporation thirty day lease sign tenant shall deliver landlord certify copy resolution tenant board director authorize execution lease evidence authority reasonably acceptable landlord tenant partnership person entity sign lease tenant represent warrant general partner partnership authority sign partnership lease bind partnership general partner partnership tenant shall write notice landlord general partner withdrawal addition thirty day lease sign tenant shall deliver landlord copy tenant record statement partnership certificate limited partnership section joint liability section addendum section section execution lease lease execute counterpart counterpart document execute counterpart shall constitute single bind instrument landlord delivery lease tenant shall deem offer lease shall bind party execute deliver party section survival representation warranty landlord tenant shall survive termination lease article fourteen broker section broker fee lease signed deliver landlord tenant landlord shall pay real estate commission landlords broker name section provide write agreement landlord landlords broker sum state section service render landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercise option extend lease term buy property similar option right landlord grant tenant landlord broker procure cause lease sale enter landlord tenant cover property commission shall set forth landlord broker commission schedule effect execution lease tenant broker name section landlords broker shall pay appropriate portion commission tenant broker provide agreement landlord broker tenant broker contain lease shall impose obligation landlord pay commission fee party landlords broker section protection broker landlord sell property assign landlord interest lease buyer assignee shall accept conveyance property assignment lease conclusively deem agree payment landlord broker require landlord article fourteen landlord broker shall right bring legal action enforce declare right provision prevail party action shall entitle reasonable attorney fee pay lose party attorney fee shall fix court action paragraph include lease benefit landlords broker section broker disclosure agency landlords broker disclose landlord tenant landlord tenant consent landlords broker act transaction agent check cid landlord exclusively cid landlord tenant section broker tenant represent warrant landlord broker name section agent broker finder party tenant deal entitle commission fee respect lease property additional provision set forth rider rider attach hereto blank space additional provision insert draw line space landlord tenant sign lease place date specify adjacent signature initial rider attach incorporate reference lease sign landlord majesticmapa property llc california limited liability company majestic realty co california corporation manager david wheeler president jay h bradford executive vice president chief financial officer sign tenant gilead sciences inc delaware corporation anthony caracciolo mark l perry executive vice president operation real estate transaction recommend consult professional civil engineer industrial hygienist person experience evaluate condition property include possible presence asbestos hazardous material underground storage tank print form lease draft legal counsel direction southern california chapter society industrial officer realtor inc representation recommendation southern california chapter society industrial office realtor inc legal counsel real estate broker name employee agent legal sufficiency legal effect tax consequence lease transaction landlord tenant retain legal counsel advise matter rely advice legal counsel exhibit southern california chapter society industrial office realtor inc industrial real estate lease singletenant facility article basic term article contain basic term lease landlord tenant name article section paragraph lease refer article explain define basic term read conjunction basic term section date lease july section landlord include legal entity majesticmapa property llc california limited liability company majestic realty co california corporation address landlord crossroad parkway north th floor city industry section tenant include legal entity gilead sciences inc delaware corporation address tenant lakeside drive foster city california section property include street address approximate square footageand description approximately square foot building situate approximately acre land commonly know west covina boulevard san dimas california outline red exhibit subject nonexclusive use area outline green section lease term year month begin date specify lease ending section permit use article general office laboratory warehousing manufacture pharmaceutical product section tenant guarantor state section broker article fourteen state landlord broker majestic realty co tenant broker julien j studley inc section commission payable landlords broker article fourteen separate agreement section initial security deposit section day later occur date exist tenant vacate property ii date landlord substantially complete landlord work fifth th anniversary lease commencement date southern california chapter society industrial nd office realtor inc singletenant net form gilead sciences inc west covina blvd san dimas section vehicle parking space allocate tenant exhibit section rent charge payable tenant base rent twentythree thousand eightyfour dollar month twentyfour month provide section shall increase day addendum section month commencement date b periodic payment real property taxis section ii utility section iii insurance premium section iv impound insurance premium property taxis section v maintenance repair alteration article section landlord share profit assignment sublease section percent profit landlord share section rider follow rider attach lease state addendum page option extend term lease rider exhibit b c e article lease term section lease property lease term landlord lease property tenant tenant lease property landlord lease term lease term period state section shall begin end date specify section begin end lease term change provision lease commencement date shall date specify section begin lease term advanced delay provision lease section delay commencement landlord shall liable tenant landlord deliver possession property landlord work substantially complete tenant april landlords nondelivery property tenant date shall affect lease obligation tenant lease commencement date shall delay landlord deliver possession property tenant lease term shall extend period equal delay delivery possession property landlord work substantially complete tenant plus number day necessary end lease term day month landlord deliver possession property landlord work substantially complete tenant eighty day tenant elect cancel lease giving write notice landlord day eighty day period end tenant give notice lease shall cancel landlord tenant shall obligation tenant notice tenant right cancel lease shall expire lease term shall commence delivery possession property landlord work substantially complete tenant delivery possession property tenant delay landlord tenant shall delivery execute amendment lease set forth actual commencement date expiration date lease failure execute amendment shall affect actual commencement date expiration date lease section early occupancy tenant occupy property purpose conduct business prior commencement date tenant occupancy property shall subject provision lease early occupancy property shall advance expiration date lease tenant shall pay base rent charge specify lease early occupancy period section hold tenant shall vacate property expiration early termination lease tenant shall reimburse landlord indemnify landlord damage landlord incur tenant delay vacate property tenant vacate property expiration early termination lease landlord accept rent tenant tenant occupancy property shall monthtomonth tenancy subject term lease applicable monthtomonth tenancy base rent effect shall increase twentyfive percent article base rent section time manner payment execution lease tenant shall pay landlord base rent state paragraph month lease term day second month lease term month tenant shall pay landlord base rent advance offset deduction prior demand base rent shall payable landlord address place landlord designate writing section intentionally delete section security deposit increase execution lease tenant shall deposit landlord cash security deposit set forth section landlord apply security deposit unpaid rent charge tenant cure default tenant landlord use security deposit tenant shall restore security deposit day landlord write request tenant failure shall material default lease interest shall pay security deposit landlord shall require security deposit separate account trust relationship create respect security deposit b time base rent increase tenant shall deposit additional fund landlord sufficient increase security deposit bear relationship adjust base rent initial security deposit bore initial base rent section termination advance payment termination lease article seven damage destruction article condemnation termination result tenant default tenant vacate property manner require lease landlord shall refund credit tenant tenant successor unused portion security deposit advance rent advance payment tenant landlord amount pay real property taxis reserve apply time period termination lease article charge payable tenant section additional rent charge payable tenant base rent call additional rent lease provide tenant shall pay additional rent monthly installment base rent term rent shall mean base rent additional rent section property taxis real property taxis tenant shall pay real property taxis property include fee taxis assessment result tenant improvement instal property benefit tenant lease term subject paragraph c section payment shall day prior delinquency date taxis day period tenant shall furnish landlord satisfactory evidence real property taxis pay landlord shall reimburse tenant real property taxis pay tenant cover period time prior lease term tenant fail pay real property taxis landlord pay taxis tenant shall reimburse landlord tax payment additional rent alternatively landlord elect bill tenant advance taxis tenant shall pay landlord taxis additional rent day prior delinquency landlord shall pay taxis prior delinquency provide tenant timely payment landlord penalty cause tenant failure timely payment shall additional rent owe tenant immediately demand b definition real property tax real property tax mean fee license fee license tax business license fee commercial rental tax levy charge assessment penalty tax impose tax authority property ii tax landlord right receive receipt rent income property landlord business leasing property iii tax charge fire protection street sidewalk road maintenance refuse service provide property governmental agency iv tax impose transaction base reassessment property change ownership define applicable law transfer landlord interest property v charge fee replace tax previously include definition real property tax real property tax include landlord federal state income franchise inheritance estate taxis c joint assessment property separately assess landlord shall reasonably determine tenant share real property tax payable tenant paragraph assessor worksheet reasonably available information tenant shall pay share landlord day receipt landlord write statement personal property taxis tenant shall pay taxis charge trade fixture furnishing equipment personal property belong tenant tenant shall try personal property tax separately property ii tenant personal property tax property tenant shall pay landlord taxis personal property day tenant receive write statement landlord personal property taxis e tenant right contest taxis tenant attempt assess valuation property reduce initiate proceeding contest real property taxis require law landlord shall join proceeding bring tenant tenant shall pay cost proceeding include cost fee incur landlord final determination proceeding contest tenant shall immediately pay real property taxis cost charge interest penalty incidental proceeding tenant pay real property taxis contest taxis tenant shall default lease nonpayment taxis tenant deposit fund landlord open interestbeare account reasonably acceptable landlord joint name landlord tenant deposit shall sufficient pay real property taxis plus reasonable estimate interest cost charge penalty accrue tenant action unsuccessful applicable tax impound previously pay tenant landlord deposit shall apply real property taxis determine proceeding real property taxis shall pay protest deposit payment protest necessary prevent property sell tax sale similar enforcement proceeding section utility tenant shall pay directly appropriate supplier cost natural gas heat light power sewer service telephone water refuse disposal utility service supply property service utility jointly meter property landlord shall reasonable determination tenant proportionate share cost utility service tenant shall pay share landlord day receipt landlord write statement section insurance policy liability insurance lease term tenant shall maintain policy commercial general liability insurance know broad form comprehensive general liability insurance insure tenant liability bodily injury property damage include loss use property personal injury arise operation use occupancy property tenant shall landlord additional insure policy initial insurance shall million dollar occurrence shall subject periodic increase base industry standard similar facility liability insurance obtain tenant paragraph shall primary noncontributing ii contain crossliability endorsement iii insure landlord tenant performance section matter give rise indemnity section result negligence tenant coverage insurance shall limit tenant liability relieve tenant obligation lease landlord obtain comprehensive public liability insurance coverage determine landlord insure landlord liability arise ownership operation use occupancy property policy obtain landlord shall contributory shall provide primary insurance b property rental income insurance lease term landlord shall maintain policy insurance cover loss damage property replacement value policy shall contain inflation guard endorsement shall provide protection peril include classification fire extend coverage vandalism malicious mischief special extend peril risk sprinkler leakage peril landlord deem reasonably necessary landlord shall right obtain flood earthquake insurance require lender hold security interest property landlord shall obtain insurance tenant fixture equipment building improvement instal tenant property lease term landlord shall maintain rental income insurance policy loss payable landlord equal year base rent plus estimate real property taxis insurance premium tenant shall liable payment deductible landlord tenant insurance policy maintain pursuant section provide landlord insurance deductible shall exceed thousand dollar tenant shall permit invalidate insurance policy tenant request landlord shall provide tenant certificate evidence insurance c payment premium subject section tenant shall pay premium insurance policy describe paragraph b obtain landlord tenant day tenant receipt copy premium statement evidence landlord shall pay premium nonprimary comprehensive public liability insurance landlord elect obtain provide paragraph insurance policy maintain landlord cover improvement real property property landlord shall deliver tenant statement premium applicable property show reasonable detail tenant share premium compute lease term expire expiration insurance policy maintain landlord tenant shall liable tenant prorate share insurance premium commencement date tenant shall deliver landlord copy policy insurance tenant require maintain section thirty day prior expiration policy tenant shall deliver landlord renewal policy alternative provide policy insurance tenant shall right provide landlord certificate insurance execute authorized officer insurance company show insurance tenant require maintain section force effect contain information landlord reasonably require general insurance provision insurance tenant require maintain lease shall include provision require insurance carrier landlord thirty day write notice prior cancellation modification coverage ii tenant fail deliver policy certificate renewal landlord require lease prescribed time period policy cancel modify lease term landlord consent landlord obtain insurance case tenant shall reimburse landlord cost insurance day receipt statement indicate cost insurance iii landlord tenant shall maintain insurance require lease company hold general policy rating well set forth current issue good key rating guide landlord tenant acknowledge insurance market rapidly change insurance form amount describe section available future tenant acknowledge insurance describe section primary benefit landlord time lease term tenant landlord unable maintain insurance require lease landlord tenant shall maintain insurance coverage customary commercially reasonable insurance industry tenant type business coverage change time time landlord make representation adequacy insurance protect landlord tenant interest tenant shall obtain additional property liability insurance tenant deem necessary protect landlord tenant iv landlord tenant waive right recovery officer employee agent representative loss damage property property control loss damage cover insurance policy force describe lease time loss damage obtain require policy insurance landlord tenant shall notice insurance carrier mutual waiver subrogation landlord tenant insurance policy describe section shall contain provision waive carrier right subrogation section late charge tenant failure pay rent promptly cause landlord incur unanticipated cost exact cost impractical extremely difficult ascertain cost include limited processing accounting charge late charge impose landlord ground lease mortgage trust deed encumber property landlord receive rent payment day provide landlord give tenant hour write notice tenant fail pay base rent fortyeight hour shall run concurrently day period tenant shall pay landlord late charge equal percent overdue party agree late charge represent fair reasonable estimate cost landlord incur reason late payment section interest past obligation owe party hereunder pay shall bear interest rate percent annum date interest shall payable late charge pay tenant lease payment interest amount shall excuse cure default lease interest rate specify lease high rate permit law interest rate decrease maximum legal interest rate permit law section impound insurance premium real property taxis tenant day late payment base rent twice consecutive month period tenant shall pay landlord sum equal onetwelfth annual real property taxis insurance premium payable tenant lease payment base rent landlord shall hold payment noninterest bear impound account unknown landlord shall reasonably estimate real property taxis insurance premium tenant shall pay deficiency fund impound account landlord write request tenant default lease landlord apply fund impound account obligation lease article use property section permit use tenant use property permit use set forth section section manner use tenant shall cause permit property way constitute violation law ordinance governmental regulation order annoy interfere right tenant landlord constitute nuisance waste tenant shall obtain pay permit include certificate occupancy require tenant occupancy property shall promptly action necessary comply applicable statute ordinance rule regulation order requirement regulate use tenant property include occupational safety health act addendum section section intentionally delete addendum section section sign auction tenant shall place sign property landlord prior write consent tenant shall conduct permit auction sheriff sale property addendum section section indemnity tenant shall indemnify landlord hold landlord harmless cost claim liability arise tenant use property b conduct tenant business permit tenant property c breach default performance tenant obligation lease misrepresentation breach warranty tenant lease e act omission tenant tenant shall defend landlord cost claim liability tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost incur landlord connection claim material consideration landlord tenant assume risk damage property injury person property arising cause tenant waif claim respect thereof landlord claim arise landlord landlord employee agent contractor active negligence willful misconduct section term tenant shall include tenant employee agent contractor invite applicable addendum section section landlord access landlord agent enter property reasonable time property potential buyer investor tenant party act inspect conduct test order monitor tenant compliance applicable environmental law law govern presence use hazardous material purpose landlord deem necessary landlord shall tenant hour prior notice entry case emergency landlord agree allow representative tenant accompany landlord agree comply tenant reasonable security measure landlord place customary sale lease sign property section quiet possession tenant pay rent complie term lease tenant occupy enjoy property lease term subject provision lease article condition property maintenance repair alteration section exist condition subject provision lease tenant accept property condition execution lease subject record matter law ordinance governmental regulation order provide tenant acknowledge landlord agent landlord representation condition property suitability property tenant intend use tenant represent warrant tenant inspection inquiry condition property rely representation landlord broker respect thereto landlord landlords broker provide property information sheet disclosure statement property copy attach exhibit lease section exemption landlord liability landlord shall liable damage injury person business loss income therefrom good ware merchandise property tenant tenant employee invite customer person property damage injury cause result fire steam electricity water gas rain b breakage leakage obstruction defect pipe sprinkler wire appliance plumb air conditioning lighting fixture cause c condition arise property source place act omission tenant landlord landlord shall liable damage injury cause mean repair damage injury accessible tenant provision section shall exempt landlord liability landlord landlord employee agent contractor active negligence willful misconduct section landlord obligation addendum section section tenant obligation provide section article seven damage destruction article condemnation tenant shall portion property include structural nonstructural interior exterior landscape area portion system equipment good order condition repair include interior repainting refinish need portion property system equipment property tenant obligate repair fully repair restore tenant shall promptly replace portion property system equipment property regardless benefit replacement extend lease term benefit useful life replacement extend lease term term extend exercise option useful life replacement shall prorate remaining portion lease term extend tenant shall liable portion cost applicable lease term extend tenant shall maintain preventive maintenance contract provide regular inspection maintenance heating air conditioning system license heating air conditioning contractor subject provision section div property damage act omission tenant tenant shall pay landlord cost repair replace damage property landlord obligate pay cost maintaining repair property intention landlord tenant times tenant shall maintain portion property tenant obligate maintain attractive firstclass fully operative condition b tenant shall fulfill tenant obligation section tenant sole expense tenant fails maintain repair replace property require section reasonable effort landlord day prior notice tenant notice shall require case emergency enter property perform maintenance repair include replacement need behalf tenant case tenant shall reimburse landlord cost incur perform maintenance repair immediately demand section alteration addition improvement tenant shall alteration addition improvement property landlord prior write consent shall unreasonably withhold nonstructural alteration exceed thousand dollar cost project visible outside build property landlord require tenant provide demolition andor lien completion bond form satisfactory landlord tenant shall promptly remove alteration addition improvement construct violation paragraph landlord write request alteration addition improvement shall good workmanlike manner conformity applicable law regulation contractor approve landlord shall unreasonably withhold completion work tenant shall provide landlord build plan copy construction contract proof payment labor materials b tenant shall pay claim labor material furnish tenant group property tenant shall landlord day prior write notice commencement work property regardless landlord consent work require landlord elect record post notice nonresponsibility property section condition termination termination lease tenant shall surrender property landlord broom clean condition receive ordinary wear tear tenant obligate remedy provision lease tenant shall obligate repair damage landlord require repair accordance lease addition landlord require tenant remove alteration addition improvement landlord consent prior expiration lease restore property prior condition tenant expense alteration addition improvement landlord require tenant remove shall landlord property shall surrender landlord expiration early termination lease tenant remove tenant machinery equipment remove material damage property tenant shall repair tenant expense damage property cause removal machinery equipment event shall tenant remove follow material equipment shall deem landlord property landlord prior write consent power wiring power panel light lighting fixture wall covering drape blind window covering carpet floor covering heater air conditioner heat air conditioning equipment fence security gate similar building operating equipment decoration addendum section article seven damage destruction section partial damage property tenant shall notify landlord write immediately occurrence damage property property partially damage ie percent property untenantable result damage percent tenant operation materially impair proceed receive landlord insurance policy describe paragraph b sufficient pay necessary repair lease shall remain effect landlord shall repair damage soon reasonably possible landlord elect require repair damage tenant fixture equipment improvement b landlord maintain insurance require maintain paragraph b insurance proceed receive landlord sufficient pay entire cost repair ii cause damage cover insurance policy iii holder mortgage property shall require insurance proceed portion thereof retire mortgage debt landlord elect repair damage soon reasonably possible case lease shall remain force effect ii terminate lease date damage occur landlord shall notify tenant thirty day receipt notice occurrence damage landlord elect repair damage terminate lease landlord elect repair damage tenant shall pay landlord deductible landlord insurance policy damage act omission tenant tenant employee agent contractor invite difference actual cost repair insurance proceed receive landlord landlord elect terminate lease tenant elect continue lease force effect case tenant shall repair damage property building property locate tenant shall pay cost repair satisfactory completion repair landlord shall deliver tenant insurance proceed receive landlord damage repair tenant tenant shall landlord write notice election day receive landlord termination notice c damage property occur month lease term damage require thirty day repair landlord tenant elect terminate lease date damage occur regardless sufficiency insurance proceed party elect terminate lease shall write notification party election thirty day tenant notice landlord occurrence damage section substantial total destruction property substantially totally destroy cause whatsoever ie damage property great partial damage describe section regardless landlord receive insurance proceed lease shall terminate later date destruction occur ii date tenant cease business property notwithstanding precede sentence property rebuild month date destruction landlord elect rebuild property landlord expense case lease shall remain force effect landlord shall notify tenant election thirty day tenant notice occurrence total substantial destruction landlord elect landlord shall rebuild property landlord sole expense destruction cause act omission tenant tenant shall pay landlord difference actual cost rebuilding insurance proceed receive landlord section temporary reduction rent property destroy damage landlord tenant repair restore property pursuant provision article seven rent payable period damage repair andor restoration shall reduce according degree tenant use property impair possible reduction base rent insurance premium real property taxis tenant shall entitled compensation reduction reimbursement landlord result damage destruction repair restoration property section waiver tenant waif protection statute code judicial decision grant tenant right terminate lease event substantial total destruction lease property tenant agree provision section shall govern right obligation landlord tenant event substantial total destruction property article condemnation portion property take power eminent domain sell threat power call condemnation lease shall terminate take sell date condemn authority take title possession whichever occur percent floor area build property locate locate property take landlord tenant terminate lease date condemn authority take title possession deliver write notice day receipt write notice take absence notice day condemn authority take title possession landlord tenant terminate lease lease shall remain effect portion property take base rent additional rent shall reduce proportion reduction floor area property condemnation award payment shall distribute follow order ground lessor mortgagee beneficiary dee trust encumber property interest property b second tenant award specifically designate loss damage tenant trade fixture removable persona property c landlord remainder award compensation reduction value leasehold taking fee lease terminate landlord shall repair damage property cause condemnation landlord shall obligate repair damage tenant reimburse condemn authority severance damage receive landlord sufficient pay repair landlord shall right terminate lease repair landlord expense article assignment subletting section landlord consent require portion property tenant interest lease acquire person entity sale assignment mortgage sublease transfer operation law act tenant landlord prior write consent provide section landlord right grant withhold consent provide section attempt transfer consent shall void shall constitute noncurable breach lease section tenant affiliate addendum section section release tenant transfer permit article landlord consent shall release tenant change tenant primary liability pay rent perform obligation tenant lease landlords acceptance rent person waiver provision article consent transfer consent subsequent transfer tenant transferee defaults lease landlord proceed directly tenant pursue remedy transferee landlord consent subsequent assignment modification lease tenant transferee notify tenant obtain consent action shall relieve tenant liability lease section offer terminate tenant desire assign lease sublease property landlord elect write terminate lease pursuant section lease shall terminate commencement date new lease landlord propose assignee subtenant term provision lease govern termination shall apply landlord elect lease shall continue effect terminate provision section respect propose transfer shall continue apply section landlord consent tenant request consent transfer describe section shall set forth write detail propose transfer include business financial condition prospective transferee financial detail propose transfer eg term rent security deposit payable propose assignment sublease information landlord reasonably deem relevant landlord shall right elect terminate lease withhold consent reasonable grant consent base follow factor business propose assignee subtenant propose use property ii net worth financial reputation propose assignee subtenant iii tenant compliance obligation lease landlord object propose assignment solely net worth andor financial reputation propose assignee tenant nonetheless sublease assign portion property propose transferee term propose transfer b tenant assign sublease follow shall apply tenant assign sublease square foot property aggregate tenant shall pay landlord additional rent lease landlord share state section profit define transaction receive tenant landlord give write notice tenant assignee subtenant landlord share shall pay assignee subtenant landlord directly profit mean amount pay tenant assignment sublease include key money monthly rent excess monthly rent payable lease fee consideration pay assignment sublease include fee collateral agreement b cost expense directly incur tenant connection execution performance assignment sublease real estate broker commission cost renovation construction tenant improvement require assignment sublease tenant entitle recover cost expense tenant obligate pay landlord share landlord profit case sublease property rent allocable sublease space percentage square footage basis ii tenant shall provide landlord write statement certify amount pay assignment sublease property thirty day transaction documentation sign landlord inspect tenant relevant book record verify accuracy statement write request tenant shall promptly furnish landlord copy transaction documentation shall certify tenant complete true correct landlord receipt landlord share shall consent assignment sublet breach tenant obligation paragraph b shall material default lease section merger merger shall result tenant sublease property article tenant surrender lease termination lease manner event landlord terminate subtenancie succeed interest tenant sublandlord subtenancie article default remedy section covenant condition tenant performance obligation lease condition covenant tenant right continue possession property condition tenant performance time essence performance covenant condition section default tenant shall material default lease tenant fail pay rent abandon property tenant vacation property result cancellation insurance describe section b tenant fail pay rent charge day receipt bill statement landlord c tenant fails perform tenant nonmonetary obligation lease period thirty day write notice landlord provide thirty day require complete performance tenant shall default tenant commence performance thirty day period diligently pursue completion notice require paragraph intended satisfy notice requirement impose law landlord addition requirement tenant make general assignment general arrangement benefit creditor ii petition adjudication bankruptcy reorganization rearrangement file tenant dismiss thirty day iii trustee receiver appoint possession substantially tenant asset locate property tenant interest lease possession restore tenant thirty day iv substantially tenant asset locate property tenant interest lease subject attachment execution judicial seizure discharge thirty day court competent jurisdiction determines act describe subparagraph default lease trustee appoint possession tenant remain debtor possession trustee tenant transfer tenant interest hereunder landlord shall receive additional rent excess rent consideration pay connection assignment sublease rent payable tenant lease e guarantor lease revoke terminate purport revoke terminate guaranty portion tenant obligation lease expressly provide guaranty lease revocable section remedy occurrence material default tenant landlord time follow day write notice demand form day notice pay rent quit time run concurrently therewith limit landlord exercise right remedy landlord terminate tenant right possession property lawful mean case lease shall terminate tenant shall immediately surrender possession property landlord tenant shall serve demand payment past rent charge payment render cure default tenant shall cashier check event landlord shall entitle recover tenant damage incur landlord reason tenant default include worth time award unpaid base rent additional rent charge landlord earn time termination ii worth time award unpaid base rent additional rent charge landlord earn termination time award exceed rental loss tenant prove landlord reasonably avoid iii worth time award unpaid base rent additional rent charge tenant pay balance lease term time award exceed rental loss tenant prove landlord reasonably avoid iv necessary compensate landlord detriment proximately cause tenant failure perform obligation lease ordinary course thing likely result therefrom include limited cost expense landlord incur maintain preserve property default cost recover possession property expense relette include necessary renovation alteration property landlord reasonable attorney fee incur connection therewith real estate commission pay payable subpart ii worth time award compute allow interest unpaid amount rate percent annum less maximum lawful rate subpart iii worth time award compute discount discount rate federal reserve bank san francisco time award plus percent tenant abandon property landlord shall option retake possession property recover tenant specify paragraph andor ii proceeding paragraph b b maintain tenant right possession case lease shall continue effect tenant abandon property event landlord shall entitle enforce landlord right remedy lease include right recover rent landlord shall remedy describe california civil code section lessor continue lease effect lessee breach abandonment recover rent lessee right sublet assign subject reasonable limitation c pursue remedy available landlord law judicial decision state property locate section intentionally delete section automatic termination notwithstanding term provision hereof contrary lease shall terminate occurrence act affirm landlords intention terminate lease provide section hereof include file unlawful detainer action tenant termination landlord damage default shall include cost fee include reasonable attorney fee landlord incur connection filing commencement pursue andor defend action bankruptcy court court respect lease obtain relief stay bankruptcy restrain action evict tenant pursue action respect landlord right possession property damage suffer apart base rent rent payable hereunder shall constitute pecuniary damage reimburse landlord prior assumption lease tenant successor tenant bankruptcy proceeding section cumulative remedy landlord exercise right remedy shall prevent exercise right remedy section addendum article protection lender section subordination landlord shall right subordinate lease ground lease deed trust mortgage encumber property advance security thereof renewal modification consolidation replacement extension thereof recorded tenant shall cooperate landlord lender acquire security interest property lease tenant shall execute document assurance lender require form attach hereto exhibit b form require landlord lender provide agreement contain nondisturbance agreement favor tenant provide tenant obligation lease shall increase material way performance ministerial act shall deem material tenant shall deprive right lease tenant right quiet possession property lease term shall distribute tenant pay rent perform tenant obligation lease default ground lessor beneficiary mortgagee elect lease prior lien ground lease deed trust mortgage give write notice thereof tenant lease shall deem prior ground lease deed trust mortgage lease date prior subsequent date say ground lease deed trust mortgage date recording thereof addendum section section attornment landlord interest property acquire ground lessor beneficiary dee trust mortgagee purchaser foreclosure sale tenant shall attorn transferee successor landlords interest property recognize transferee successor landlord lease tenant waive protection current future statute rule law give purport tenant right terminate lease surrender possession property transfer landlord interest section sign document tenant shall sign deliver instrument document necessary appropriate evidence attornment subordination agreement provide agreement include nondisturbance provision favor tenant tenant fail day write request tenant make constitute irrevocably appoint landlord transferee successor landlord attorneyinfact tenant execute deliver instrument document long instrument complie provision article section estoppel certificate landlord write request tenant shall execute acknowledge deliver landlord write statement form attach hereto exhibit c form require landlord lender certify term provision lease change change state change ii lease cancel terminate iii date payment base rent charge time period cover payment iv landlord default lease landlord claim default state v representation information respect tenant lease landlord reasonably request prospective purchaser encumbrancer property require tenant shall deliver statement landlord day landlord request landlord statement tenant prospective purchaser encumbrancer property purchaser encumbrancer rely conclusively statement true correct b tenant deliver statement landlord day period landlord prospective purchaser encumbrancer conclusively presume rely follow fact term provision lease change represent landlord ii lease cancel terminate represent landlord iii month base rent charge pay advance iv landlord default lease event tenant shall estop deny truth fact section tenant financial condition day write request landlord tenant shall deliver landlord tenant exist financial statement verify net worth tenant assignee subtenant guarantor tenant addition tenant shall deliver lender designate landlord financial statement require lender facilitate financing refinance property tenant represent warrant landlord financial statement true accurate statement date statement financial statement shall confidential shall purpose set forth lease article legal cost section legal proceeding tenant landlord shall breach default lease party default party shall reimburse party nondefaulte party demand cost expense nondefaulte party incur connection breach default default party lease suit commence judgment enter cost shall include legal fee cost incur negotiation settlement enforcement right furthermore action breach enforce provision lease commenced court action shall award party favor judgment enter reasonable sum attorney fee cost lose party action shall pay attorney fee cost tenant shall indemnify landlord hold landlord harmless cost expense demand liability landlord incur landlord party claim action institute tenant party party tenant person hold interest property license agreement tenant b foreclosure lien labor material furnish tenant group c arise result act transaction tenant group necessary protect landlord interest lease bankruptcy proceeding proceeding title united states code amend tenant shall defend landlord claim action tenant expense counsel reasonably acceptable landlord landlord election tenant shall reimburse landlord legal fee cost landlord reasonably incur claim action section landlord consent tenant shall pay landlord reasonable attorney fee incur connection tenant request landlord consent article assignment sublet connection act tenant propose require landlord consent article thirteen miscellaneous provision section nondiscrimination tenant promise condition continuance lease discrimination segregation person group person basis race color sex creed national origin ancestry lease sublease transfer occupancy tenure use property portion thereof section landlord liability certain duty lease term landlord mean current owner owner fee title property leasehold estate ground lease property time question landlord obligate perform obligation landlord lease time landlord own interest title landlord transfer title interest relieve liability respect obligation landlord lease perform date transfer provide transferee assume landlord obligation date transfer landlord shall deliver transferee fund tenant previously pay fund apply term lease b tenant shall write notice failure landlord perform obligation lease landlord ground lessor mortgagee beneficiary dee trust encumber property address furnish tenant write landlord shall default lease landlord ground lessor mortgagee beneficiary fail cure nonperformance thirty day receipt tenant notice nonperformance reasonably require thirty day cure landlord shall default cure commence thirty day period diligently pursue completion c notwithstanding term provision contrary liability landlord performance duty obligation lease limited landlord interest property landlord partner shareholder officer principal shall personal liability lease section severability determination court competent jurisdiction provision lease thereof illegal unenforceable shall cancel invalidate remainder provision lease shall remain force effect section interpretation caption article section lease assist party read lease term provision lease require context lease singular shall include plural plural shall include singular masculine feminine neuter gender shall include provision relate conduct act omission tenant term tenant shall include tenant agent employee contractor invite successor property tenant express imply permission section incorporation prior agreement modification lease agreement party pertain lease property agreement effective amendment lease shall write sign party attempt amendment shall void section notice notice require permit lease shall writing shall personally deliver send national overnight carrier certify mail return receipt request postage prepay notice tenant shall deliver address specify section notice landlord shall deliver address specify section notice shall effective delivery party change notice address write notice party section waiver waiver write sign waive party landlord failure enforce provision lease acceptance rent shall waiver shall prevent landlord enforce provision provision lease future statement payment check tenant letter accompany payment check shall bind landlord landlord notice tenant negotiate check bind condition statement section recordation tenant shall record lease prior write consent landlord landlord tenant require short form memorandum lease execute party record party require recording shall pay transfer taxis recording fee section bind effect choice law lease bind party legally acquire right interest lease landlord tenant landlord shall obligation tenant successor right interest tenant successor acquire accordance term lease law state property locate shall govern lease section corporate authority partnership authority tenant corporation corporation represent warrant person sign lease behalf tenant authority lease bind corporation thirty day lease sign tenant shall deliver landlord certify copy resolution tenant board director authorize execution lease evidence authority reasonably acceptable landlord tenant partnership person entity sign lease tenant represent warrant general partner partnership authority sign partnership lease bind partnership general partner partnership tenant shall write notice landlord general partner withdrawal addition thirty day lease sign tenant shall deliver landlord copy tenant record statement partnership certificate limited partnership section joint liability section addendum section section execution lease lease execute counterpart counterpart document execute counterpart shall constitute single bind instrument landlord delivery lease tenant shall deem offer lease shall bind party execute deliver party section survival representation warranty landlord tenant shall survive termination lease article fourteen broker section broker fee lease signed deliver landlord tenant landlord shall pay real estate commission landlords broker name section provide write agreement landlord landlords broker sum state section service render landlord landlords broker transaction landlord shall pay landlords broker commission tenant exercise option extend lease term buy property similar option right landlord grant tenant landlord broker procure cause lease sale enter landlord tenant cover property commission shall set forth landlord broker commission schedule effect execution lease tenant broker name section landlords broker shall pay appropriate portion commission tenant broker provide agreement landlord broker tenant broker contain lease shall impose obligation landlord pay commission fee party landlords broker section protection broker landlord sell property assign landlord interest lease buyer assignee shall accept conveyance property assignment lease conclusively deem agree payment landlord broker require landlord article fourteen landlord broker shall right bring legal action enforce declare right provision prevail party action shall entitle reasonable attorney fee pay lose party attorney fee shall fix court action paragraph include lease benefit landlords broker section broker disclosure agency landlords broker disclose landlord tenant landlord tenant consent landlords broker act transaction agent check cid landlord exclusively cid landlord tenant section broker tenant represent warrant landlord broker name section agent broker finder party tenant deal entitle commission fee respect lease property additional provision set forth rider rider attach hereto blank space additional provison insert draw line space landlord tenant sign lease place date specify adjacent signature initial rider attach incorporate reference lease landlord igne majesticmapa property llc california limited liability company majestic realty co majestic realty co california corporation california corporation manager edward p roski jr david wheeler executive vice president david wheeler edward p roski jr president tenant sign gilead sciences inc delaware corporation crispin gs eley vp pharmaceutical operation anthony caracciolo vp manufacture real estate transaction recommend consult professional civil engineer industrial hygienist person experience evaluate condition property include possible presence asbestos hazardous material underground storage tank print form lease draft legal counsel direction southern california chapter society industrial office realtor inc representation recommendation southern california chapter society industrial office realtor inc legal counsel real estate broker name employee agent legal sufficiency legal effect tax consequence lease transaction landlord tenant retain legal counsel advise matter rely advice legal counsel addendum industrial real estate lease addendum addendum enter majesticmapa property llc california limited liability company majestic realty co california corporation collectively landlord gilead sciences inc delaware corporation tenant date date set forth section industrial real estate lease landlord tenant lease addendum attach promise covenant agreement declaration set forth intend shall force effect set forth length body lease extent provision addendum inconsistent term condition lease term condition addendum shall control section base rent commence twentyfifth th lease month term define continue thirtysixth th lease month monthly base rent shall equal twentyfour thousand fiftysix dollar commencing thirtyseventh th lease month continue sixtieth th lease month monthly base rent shall equal twentyfive thousand seven twentyeight dollar term lease month shall mean consecutive month lease term lease month commencing lease commencement date section manner use section amend add follow end thereof tenant shall suffer property way conflict law statute ordinance governmental rule regulation requirement force enact promulgate collectively applicable law tenant shall sole cost expense promptly comply applicable law relate tenant specific use property ii alteration tenant improvement trigger alteration tenant improvement tenant standard regulation impose landlord tenant state federal local governmental body charge establishment regulation enforcement occupational health safety standard employer employee landlord tenant landlord tenant applicable agree sole cost expense comply promptly standard regulation judgment court competent jurisdiction admission tenant judicial action regardless landlord party thereto tenant violated say governmental measure shall conclusive fact landlord tenant landlord shall comply applicable law relate property lease commencement date compliance applicable law require governmental agency provide compliance applicable law responsibility tenant lease provide landlord failure comply therewith unreasonably materially affect safety tenant employee create significant health hazard tenant employee section hazardous material definition hazardous material mean substance solid liquid gaseous nature presence require investigation remediation federal state local statute regulation ordinance order action policy common law ii define hazardous waste hazardous substance pollutant contaminant federal state local statute regulation rule ordinance west covina blvd san dimas september gilead sciences inc amendment thereto include limitation comprehensive environmental response compensation liability act usc section et seq andor resource conservation recovery act usc section et seq hazardous material transportation act usc section et seq federal water pollution control act usc section et seq clean air act usc section et seq toxic substance control act amend usc section et seq occupational safety health act usc section et seq law amend supplement iii toxic explosive corrosive flammable infectious radioactive carcinogenic mutagenic hazardous regulated governmental authority agency department commission board agency instrumentality united states state california political subdivision thereof iv presence property cause threaten cause nuisance property adjacent property pose threatens pose hazard health safety person property v presence adjacent property constitute trespass tenant vi limitation contain gasoline diesel fuel petroleum hydrocarbon vii limitation contain polychlorinated biphenyls pcb asbestos urea formaldehyde foam insulation viii limitation contain radon gas b environmental requirement mean applicable present future statute regulation rule ordinance code license permit order approval plan authorization concession franchise similar item include limited pertaining report licensing permit investigation remediation governmental agencies ii applicable judicial administrative regulatory decree judgment order relate protection human health environment include limitation requirement pertain emission discharge release threaten release hazardous material chemical substance air surface water groundwater land relate manufacture processing distribution use treatment storage disposal transport handle hazardous material chemical substance c environmental damage mean claim judgment damage loss penaltie fine liability include strict liability encumbrance lien cost expense include expense investigation defense claim claim ultimately defeat good faith settlement judgment arise claim kind nature contingent mature unmatured foreseeable unforeseeable include limitation reasonable attorney fee disbursement consultant fee incur time result existence hazardous material beneath property migrating threaten migrate property existence violation environmental requirement pertain property activity thereon regardless existence hazardous material violation environmental requirement arise prior present ownership operation property environmental damage include limitation damage personal injury injury property natural resource occur property include limitation lose profit consequential damage cost demolition rebuilding improvement real property interest penalty damage arise claim bring behalf employee tenant respect tenant waif right raise defense landlord immunity entitle industrial worker compensation law ii fee cost expense incur service attorney consultant contractor expert laboratory cost incur connection investigation remediation hazardous material violation environmental requirement include limited preparation feasibility study report performance cleanup remediation removal response abatement containment closure restoration monitoring work require governmental agency reasonably necessary economic use property property manner consistent current use expend connection condition include limitation attorney fee cost expense incur enforce provision lease collect sum hereunder iii liability person governmental agency indemnify person governmental agency cost expend connection item reference subparagraph ii iv diminution fair market value property include limitation reduction fair market rental value life expectancy property improvement locate thereon restriction use adverse impact marketing property portion thereof governmental agency mean governmental agency department commission board bureaus instrumentality united states state county citie political subdivision thereof e tenant group mean tenant tenant successor assignee guarantor officer director agent employee invitees permitee party supervision control tenant enter property term lease permission knowledge tenant landlord agent employee prohibition normal quantity general office supply specify exhibit attach hereto tenant shall cause permit suffer hazardous material bring treat keep store dispose discharged release produce manufacture generate refine beneath property tenant group person prior write consent landlord time time term lease tenant request landlord approval tenant use hazardous material approval withheld landlord sole discretion tenant shall prior commencement date provide landlord hazardous material describe exhibit description handle storage use disposal procedure b community right know plan disclosures andor emergency response plan tenant require supply local governmental agency pursuant environmental requirement b tenant shall cause permit suffer existence commission tenant group person violation environmental requirement beneath property c tenant shall create suffer exist permit tenant group create suffer exist lien security interest charge encumbrance kind respect property include limitation lien impose pursuant section f superfund amendments reauthorization act usc section similar state statute tenant shall install operate maintain grade tank sump pit pond lagoon storage treatment vessel device property landlord prior write consent indemnity tenant successor assign guarantor agree indemnify defend reimburse hold harmless landlord ii person acquire portion property manner include purchase foreclosure sale entitle exercise right remedy landlord lease iii director officers shareholder employee partner agent contractor subcontractor expert licensee affiliate lessee mortgagee trustee heir devisee successor assign invitee person environmental damage exist result activity negligence tenant group exist result breach warranty covenant inaccuracy representation tenant contain lease tenant remediation property failure meet obligation contain lease b obligation contain section shall include limited burden expense defend claim suit administrative proceeding claim suit proceeding groundless false fraudulent conducting negotiation description pay discharge judgment penalty sum indemnify person landlord sole expense employ additional counsel choice associate counsel represent tenant c landlord shall right obligation join participate control elect legal proceeding action initiate connection tenant hazardous material activity landlord negotiate defend approve appeal action take issue applicable governmental authority regard contamination property hazardous material obligation tenant paragraph shall survive expiration termination lease e obligation tenant paragraph shall affect investigation behalf landlord information landlord obtain respect thereto obligation remediate addition obligation tenant indemnify landlord pursuant lease tenant shall approval demand landlord sole cost expense contractor approve landlord promptly action remediate property require governmental agency reasonably necessary mitigate environmental damage allow economic use property remediation necessitate presence beneath property time termination lease hazardous material violation environmental requirement exist result activity negligence tenant group action shall include limited investigation environmental condition property preparation feasibility study report remedial plan performance cleanup remediation containment operation maintenance monitoring restoration work property shall perform manner approve landlord tenant shall action necessary restore property condition exist prior tenant group introduction hazardous material beneath property notwithstanding less standard remediation allowable applicable law governmental policy right inspect landlord shall right sole absolute discretion duty enter conduct inspection property include invasive test reasonable time determine tenant comply term lease include limited compliance property activity thereon environmental requirement existence environmental damage result condition property surround property activity thereon landlord shall right duty retain independent professional consultant consultant enter property conduct inspection review report prepared tenant concern compliance cost consultant shall pay landlord investigation disclose violation environmental requirement tenant group existence hazardous material property property cause activity negligence tenant group hazardous material compliance environmental requirement previously approve landlord case tenant shall pay cost consultant tenant grant landlord agent employee consultant contractor landlord right enter property perform test property reasonably necessary conduct review investigation landlord shall use commercially reasonable effort minimize interference business tenant notification tenant shall aware receive notice communication concern actual allege suspect threatened violation environmental requirement liability tenant environmental damage connection property pastor present activity person thereon include limited notice communication concern actual threaten investigation inquiry lawsuit claim citation directive summon proceeding complaint notice order writ injunction relate tenant shall deliver landlord day receipt notice communication tenant write description say violation liability actual threaten event condition copy document evidence receipt notice shall deem create obligation landlord defend respond notification request landlord tenant shall disclose landlord name amount hazardous material general office supply refer section addendum generate treat handle store disposed property tenant intend use generate treat handle store dispose property foregoing way shall limit necessity tenant obtain landlord consent pursuant section addendum surrender property ninety day prior expiration termination lease term ninety day tenant fully surrender possession property landlord environmental assessment property perform accordance section addendum tenant shall perform sole cost expense cleanup remedial work recommend consultant necessary remove mitigate remediate hazardous material andor contamination property cause activity negligence tenant group assignment sublet event lease provide tenant assign lease sublet property subject landlord consent andor certain condition propose assignee sublessee activity property involve use handle storage disposal hazardous material general office supply tenant quantity process similar tenant use compliance addendum shall reasonable landlord withhold consent assignment sublease light risk contamination pose activity andor ii landlord impose additional condition assignment sublease require tenant reasonably establish assignee sublessee activity pose materially great risk contamination property tenant permit activity view quantitie toxicity property hazardous material assignee sublessee b precaution release hazardous material assignee sublessee agree implement c assignees sublessee financial condition relate ability fund major cleanup assignee sublessee policy historical record respecting willingness respond clean release hazardous material survival hazardous material obligation tenant breach covenant obligation addendum shall constitute material default lease obligation tenant addendum shall survive expiration early termination lease limitation shall constitute obligation independent severable tenant covenant obligation pay rent lease landlord hazardous material obligation landlord shall solely responsible remediate claim judgment damage penaltie fine cost liability loss arise result contamination directly arise introduction hazardous material property landlord agent employee contractor compliance applicable law notwithstanding forego landlord shall responsible liable consequential damage obligation landlord section shall survive expiration termination lease section sign notwithstanding forego subject landlord prior write approval shall unreasonably withhold delay condition provide sign keep quality design style industrial park property locate tenant sole cost expense install identification signage limit monument sign monument sign property building sign build sign street frontage collectively sign property provide size color location material design sign shall subject landlord prior write consent shall unreasonably withhold delay condition ii sign shall comply applicable governmental rule regulation propertys covenant condition restriction iii sign shall personal original tenant name section lease assignee sublessee transferee tenant interest lease original tenant iv building sign shall paint directly build attach place roof build v sign shall advertise gilead sciences pharmaceutical business vi consistent landlord signage program rule vii tenant continue signage right shall contingent original tenant actually occupy entire property viii tenant continue signage right shall contingent tenant maintain sign firstclass condition tenant shall responsible cost incur connection design construction installation repair maintenance tenant sign expiration early termination lease tenant shall cause tenant sign remove shall repair damage cause removal sign notice logo picture name advertisement instal separately approve landlord remove landlord notice landlord tenant tenant sole cost expense section landlord indemnity landlord agree indemnify hold harmless tenant claim cost reasonable attorney fee liability incur direct result claim action proceed directly arise follow extent tenant action omission breach default performance obligation landlord hereunder ii active negligence willful misconduct landlord agents employee invite licensee contractor notwithstanding contrary set forth lease party agreement indemnify party set forth section shall ineffective extent matter party agree indemnify party cover insurance require carry nonindemnifye party pursuant lease tenant agreement indemnify landlord landlords agreement indemnify tenant pursuant section intend shall relieve insurance carrier obligation policy require carry pursuant provision lease extent policy cover carry cover matter subject party respective indemnification obligation shall supersede inconsistent agreement party set forth provision lease notwithstanding contrary contain lease lease shall impose obligation tenant landlord responsible liable release liability consequential damage consequential damage incur landlord connection holdover property tenant expiration early termination lease incur landlord connection contamination property property result presence use hazardous material cause permit tenant group incur landlord connection repair physical construction improvement work perform behalf tenant property party breach lease failure carry require insurance hereunder failure shall automatically deem covenant agreement fail party selfinsure require coverage waiver subrogation favor party section landlord obligation subject provision article seven damage destruction article condemnation damage cause act omission tenant tenant employee agent contractor invite result tenant alteration landlord shall structural portion build foundation roof structure exterior wall property good order condition repair landlord shall obligate maintain repair roof membrane window door plate glass surface wall landlord shall obligate repair section reasonable time receipt write notice tenant need repair tenant waif benefit present future law tenant right repair property landlord expense terminate lease condition property landlord assign tenant warranty guaranty contractor construct building tenant improvement locate property tenant waif claim landlord relate thereto section condition termination section amend add follow end thereof notwithstanding forego tenant request time seek landlord consent alteration addition improvement collectively alteration landlord state time grant approval removal require end lease term request shall specifically cite lease provision landlord obligation statement section tenant affiliate notwithstanding contrary contain section lease assignment sublet portion property affiliate tenant entity control control common control tenant corporation result merger consolidation acquisition tenant collectively tenant affiliate shall deem transfer section consent require provide tenant notifie landlord assignment sublease ii promptly supply landlord document information request landlord assignment sublease affiliate iii request landlord guaranty lease landlord standard guaranty form iv tenant affiliate assume tenant obligation lease v assignment sublease subterfuge tenant avoid obligation lease control shall mean ownership directly indirectly fiftyone percent vote security possession right vote ordinary direction affair fiftyone percent vote interest person entity instance tenant shall obligate pay landlord increase base rent describe section bi result profit derive tenant affiliate section arbitration general submittal arbitration submittal matter arbitration accordance term section sole exclusive method mean procedure resolve claim dispute disagreement arise lease include limited matter relate landlord failure approve assignment sublease transfer tenant interest lease term lease default landlord default tenant determination fair rental value determination shall pursuant option extend term lease rider attach lease ii claim party seek enforcement right lease include limitation claim constructive eviction b primarily found matter fraud willful misconduct bad faith allegation tortious action seek award punitive exemplary damage iii landlord exercise unlawful detainer right pursuant california law right remedy landlord gain possession property terminate tenant right possession property dispute relate thereto matter shall resolve suit file superior court los angeles county california decision court shall subject appeal pursuant applicable law iv claim restrain order injunctive relief party irrevocably waive right contrary shall time conduct strict complete timely accordance term section attempt circumvent term section shall absolutely null void force effect whatsoever matter submit arbitration respect payment money determine matter passage time constitute default lease passage time shall commence run affirmative arbitrate determination long simultaneously determined arbitration challenge matter potential default tenant landlord case good faith matter submit arbitration respect payment money determine matter passage time constitute default lease passage time shall commence run event party obligate payment fact payment party payment protest shall occur payment accompany good faith notice state reason party elect payment protest protest deem waive subject matter identify protest submit arbitration set forth section retire judge dispute arbitrate pursuant provision section shall determine bind arbitration retire judge superior court state california retired judge california court appeal arbitrator arbitration shall initiate party day party send write notice arbitration notice demand arbitrate register certify mail party arbitration notice shall contain description subject matter arbitration dispute respect thereto involve remedy determination seek party shall select retired judge superior court california california court appeal serve arbitrator party unable promptly agree identity arbitrator retired judge shall serve arbitrator shall select preside judge los angeles county superior court selection arbitrator party dispute shall resolve binding arbitration commercial arbitration rule american arbitration association effect arbitration procedure predecision action arbitrator shall schedule preheare conference resolve procedural matter arrange exchange information obtain stipulation narrow issue party submit propose discovery schedule arbitrator preheare conference scope duration discovery sole discretion arbitrator arbitrator shall discretion order preheare exchange information party include limitation production request document exchange summary testimony propose witness examination deposition party thirdparty witness discretion shall exercise favor discovery reasonable circumstance decision arbitration shall conduct los angeles california party represent counsel authorize representative rendering decision arbitrator shall determine right obligation party accord substantive procedural law california term provision lease arbitrator decision shall base evidence introduce hearing include logical reasonable inference therefrom arbitrator determination andor grant remedy relief equitable decision base accompany write statement decision explain factual legal basis decision principal controvert issue decision shall conclusive binding confirm judgment superior court state california subject challenge ground set forth california code civil procedure section validity enforceability arbitrator decision determine exclusively california court pursuant provision lease arbitrator award cost include limitation attorney fee expert witness cost prevail party determined arbitrator arbitrator discretion arbitrator fee cost shall pay nonprevaile party determine arbitrator arbitrator discretion party shall determine arbitrator prevail party proposal resolution dispute close adopt arbitrator section nondisturbance landlord shall use commercially reasonable effort provide tenant nondisturbance agreement form attach hereto exhibit b landlord presently exist lender section force majeure landlord tenant perform obligation event applicable party control respect obligation impose regard base rent additional rent charge pay tenant pursuant lease time provide perform obligation shall extend period time equal duration event event landlord tenant control include limited act god war civil commotion labor dispute strike fire flood casualty shortage labor material government regulation restriction waiting period obtain governmental permit approval weather condition article revenue expense accounting landlord tenant agree purpose include determination section internal revenue code rental income accrue landlord rental expense accrue tenant amount date rent payable lease article sixteen landscape maintenance notwithstanding provision section landlord shall maintain tenant expense landscaping property applicable common area maintenance shall include garden tree trim replacement repair landscape landscape irrigation system similar item maintenance shall include sweep clean asphalt concrete surface driveway parking area yard area load area pave covered surface connection landlord obligation article landlord enter contract landscape contractor landlord choice provide necessarily maintenance service list tenant monthly cost contract hereinafter refer landscape fee currently dollar landlord shall use commercially reasonable effort maintain competitive contract shall promptly notify tenant increase landscape fee tenant agree pay monthly landlord additional rent landscape fee tenant shall payment tenant monthly rental payment necessity notice landlord understand party landscape fee pertain routine landscape maintenance property landlord incur expense addition landscape fee shall include landlord overhead landlords administrative expense meet obligation set forth tenant shall pay landlord additional rent day demand cost additional expense article seventeen purchase option right refusal landlord grant original tenant set forth section lease original tenant tenant affiliate onetime right refusal purchase property accordance term article landlord agrees provide tenant default lease landlord shall deliver write notice tenant landlord refusal notice prior time landlord intends submit party accept party bona fide proposal purchase entire property purpose article party shall include party affiliate relate landlord landlord shall identify landlord refusal notice economic term landlord sell property tenant include limitation anticipate closing date purchase price pay property collectively economic term section procedure acceptance date seven day tenant receipt landlord refusal notice election day tenant shall deliver write notice landlord tenant election notice pursuant tenant shall onetime right elect purchase property economic term set forth refusal notice ii refuse purchase property tenant respond write landlord refusal notice election date tenant shall deem elect purchase property section tenant election purchase tenant elect deem elect purchase property tenant refusal right set forth article shall terminate respect property landlord shall right sell property landlord desire term landlord desire provide tenant send notice accordance section ii tenant right refusal arise landlord intend sell property purchase price percent purchase price set forth landlord refusal notice economic term materially favorable set forth landlord refusal notice section condition property tenant elect purchase property pursuant article landlord tenant shall promptly execute proper document necessary memorialize tenant purchase property term condition set forth article tenant purchase property pursuant term article tenant shall property asis condition specify economic term landlord refusal notice subject tenant review approval preliminary title report day receipt thereof section suspension right refusal tenant shall right purchase property provide article date attempt exercise right refusal tenant date escrow close tenant default lease applicable notice cure period addition notwithstanding contrary contain article right purchase property contain article shall personal original tenant tenant affiliate exercise original tenant assignee sublessee transferee tenant interest lease tenant affiliate time attempt exercise right refusal original tenant tenant affiliate occupy entire property section multiple building transaction notwithstanding contrary tenant right refusal shall apply shall include reit transactions ii property multiple property include package sale iii sale transfer property iv sale transfer party affiliate relate landlord section exchange accommodation landlord tenant agree cooperate landlord effectuate likekind exchange property pursuant section internal revenue code amend exchange include execution document relate thereto amendment industrial real estate lease amendment industrial real estate lease amendment enter march amendment date majesticmapa property llc california limited liability company landlord gilead sciences inc delaware corporation tenant r e c l tenant landlord enter certain industrial real estate lease lease date july landlord lease tenant tenant lease landlord approximately square foot space property commonly know west covina boulevard san dimas california b party desire amend lease term condition set forth amendment g r e e e n consideration forego recital mutual covenant contain good valuable consideration receipt sufficiency acknowledge party hereto agree follow term undefined term shall respective meaning give term lease expressly provide amendment lease term extend lease term lease term currently schedule expire lease expiration date amendment date lease term extend november revise lease expiration date soon terminate term lease amend amendment expire revise lease expiration date period time begin day follow lease expiration date continue revise lease expiration date extend lease term termination right tenant shall onetime right terminate lease amend effective december termination date provide landlord receive write notice termination notice tenant date month prior termination date state tenant intend terminate lease amend pursuant term condition section b concurrent landlord receipt termination notice landlord receive tenant sum fiftyfive thousand fiftyfour dollar consideration condition precedent early termination c tenant default lease amend date west covina blvd san dimas april gilead sciences inc tenant delivery termination notice termination date provide tenant terminate lease amend pursuant term section lease amend shall automatically terminate force effect termination date landlord tenant shall relieve respective obligation lease amend specifically include limitation right tenant audit review landlord book record contest tenant payment additional rent provide notwithstanding contrary contain lease amend respect obligation tenant lease amend accrue prior termination date satisfy tenant prior termination date eg tenant payment rent tenant maintenance repair obligation tenant obligation survive termination lease amend include limit tenant obligation remediate environmental damage landlord shall right remedy respect obligation set forth lease amend tenant shall vacate property pursuant lease amend surrender deliver exclusive possession thereof landlord termination date accordance provision lease amend event tenant retain possession property thereof termination date provision section lease amend shall apply right contain section shall personal tenant name summary assignee sublessee transferee tenant interest lease amend original tenant exercise original tenant original tenant occupy entire property rent base rent commence june continue tenant pay equal twentyfive thousand fortytwo dollar month base rent lease amend amendment commencing june continue revise lease expiration date tenant pay equal twentyeight thousand thirtysix dollar month base rent lease amend amendment security deposit termination advance payment section lease shall delete replace follow termination lease article seven damage destruction article condemnation termination result tenant default tenant vacate property manner require lease landlord shall day tenant deliver exclusive possession property landlord refund tenant tenant successor unused portion security deposit advance rent advance payment tenant landlord amount pay real property taxis reserve apply time period termination lease real estate taxis tenant shall set forth section lease pay real property taxis directly respective tax authority real property tax penalty section lease shall revise tenant shall responsible real property tax penalty extent penalty cause tenant act omission late charge effective commencement extend lease term late charge set forth section lease shall reduce percent landlord book record event tenant dispute statement statement deliver landlord month receipt statement tenant tenant shall right request receive landlord reasonable backup information landlord possession statement hazardous material effective commencement extend lease term follow revision shall section lease set forth section c lease shall delete replace follow landlord shall right obligation join participate control tenant commercially reasonable consent consent shall unreasonably withhold elect legal proceeding action initiate connection tenant hazardous material activity property landlord negotiate defend approve appeal action take issue applicable governmental authority regard contamination property hazardous material follow shall add end section e lease landlord shall provide tenant copy information report relate document landlord acquire thirty day completion receipt say report sentence section lease shall delete replace follow landlord shall right sole absolute discretion duty enter twentyfour hour notice notice require landlord reasonable belief tenant create environmental damage property conduct inspection property include invasive test regular operative hour determine tenant comply term lease include limited compliance property activity thereon environmental requirement existence environmental damage result condition property surround property activity thereon paragraph section lease shall delete replace follow tenant landlord shall aware receive notice communication concern actual allege suspect threatened violation environmental requirement liability tenant landlord environmental damage connection property past present activity person thereon include limited notice communication concern actual threaten investigation inquiry lawsuit claim citation directive summon proceeding complaint notice order writ injunction relate tenant landlord shall deliver party day receipt notice communication write description say violation liability actual threaten event condition copy document evidence receipt notice shall deem create obligation landlord defend respond notification follow shall add end section lease tenant shall right observe landlord environmental assessment section lease shall delete replace follow landlord shall solely responsible remediate claim judgment damage penaltie fine cost liability loss arise result contamination directly arise introduction hazardous material property prior tenant occupancy landlord agent employee contractor compliance applicable law notwithstanding forego landlord shall responsible liable consequential damage obligation landlord section shall survive expiration termination lease alteration addition improvement effective commencement extend lease term sentence section lease shall delete replace follow tenant shall alteration addition improvement property landlord prior write consent shall unreasonably withhold nonstructural alteration exceed thousand dollar cost project visible outside build property estoppel certificate effective commencement extend lease term follow shall add section c lease tenant write request landlord shall execute estoppel certificate certify landlord actual knowledge duty investigate lease modified ii lease cancel iii tenant default lease tenant financial condition effective commencement extend lease term follow shall add section lease original tenant monetary default lease landlord right request financial statement shall exceed time calendar year financial statement request landlord lender tenant acceptance property landlord tenant acknowledge tenant occupy property pursuant lease april tenant continue accept property presently exist condition landlord representation warranty regard condition property suitability thereof tenant business shall landlord obligate provide pay improvement work service relate improvement property deletion effective amendment date option extend term lease rider attach lease delete shall force effect broker party recognize broker involve negotiation amendment majestic realty co agree landlord shall solely responsible payment brokerage commission broker party represent warrant deal broker connection negotiation consummation amendment know real estate broker agent finder entitle commission compensation connection amendment party agree indemnify defend party hold party harmless claim demand loss liability damage lawsuit judgment cost expense include limitation reasonable attorney fee cost respect leasing commission equivalent compensation allege owe account indemnify party dealing real estate broker agent modification provide term provision lease shall remain force effect unmodified amendment bind effect provision amendment shall bind inure benefit heir representative successor permit assign party hereto authority party represent warrant requisite authority bind entity behalf sign counterpart amendment execute number original counterpart counterpart execute shall constitute original amendment counterpart shall constitute amendment signature witness whereof party enter amendment date set forth landlord tenant majesticmapa property llc gilead sciences inc california limited liability company delaware corporation majestic realty co anthony caracciolo california corporation manager david wheeler president mark l perry b jay h bradford ts e xecutive vice president operation executive vice president chief financial officer exhibit certain confidential information contain document mark bracket omit file separately security exchange commission pursuant rule b securities exchange act amend collaboration agreement gilead sciences inc gilead holdings llc bristolmyers squibb company er squibb son llc bristolmyers squibb gilead sciences llc date december table content section definition section collaboration management general role joint executive committee joint development committee joint commercialization committee joint finance committee procedural rule operate committee alliance manager dispute resolution collaboration principle commercialization budgetplan deadlock expense section development activity general clinical development formulation cmc datum regulatory matter performance subcontracting record update development plan development budget development expense report new product publication certain inspection medical affair medical communication section manufacture supply clinical supply commercial supply section commercialization activity copromotion obligation distribution obligation pricing combination product national account performance subcontract conflict avoidance marketing material development use trademark insurance record commercialization plan budget commercialization expense report section license grant technology license member party jv license sublicense jv member party license right reference member party right reference jv relate matter sublicense trademark license member party jv trademark license jv gilead retain right combination product sale outside territory canada europe combination product sale europe efv license agreement jv obligation sublicensee section payment party royalty payment member party royalty payment party authorize expense mode time payment taxis section financial record financial record audit record certain report section adverse event information exchange pharmacovigilance material communication section product recall notification recall recall expense section intellectual property right ownership intellectual property prosecution patent enforcement patent infringement party right trademark section confidentiality treatment confidential information permit disclosure confidential information use publicity term agreement notification permit use remedy section warranty indemnity representation warranty covenant ii additional representation warranty covenant bms additional representation warranty covenant gilead disclaimer indemnification jv indemnification member party general indemnification certain product liability relate matter indemnification procedure limitation damage ancillary agreement employee section term termination term certain litigation termination nda filing delay material default termination generic launch consequence termination right bankruptcy accrue right survive obligation section general provision force majeure notice assurance successor assign govern law arbitration waiver severability counterpart construction status party standstill nonsolicitation employee entire agreement consent jurisdiction party iiiannexes annex initial committee member alliance manager annex b development plan development budget effective date annex c commercialization plan commercialization budget effective date annex bms patent annex e gilead patent annex f gilead license trademark annex g bms license trademark annex h quarterly detail report annex manner calculation net selling price annex j calculation cost good annex k calculation transfer price annex l joint press release annex certain financial datum annex n datum provide independent accounting expert pursuant section annex jv obligation sublicensee annex p key term service agreement annex q pricing annex r list country comprise develop world ivthis collaboration agreement agreement december effective date gilead sciences inc corporation organize exist law state delaware principal place business lakeside drive foster city gilead parent gilead holdings llc delaware limited liability company whollyowne subsidiary gilead parent gilead sub collectively gilead parent gilead bristolmyers squibb company corporation organize exist law state delaware principal place business park avenue new york ny bms parent er squibb son llc delaware limited liability company whollyowne subsidiary bms parent bms sub collectively bms parent bms bristolmyers squibb gilead sciences llc limited liability company organize exist law state delaware principal place business lakeside drive foster city jv gilead bms jv collectively party party recital gilead develop marketing proprietary nucleotide reverse transcriptase inhibitor viread know generic tenofovir disoproxil fumarate tdf proprietary nucleoside reverse transcriptase inhibitor emtriva know generic emtricitabine ftc fixeddose coformulated product contain tdf ftc active pharmaceutical ingredient truvada treatment hiv infection adult bms develop marketing proprietary nonnucleoside reverse transcriptase inhibitor sustiva know generic efavirenz efv treatment hiv infection adult gilead bms desire develop commercialize united states joint venture entity fix dose coformulated combination product contain tdf ftc efv active pharmaceutical ingredient purpose gilead bms form jv pursuant certain operating agreement enter effective date gilead sub bms sub operating agreement party wish allocate certain right duty relate development commercialization combination product term condition agreement operating agreement ancillary agreement define pursuant bms guarantee agreement gilead guarantee agreement term define dated effective date bms parent gilead parent guarantee performance obligation certain confidential information contain document mark bracket omit file separately security exchange commission pursuant rule b securities exchange act amend bms sub gilead sub respectively agreement operating agreement ancillary agreement applicable affiliate define party consideration mutual promise covenant set forth good valuable consideration receipt sufficiency acknowledge party agree follow section definition act shall mean united states food drug cosmetic act amend actual bms percentage shall mean calendar year percentage applicable bms calendar year base historical datum determine pursuant section b actual gilead percentage shall mean calendar year percentage applicable gilead calendar year base historical datum determine pursuant section b actual percentage shall mean respect bms actual bms percentage respect gilead actual gilead percentage actual yield shall mean set forth annex k affiliate person shall mean person directly indirectly intermediary control control common control person purpose definition control correlative meaning term control common control shall mean possession directly indirectly power direct management policy person ownership vote security contract relate voting right corporate governance b ownership directly indirectly percent vote security ownership interest person provide local law restrict foreign ownership control shall establish direct indirect ownership maximum ownership percentage local law own foreign interest purpose agreement operating agreement ancillary agreement jv shall deem affiliate gilead bms agreement shall mean set forth paragraph alliance manager shall mean set forth section allocate cost shall mean set forth section amp shall mean set forth annex q ancillary agreement shall mean collectively bms supply agreement gilead supply agreement service agreement sdea shall mean set forth section f applicable efv territory shall mean respect bms technology license bms efv licensor license efv licensor bms case efv license agreement efv license agreement territory b respect bms technology worldwide applicable law shall mean applicable law rule regulation include limitation rule regulation guideline requirement regulatory authority effect time time territory approval shall mean collectively approval grant regulatory authority manufacture marketing sale andor use combination product field territory include limitation pricing reimbursement approval approve marketing material shall mean set forth section representative shall mean set forth section b authorize commercialization expense shall mean set forth section authorize development expense shall mean set forth section authorize expense shall mean collectively authorize commercialization expense authorize development expense authorize expense authorize expense shall mean jv expense expressly state agreement operating agreement ancillary agreement authorize expense agree jec authorize expense awp shall mean set forth annex q bms shall mean set forth paragraph agreement bms core improvement shall mean improvement pertain specifically bms core technology improvement conceive discover develop necessary establish authorship inventorship united states copyright patent law case solely jointly behalf gilead affiliate jv course result connection project activity conduct pursuant development plan connection cofunde clinical trial provide bms core improvement shall include dual improvement bms core technology shall mean bms proprietary technology relate specifically exploitation efv bms guarantee agreement shall mean guarantee agreement execute bms parent favor gilead jv date effective date agreement amend time time bms indemnify party shall mean bms sub bms parent affiliate officer director employee bms invention shall mean information invention patentable improvement thereto include gilead core improvement extent own bms conceive discover develop necessary establish authorship inventorship united states copyright patent law case solely case gilead core improvement solely jointly behalf bms affiliate course result connection project activity conduct pursuant development plan connection cofunde clinical trial exclude joint invention bms knowhow shall mean information invention control bms affiliate effective date time term agreement necessary reasonably useful exploitation combination product generally know exclude information invention extent claim bms patent b joint knowhow bms license trademark shall mean set forth section b bms parent shall mean set forth paragraph agreement bms patent shall mean patent bms affiliate control effective date time term agreement absence license grant bms section b assume efv active pharmaceutical ingredient purchase bms infringe exploitation combination product jv country world list bms patent territory effective date attach hereto annex bms regulatory documentation shall mean regulatory documentation applicable sustiva efv sustiva efv coformulation viread tdf emtriva ftc truvada tdf ftc develop behalf bms affiliate sublicensee prior effective date term agreement bms sub shall mean set forth paragraph agreement bms supply agreement shall mean supply agreement enter bms sub jv concurrently execution delivery agreement agreement amend time time bms technology shall mean collectively bms knowhow bms patent bms transfer price shall mean set forth section breach member party shall mean set forth section business day shall mean day saturday sunday day banking institution new york new york san francisco california require law remain closed representative shall mean set forth section b calendar quarter shall mean period consecutive calendar month end march june september december calendar year shall mean period consecutive calendar month commence january end december change control shall mean respect person follow transaction party party acquirer merger consolidation person party acquirer result holder vote security person outstanding immediately prior thereto party acquirer affiliate associate term exchange act ceasing represent percent combine voting power survive entity applicable parent company immediately merger consolidation b sale party acquirer substantially business person agreement relate merger consolidation sale stock sale asset similar transaction c party acquirer shall trustee fiduciary hold security employee benefit plan person corporation own directly indirectly stockholder person substantially proportion ownership stock person party acquirer affiliate associate term exchange act beneficial owner percent combine voting power outstanding security person contract right control board director equivalent govern body person ability cause direction management person clinical datum shall mean datum result analysis thereof derive generate clinical trial pharmaceutical product test analysis subject sample clinical trial eg vitro test tissue sample subject enrol clinical trial case clinical trial involve single agent product double agent product combination product ii combination product combination product clinical trial registry shall mean set forth section b clinical trial result database shall mean set forth section b cmc datum shall mean information contain datum support chemistry manufacturing control facility section section correspond thereto nda include limitation drug master file reference nda cofunde clinical trial shall mean set forth section b collaboration principle shall mean set forth section combination product shall mean fixeddose coformulated product develop pursuant agreement contain active pharmaceutical ingredient single daily dose mg tdf mg ftc mg efv combination product regulatory documentation shall mean regulatory documentation applicable combination product develop behalf party pursuant term agreement exclude bms regulatory documentation gilead regulatory documentation combination product trademark shall mean trademark trademark select jcc combination product packaging design trade dress connection combination product trademark relate thereto registration thereof pende application relate thereto avoidance doubt follow shall consider combination product trademark bms license trademark b gilead license trademark c name logo trademark member party commercialization activity shall mean marketing activity commercialization combination product include set forth commercialization plan follow conduct combination product execution product position preparation promotional marketing material market research advertising activity promotion advocacy national account government relation activity price reimbursement patient assistance program commercialization budget shall mean set forth section b initial commercialization budget attach hereto annex c commercialization budget deadlock shall mean set forth section commercialization plan shall mean plan marketing commercialize combination product describe section b update time time pursuant section c initial commercialization plan attach hereto annex c commercialization plan deadlock shall meaning set forth section commercially reasonable effort shall mean respect development activity member party require perform respect combination product pursuant development plan b commercialization activity member party require perform respect combination product pursuant commercialization plan case level effort generally member party conduct development commercialization activity manner consistent minimum level expenditure contemplate activity development budget commercialization budget case product compound own right comparable market potential profit potential strategic value member party similar stage development product life take account limitation issue safety efficacy product profile proprietary position thencurrent competitive environment product compound individual agent comprise product compound likely time product compound individual agent entry market thencurrent market penetration return investment potential product individual agent comprise product regulatory environment status product individual agent comprise product relevant scientific technical commercial factor case measure fact circumstance time effort commercial record request shall mean set forth section b compete product shall mean case gilead assign member party b case bm assign member party confidential information shall mean set forth section continue member party shall mean member party designate pursuant section control control shall mean respect item information invention patent intellectual property right right ownership license grant license sublicense right item patent right provide agreement violate term agreement bind arrangement party purpose section consent refer section shall deem obtain effective date core technology shall mean bms core technology gilead core technology case cost allocation proposal shall mean set forth section cost good shall mean set forth annex j hereto court shall mean set forth section detail shall mean inperson presentation health care provider specialize treatment hiv infection aid prescribe authority sale representative fully equip knowledge subject section approve marketing material product label insert respect combination product characteristic combination product describe sale representative fair balanced manner consistent requirement applicable law agreement manner customary industry purpose promote prescription pharmaceutical product regard position presentation health care provider avoidance doubt promotional material drop product reminder shall constitute detail verb detail shall mean engage detail detail equivalent shall mean calendar year calendar year successive calendar year adjust calendar year develop world shall mean territory comprise country list annex r additional country outside territory canada europe gilead include gilead access program indicate website program wwwgileadaccessorg development activity shall mean activity set forth development plan update time time pursuant section respect period prior effective date activity pursuant mtta development budget shall mean budget respect expense relate development activity combination product chargeable jv update time time pursuant section initial development budget attach hereto annex b development plan shall mean plan regulatory clinical formulation manufacturing process cmc datum development activity conduct combination product include phase iv clinical study medical information medical education program update time time pursuant section initial development plan attach hereto annex b development record request shall mean set forth section b disclosing party shall mean set forth section shall mean set forth annex q double agent product shall mean truvada coformulate product develop gilead contain active pharmaceutical ingredient tdf ftc dual improvement shall mean improvement constitute improvement pertain specifically gilead core technology improvement pertain specifically bms core technology improvement conceive discover develop necessary establish authorship inventorship united states copyright patent law case solely jointly behalf bms affiliate gilead affiliate jv jointly combination course result connection project activity conduct pursuant development plan connection co fund clinical trial dual improvement shall constitute joint invention effective date shall mean set forth paragraph agreement efv shall mean set forth recital agreement efv license agreement shall mean certain license agreement date september amend efv licensor er squibb son llc successor interest dupont pharmaceutical company name dupont merck pharmaceutical company efv license agreement territory shall mean bms territory efv license agreement effective date consist united states include territory possession canada france continental area germany italy spain united kingdom republic ireland provide efv license agreement amend expand bms territory efv license agreement territory shall forthwith mean bms territory expand b efv license agreement terminate result bms acquisition right efv licensor thereunder efv license agreement territory shall forthwith mean country world efv licensor shall mean collectively merck co inc new jersey corporation merck company incorporate delaware corporation respective successor interest estimate net selling price shall mean set forth section cii exchange act shall mean set forth section b exploitation shall mean make importation use sale offer sale disposition product process include limitation research development registration modification enhancement improvement manufacturing storage formulation optimization import export transport distribution promotion marketing product process verb exploit shall mean engage forego activity europe shall mean country comprise european union constituted time time fda shall mean united states food drug administration successor agency thereto field shall mean treatment hiv infection adult human field force shall mean sale representative regional subnational manager forego final invoice date shall mean set forth section finish product manufacturing datum shall mean data information necessary useful manufacture finish product package label active pharmaceutical ingredient thereof tablet capsule form expressly exclude manufacture active pharmaceutical ingredient include cmc datum finish product customer shall mean set forth annex q ftc shall mean set forth recital agreement gaap shall mean united states generally accept accounting principle effect time time consistently apply generic version shall mean respect combination product single agent product double agent product product contain active pharmaceutical ingredient combination product single agent product double agent product case active pharmaceutical ingredient product product approve united states abbreviate new drug application ie anda generic version launch shall mean set forth section gilead shall mean set forth paragraph agreement gilead core improvement shall mean improvement pertain specifically gilead core technology improvement conceive discover develop necessary establish authorship inventorship united states copyright patent law case solely jointly behalf bms affiliate jv course result connection project activity conduct pursuant development plan connection cofunde clinical trial provide gilead core improvement shall include dual improvement gilead core technology shall mean gilead proprietary technology relate specifically exploitation ftc tdf combination ftc tdf include limitation double agent product exclude combination product gilead guarantee agreement shall mean guarantee agreement execute gilead parent favor bms jv date effective date agreement amend time time gilead indemnify party shall mean gilead sub gilead parent affiliate officer director employee gilead invention shall mean information invention patentable improvement thereto include bms core improvement extent own gilead conceive discover develop necessary establish authorship inventorship united states copyright patent law case solely case bms core improvement solely jointly behalf gilead affiliate course result connection project activity conduct pursuant development plan connection cofunde clinical trial exclude joint invention gilead knowhow shall mean information invention control gilead affiliate effective date time term agreement necessary reasonably useful exploitation combination product generally know exclude information invention extent claim gilead patent b joint knowhow gilead license trademark shall mean set forth section gilead parent shall mean set forth paragraph agreement gilead patent shall mean patent gilead affiliate control effective date time term agreement absence license grant gilead section assume tdf ftc active pharmaceutical ingredient purchase gilead infringe exploitation combination product jv country world list gilead patent territory effective date attach hereto annex e gilead regulatory documentation shall mean regulatory documentation applicable viread tdf emtriva ftc truvada tdf co formulation ftc viread tdf emtriva ftc truvada tdf ftc coformulation sustiva efv develop behalf gilead affiliate sublicensee prior effective date term agreement gilead sub shall mean set forth paragraph agreement gilead supply agreement shall mean supply agreement enter gilead parent jv concurrently execution delivery agreement agreement amend time time gilead technology shall mean collectively gilead knowhow gilead patent gilead transfer price shall mean set forth section shall mean set forth shall mean set forth section good clinical practice gcp shall mean thencurrent standard clinical trial pharmaceutical product set forth act applicable regulation promulgate thereunder amend time time good laboratory practice glp shall mean thencurrent standard laboratory activity pharmaceutical product set forth act applicable regulation promulgate thereunder amend time time good manufacturing practice gmp shall mean regulatory requirement current good manufacturing practice pharmaceutical product promulgate fda include set forth food drug cosmetic act cfr part amend time time improvement shall mean modification compound composition product technology discovery device process formulation relate compound composition product technology patent patentable include limitation enhancement efficiency operation manufacture ingredient preparation presentation formulation mean delivery packaging dosage compound composition product technology discovery device process formulation relate thereto discovery development new expand indication application compound composition product technology discovery development improve stability safety efficacy compound composition product technology discovery development new dosage regimen product method use administration compound composition product technology ind shall mean investigational new drug application file fda accordance applicable law indemnify party shall mean person seek indemnification loss pursuant section indemnify member party shall mean set forth section indemnify party shall mean party indemnification seek pursuant section independent accounting expert shall mean set forth section information invention shall mean technical scientific knowhow information trade secret knowledge technology mean method process practice formula instruction skill technique procedure experience idea technical assistance design drawing assembly procedure computer program apparatuse specification data result material include limitation preclinical clinical trial result manufacturing procedure test procedure purification isolation technique confidential proprietary patent patentable write electronic form know develop improvement forego discovery development invention confidential proprietary patent patentable tangible embodiment forego infringement shall mean set forth section infringe combination product shall mean set forth section initial launch period shall mean commence launch combination product territory initiate member shall mean set forth section e interim bms unit transfer price shall mean set forth section interim gilead unit transfer price shall mean set forth section interim unit transfer price shall mean calendar year respect bms interim bms unit transfer price respect gilead interim gilead unit transfer price joint commercialization committee jcc shall mean set forth section joint development committee jdc shall mean set forth section joint executive committee jec shall mean set forth section operating agreement joint finance committee jfc shall mean set forth section joint invention shall mean information invention pertain specifically combination product patentable improvement thereto conceive discover develop necessary establish authorship inventorship united states copyright patent law case behalf bms affiliate gilead affiliate jv jointly combination course result connection project activity conduct pursuant development plan connection cofunde clinical trial b dual improvement joint knowhow mean information invention include joint invention generally know exclude information invention extent claim joint patent avoidance doubt joint knowhow shall include clinical datum propose bioequivalence study contemplate development plan joint patent shall mean patent extent patent claim joint invention joint technology shall mean collectively joint knowhow joint patent jv shall mean set forth paragraph agreement jv expense shall mean direct outofpocket expense gilead bms incur cause affiliate incur perform project activity behalf jv avoidance doubt respect jv expense incur member party affiliate expense chargeable jv member party expense constitute authorized expense key regulatory submission shall mean set forth section launch shall mean respect territory date combination product ship behalf jv commercial sale party b generic version product refer section date available commercial sale purchase case loss shall mean judgment fine amount pay settlement outofpocket expense include reasonable attorney fee reasonably incur party indemnitee provide section proceeding shall mean set forth annex q manufacture manufacturing mean respect product compound manufacturing processing formulate packaging labeling hold quality control testing product compound manufacturing process shall mean process step thereof necessary useful manufacture combination product bulk active pharmaceutical ingredient improvement thereto intermediate forego market marketing shall mean program activity relate promotion sale commercialization combination product territory include limitation detail advertising sell contracting sale distribute combination product material default shall mean set forth section member party shall mean collectively gilead bms member shall mean collectively gilead sub bms sub member vote shall mean set forth section f shall mean set forth section f shall mean set forth section f mtta shall mean set forth section nda shall mean new drug application file fda accordance applicable law purpose obtain marketing approval pharmaceutical product united states shall mean set forth annex q net sale shall mean respect product period gross invoice commercial sale product period behalf sell party party provide amount invoice product sell provide use develop world shall include deduction normal customary quantity andor cash discount sale return allowance include limitation grant account price adjustment billing error reject good damage good return rebate administrative fee reimbursement similar payment wholesaler distributor include limitation pursuant inventory management agreement buy group aid drug assistance program pharmacy benefit management organization health care insurance carrier institution allowance rebate fee pay distributor chargeback actually allow give b freight postage shipping insurance expense separately identify invoice c customs excise duty duty relate sale make gross invoice separately identify invoice rebate similar payment accrue respect sale pay governmental regulatory authority way illustration limitation forego clause united states federal state medicaid medicare similar state program government impose retroactive price reduction e sale taxis duty directly related sale extent item include gross invoice price include taxis assess income derive sale deduction list involve payment party shall take deduction prior date accrue accordance gaap consistently apply party audit financial statement purpose determine net sale pursuant section bii combination product shall deemed sell invoice purpose calculate net sale sale party andor affiliate shall exclude computation net sale sale party affiliate party shall include computation net sale net selling price shall mean price pharmaceutical product calculate accordance annex hereto nonbreache member party shall mean set forth section operating agreement shall mean set forth recital agreement operate committee shall mean collectively jcc jdc jfc optional update shall mean set forth section paragraph iv certification shall mean set forth section party party shall meaning set forth paragraph agreement patent shall mean patent patent application include limitation provisional application b substitution division continuation continuationsinpart reissue renewal registration confirmation reexamination extension supplementary protection certificate like c foreign international equivalent forego pct shall mean patent cooperation treaty open signature june ust permit assignee shall mean set forth section person shall mean individual sole proprietorship partnership limited partnership limited liability partnership corporation limited liability company business trust joint stock company trust unincorporated association joint venture similar entity organization include limitation government political subdivision department agency government prescription drug marketing act pdma shall mean set forth section pricing committee shall mean set forth section b pricing information shall mean set forth section h proceeding shall mean civil criminal administrative investigative proceeding bring demand party product detail period shall mean set forth section e product efv yield shall mean set forth annex k product ftc yield shall mean set forth annex k product tdf yield shall mean set forth annex k project activity shall mean activity undertake perform behalf party pursuant agreement mtta course result connection research development marketing sale use combination product include limitation development activity commercialization activity provide project activity shall include activity undertake perform behalf member party affiliate sublicensee extent arise course result connection exploitation combination product use outside territory include limitation activity undertake perform gilead exercise right license grant section promotion shall mean conduct activity normally undertake pharmaceutical company field force implement plan strategy marketing commercialization aim encourage approve use pharmaceutical product include limited detail verb promote shall mean engage forego activity psur mean periodic safety update report require submit fda publication standard shall mean set forth section shall mean set forth section f recalculate transfer price shall mean set forth section ciii receive party shall mean set forth section regulatory authority shall mean applicable supranational federal national regional state provincial local regulatory agency department bureaus commission council government entity include limitation fda entity exercise regulatory authority respect exploitation combination product territory regulatory documentation shall mean submission regulatory authority territory include limitation ind nda sndas cmc datum drug master file correspondence regulatory agency registration license regulatory drug list advertising promotion document psur adverse event file complaint file manufacturing record relevant experience information shall mean adverse experience report report base marketing datum documentation relevant drug experience request member shall mean set forth section g require update shall mean set forth section b respective percentage shall mean respect gilead actual gilead percentage respect bms actual bms percentage provide agreement provide shall allocate member party base respective percentage allocation shall basis member party respective working percentage time relevant event allocation shall adjust applicable determination member party respective actual percentage calendar year relevant event occur adjustment shall occur later april calendar year provide agreement operating agreement agree write member party right reference shall mean set forth cfr b alternatively shall mean equivalent thereto jurisdiction outside territory avoidance doubt agreement right reference shall refer right regulatory authority rely use applicable information shall confer member party right reference grant right receive access information shall mean set forth section sdea safety datum exchange agreement shall mean set forth section select product liability claim shall mean set forth section c service agreement shall mean distribution service agreement enter gilead parent jv effective date key term outline annex p hereto agreement amend time time single agent product shall mean viread emtriva sustiva study shall mean clinical study initiate gilead prior effective date gilead clinical study protocol entitle phase randomize openlabel multicenter study treatment antiretroviralnave hivinfecte subject compare tenofovir disoproxil fumarate emtricitabine combination efavirenz versus combivir lamivudinezidovudine efavirenz protocol revise study extended expand time time case gilead avoidance doubt conduct study shall deem development activity project activity purpose agreement clinical datum derive generate study test analysis subject sample study shall gilead know joint knowhow subsequent launch period shall mean launch combination product territory supplier shall mean person select commercial supplier combination product pursuant section supply agreement shall mean collectively bms supply agreement gilead supply agreement supply party shall mean respect supplier member party supplier member party b party supplier member party designate pursuant section manage relationship supplier tdf shall meaning set forth recital agreement technology shall mean bms technology gilead technology case terminate member party shall mean member party designate pursuant section territory shall mean united states commonwealth puerto rico territory possessions united states party shall mean person gilead bms jv respective affiliate party acquirer shall mean set forth section trademark shall include word symbol color designation device combination thereof include limitation trademark trade dress service mark service brand mark trade brand logo business symbol transfer price shall mean bms transfer price gilead transfer price case transfer member party shall mean set forth section b shall mean set forth section wac shall mean set forth annex q work bms percentage shall mean calendar year preliminary percentage applicable bms calendar year determine pursuant section ci work gilead percentage shall mean calendar year preliminary percentage applicable gilead calendar year determine pursuant section ci work percentage shall mean respect bms work bms percentage respect gilead work gilead percentage section collaboration management general set forth agreement operating agreement member party desire establish joint executive committee shall oversee member party collaboration agreement facilitate communication member party respect development approval manufacturing commercialization combination product territory subject forego member party desire establish specialized committee focus closely party development activity commercialization activity finance activity hereunder committee shall responsibility authority delegate vest committee section agreement operating agreement role joint executive committee establishment composition governance power limitation power joint executive committee jec govern section operating agreement section initial jec member identify annex hereto jec shall overall authority responsibility respect development activity commercialization activity combination product matter reserve member party pursuant agreement operating agreement limitation forego jec shall follow power duty oversee work operate committee possible resolve dispute refer alliance manager pursuant section ii oversee activity gilead keep jvs books record pursuant section iii adopt guideline compliance party antitrust law connection jv activity iv approve initial capital contribution define operating agreement member approve capital contribution planning schedule issue certain request additional capital contribution case pursuant section operating agreement v approve x annual update development plan development budget interim update development plan development budget case jdc unable reach agreement vi approve x annual update commercialization plan commercialization budget interim update commercialization plan commercialization budget case jcc unable reach agreement vii approve unit volume forecast jcc unable reach agreement use preparation commercialization plan commercialization budget regardless commercialization plan commercialization budget use planning manufacture combination product planning commercialization activity member party financial planning purpose viii approve cost allocation proposal ix approve jfc report financial matter jec determine reasonably necessary appropriate implementation financial aspect jv x review recommendation jfc respect approve mean reconcile internal reporting accounting standard member party reasonably necessary method charge cost expense member party xi review applicable recommend member party change pursuant section xii resolve dispute jdc respect require approval publication presentation pursuant section b member party obligation section b provide member party access certain member party record documentation datum xiii resolve dispute jcc respect initially propose marketing material combination product territory update approve marketing material b member party obligation pursuant section provide member party access certain member party record documentation datum c issue relate patient assistance program arise section bvii issue relate supplier alternate supplier arise section bix xiv decide major strategic issue matter relate jv purview operating committee ii reserve member party pursuant agreement operating agreement xv action reserve jec agreement operating agreement party mutually agree write jec amend action conflict provision agreement operating agreement ancillary agreement resolve issue termination agreement potential actual material default joint development committee member shall appoint member joint development oversight management committee joint development committee jdc gilead sub shall appoint member designate gilead sub serve chairperson jdc anniversary effective date member designate bms sub member designate gilead sub shall serve alternately chairperson rotate annual basis anniversary effective date initial jdc member chairperson identify annex hereto b subject oversight jec jdc shall follow power duty x review propose jec approval annual update development plan development budget review approve interim update development plan development budget case propose pursuant section ii oversee coordinate party activity development plan iii oversee manage matter relate clinical supply combination product include limitation manufacturing requirement inventory projection inventory control iv alliance manager x assist coordinate scientific interaction party course implement development plan facilitate exchange party datum information material result relate clinical manufacture clinical trial communication filing regulatory authority combination product case solely extent datum information material require exchange party respect member party right gain access member party jv pursuant agreement operating agreement v oversee regulatory matter jv include limitation approve combination product regulatory documentation extent require pursuant section oversee gilead activity jvs liaison regulatory authority territory overseeing activity conduct pursuant sdea pharmacovigilance safety report vi oversee member party activitie pursuant respective supply agreement oversee coordinate jcc respect matter relate monitoring manufacturing capacity forecast order active pharmaceutical ingredient combination product vii resolve dispute member party respect require approval publication presentation pursuant section b member party obligation section b provide member party access certain member party record documentation datum viii oversee medical affair medical communication activity ix review approve reject proposal phase iv clinical study combination product x provide update jdcs activity achievement jec calendar quarter xi perform function member party mutually agree write time time joint commercialization committee member shall appoint member joint commercialization oversight management committee joint commercialization committee jcc bms sub shall appoint member designate bms sub serve chairperson jcc anniversary effective date member designate gilead sub member designate bms sub shall serve alternately chairperson rotate annual basis anniversary effective date initial jcc members chairperson identify annex hereto b subject oversight jec jcc shall follow power duty oversee coordinate party activity commercialization plan ii x review propose jec approval annual update commercialization plan commercialization budget review approve interim update commercialization plan commercialization budget case propose pursuant section c iii oversee gilead activity pursuant service agreement iv develop approve x initial marketing material combination product territory update material time time reasonably necessary appropriate accordance section v develop approve unit volume forecast use preparation commercialization plan commercialization budget regardless commercialization plan commercialization budget use planning manufacture combination product planning commercialization activity member party financial planning purpose vi coordinate jdc respect manufacturing labeling matter vii x determine jv respond request health care provider individual patient obtain prescription combination product unable afford establish appropriate procedure response time shall apply respond request case x accordance section viii recommendation jec respect cost allocation proposal ix maintain supplier alternate supplier pursuant section manufacture commercial supply combination product x oversee coordinate jdc respect matter relate manufacturing labeling combination product commercial supply include case manufacturing respect quality control matter monitor manufacturing capacity forecast order combination product ensure adequate commercial supply meet demand therefor territory project jcc approve jec xi resolve dispute member party respect member party obligation pursuant section provide member party access certain member party record documentation datum xii provide update jccs activity achievement jec calendar quarter xiii perform function member party mutually agree write time time joint finance committee member shall appoint member joint finance committee support jec jdc jcc joint finance committee jfc gilead sub shall appoint member designate gilead sub serve chairperson jfc anniversary effective date member designate bms sub member designate gilead sub shall serve alternately chairperson rotate annual basis anniversary effective date initial jfc members chairperson identify annex hereto b subject oversight jec jfc shall follow power duty work jec operate committee assist financial budgeting planning matter require include assist preparation budget annual longterm plan ii recommend approval jec procedure format timeline consistent agreement report financial datum additional alternative reporting procedure concern financial aspect jv iii prepare report financial matter approve jec implementation financial aspect jv iv coordinate audits financial datum appropriate require allow agreement v address issue implementation relate financial mechanic calculation agreement operating agreement vi recommend approval jec mean reconcile internal reporting accounting standard member party necessary method charge cost expense member party vii review appropriate allocation cost expense respect authorize expense viii calculate cause calculated case matter expressly require calculate cause calculated jfc pursuant agreement include section c pursuant operating agreement address issue implementation relate cash netting procedure set forth section c operating agreement ix develop recommend jec approval initial capital contribution define operating agreement member capital contribution planning schedule recommend jec certain request additional capital contribution case pursuant section operating agreement x provide update jfc activity achievement jec calendar quarter xi perform function member party mutually agree write time time procedural rule operate committee bms sub gilead sub shall designate representative appropriate expertise serve member operate committee representative serve operating committee andor jec appropriate view individual expertise member shall endeavor match respective representation operating committee term functional area management level b member operating committee remove replace time cause member appoint committee member action shall accomplish write notice member member operating committee shall serve successor name member appoint committee member early resignation removal c jfc shall meet time calendar quarter term agreement jdc shall meet time calendar quarter anniversary launch combination product semiannually schedule determine jdc jcc shall meet time calendar quarter second anniversary launch combination product semiannually schedule determined jcc operating committee shall meet time place united states mutually agree bms sub gilead sub respective operating committee shall meet discuss overall progress development activity development plan commercialization activity commercialization plan financial aspect jv case problem arise course activity status development plan development budget commercialization plan commercialization budget financial aspect jv case matter member operating committee reasonably request operating committee shall accurate complete minute meeting record proposal recommendation action take minute record operate committee shall available member party chairperson shall organize committee meeting prepare meeting agenda base item submit committee member cause take accurate minute meeting circulate draft minute seven day meet approval member committee member circulate final minute committee member promptly follow approval notice agenda meeting accompany material shall circulate member applicable operating committee sufficiently advance normal course material receive business day advance meeting provide reasonable circumstance material circulate less period time advance meeting long member agree inclusion agenda item propose consideration member member operating committee waive notice meeting thereof shall deem waive notice applicable right object inclusion particular agenda item item set forth proviso previous sentence attend meet object meeting lack notice prior commencement e member appoint gilead sub member appoint bms sub attendance meeting operating committee establish quorum conduct business committee member attend meeting person long attendee able hear telephone video conference equipment provide meeting calendar year operating committee shall hold person launch combination product meeting calendar year operating committee shall hold person operate committee act unanimous write consent member meet f meeting operating committee member designee operate committee shall collectively vote matter act member vote operating committee shall action unanimous member vote operating committee unable reach agreement matter properly present operating committee consideration matter shall resolve procedure set forth section provide g operating committee deem appropriate delegate decisionmake authority specific matter type matter applicable case jdc jcc approval update development plan commercialization plan development budget commercialization budget operating committee responsible provide section subcommittee specific group representative member shall decision consensus subcommittee group reach consensus matter member refer matter operating committee resolution h notwithstanding enumerate authority jec agreement operating agreement express reservation decisionmake authority member party certain matter event jec act unanimous affirmative member vote define operating agreement pursuant section operating agreement ii unanimous write consent pursuant section c operating agreement take action matter relate exploitation combination product respect matter authority responsibility delegate vested jec member party shall deem waive objection effect jec act scope authority responsibility resolution matter shall bind member party purpose agreement operating agreement alliance manager gilead bms shall designate respective organization alliance manager alliance manager responsibility facilitate interaction cooperation gilead bms respect jv exploitation combination product territory initial alliance manager identify annex hereto member party change alliance manager time time write notice member party b alliance manager shall attend meeting jec operating committee jfc support chairperson jec operate committee discharge responsibility alliance manager shall nonvoting participant meeting appoint member applicable committee alliance manager shall endeavor create maintain collaborative work environment jec operate committee addition alliance manager shall point referral certain matter subject dispute resolution provide section ii shall coordinate relevant functional representative member party iii shall provide single point communication seek consensus internally respective member party organization member party iv shall identify bring dispute attention jec operating committee appropriate timely manner v shall plan coordinate cooperative effort internal external communication vi shall responsibility ensure governance activity conduct require jec operating committee meeting production meeting minute occur set forth agreement operating agreement relevant action item agree meeting appropriately carry address c notice give member party member party respect development activity combination product efv tdf ftc bulk active pharmaceutical ingredient manufacturing commercialization activity shall member partys alliance manager operating committee jec member member party directly involve informed relevant activity gilead bms select supplier pursuant section shall required provide notice member partys alliance manager respect toll manufacturing activity dispute resolution dispute refer jec resolution follow operate committee unable reach agreement matter properly present operating committee decision operating committee shall refer matter alliance manager gilead bms alliance manager unable resolve dispute referral matter shall refer jec ii member party refer jec issue arise agreement operating agreement cover clause b jec unable resolve dispute refer alliance manager member party pursuant section referral event jec unable resolve dispute arise jec dispute shall refer resolution chief executive officer gilead parent bms chief executive officer bms parent direct report designate chief executive officer bms parent shall member jec operating committee c chief executive officer gilead parent chief executive officer designee applicable bms parent unable reach agreement dispute matter refer pursuant section b referral gilead bms refer dispute matter bind arbitration pursuant section extent dispute matter relate arise validity interpretation construction compliance breach agreement operating agreement ancillary agreement agreement contemplate agreement member party affiliate jv andor member party affiliate party b dispute matter come jec pursuant section section provide dispute relate submit arbitration respect issue specific dispute relate pursuant submit arbitration respect issue dispute relate submit arbitration respect matter arise pursuant dispute relate submit arbitration respect matter arise pursuant c dispute satisfied respect matter avoidance doubt dispute resolution procedure set forth section b c shall apply deadlock jec operating committee result proposal member committee member reverse modify decision jec operating committee respect matter previously present decision approve unanimous member vote unanimous write consent member follow condition satisfied proposal applicable jec operating committee decision ii deadlock involve iii applicable jec operating committee decision reverse modify pursuant agreement understand certain aspect applicable jec operating committee decision produce result shall subject dispute resolution procedure set forth section b c balance decision shall remain effect provide section shall apply deliberation decision jcc pursuant section deliberation decision jec respect dispute arise jcc respect thereto provide jccs jecs reconsideration prior decision respect matter cover precede proviso shall govern respectively event reconsideration dispute resolution arbitration connection therewith prior decision force time reconsideration shall remain force continue apply time modify position agree jcc jec adopt arbitrator case e section shall affect right member party exercise right section respect material default member party concurrently exercise right section event time prior completion dispute resolution procedure set forth section nonbreache member party deliver notice material default breach member party day cure period refer section shall begin run receipt notice shall run concurrently procedure set forth section collaboration principle party agree abide follow principle collaboration principle conduct development activity commercialization activity cause representative jec operate committee observe principle connection committeerelate activity subject section b c purpose jv develop manufacture commercialize combination product use territory ii optimize commercial potential combination product commercialization plan subject commercialization budget avoidance doubt agreement operating agreement shall deem restrict prohibit member party affiliate x commercialize single agent product andor double agent product applicable subject section develop manufacturing commercialize combination product combination product treatment hiv infection include limitation product contain party single agent product andor double agent product z conduct clinical study involve efv ftc tdf combination thereof include combination product b subject section party promotion combination product territory shall accordance approve marketing material fdaapprove label package insert combination product provide subject forego party shall right position combination product hiv product portfolio sole discretion c expressly provide agreement operating agreement ancillary agreement notwithstanding power authority delegate party jec operating committee party shall obligation conduct activity support furtherance exploitation combination product mutually agree write party expressly set forth agreement commercialization plan development plan ii payment incur expense liability support furtherance exploitation combination product mutually agree write party expressly set forth commercialization budget development budget commercialization budgetplan deadlock event commercialization budget deadlock commercialization plan deadlock term define respect portion period effective date end subsequent launch period lieu dispute resolution procedure set forth agreement operating agreement party agree dispute shall conclusively resolve follow commercialization budget deadlock relate calendar year thereof period effective date end initial launch period level aggregate expenditure calendar year thereof dispute shall fix notice give member party member party case dispute annual update level calendar year dispute provide initial version commercialization budget include annex c hereto recently update applicable ii case dispute interim update level effect relevant current calendar year b commercialization budget deadlock relate calendar year thereof subsequent launch period level aggregate expenditure calendar year thereof dispute shall fix notice give member party member party case dispute annual update level recently update budget calendar year immediately precede calendar year dispute member respective representative jec propose level aggregate expenditure low aforesaid level case level aggregate expenditure calendar year dispute shall instead fix member respective representative jec b case dispute interim update level effect relevant current calendar year ii dispute level aggregate expenditure provide subsequent annual update commercialization budget cover forego clause level shall fix notice give member party member party member respective representative jec c commercialization plan deadlock relate calendar year thereof initial launch period calendar year thereof dispute shall fix notice give member party member party case dispute annual update level calendar year dispute provide initial version commercialization plan include annex c hereto recently update applicable ii case dispute interim update level effect relevant current calendar year commercialization plan deadlock relate calendar year thereof subsequent launch period calendar year thereof dispute shall fix notice give member party member party case dispute annual update level recently update effect calendar year immediately precede calendar year dispute member respective representative jec propose low aforesaid level case product year dispute shall instead fix member respective representative jec b case dispute interim update level effect relevant current calendar year ii dispute provide subsequent annual update commercialization plan cover forego clause level shall fix notice give member party member party member respective representative jec calendar year thereof commence subsequent launch period aggregate expenditure commercialization budget commercialization plan shall decide mutual agreement write member party failure reach agreement thereon shall subject dispute resolution hereunder agreement x commercialization budget deadlock shall mean jec unable reach agreement unanimous member vote define operating agreement unanimous write consent member jec level aggregate expenditure annual case clause section vi interim update commercialization budget covering portion period effective date end initial launch period portion subsequent launch period commercialization plan deadlock shall mean jec unable reach agreement unanimous member vote unanimous write consent member jec conduct annual case clause section vi interim update commercialization plan cover portion initial launch period subsequent launch period expense gilead bms shall bear expense relate management jv include limitation expense relate meeting jec operate committee participation member representative meeting communication member connection meeting matter authority committee travel meeting expense shall deem jv expense authorize expense section development activity general oversight jdc gilead bms shall perform cause affiliate perform behalf jv development activity designate member party development plan case accordance timeline set forth development plan avoidance doubt gilead behalf shall sole right sole discretion oversight jdc jec shall respect clinical development limitation section gilead oversight jdc shall primary responsibility development combination product conduct clinical trial bioequivalence study require obtain approval nda combination product territory field case set forth development plan mutually agree member party b event member party desire conduct sponsor cause conduct sponsor jointly member party jv clinical trial combination product clinical trial involve combination product product clinical trial contemplate development plan include limitation expand access program phase iiibiv study ii support jointly member party behalf jv clinical trial sponsor investigator member party shall notify member party member party shall discuss particular propose clinical trial event member party sole discretion agree conduct jointly sponsor jointly clinical trial behalf jv jdc representative shall prepare agree trial protocol designate member party lead conduct supervise clinical trial negotiate necessary clinical trial agreement case external outof pocket cost member party markup relate clinical trial shall treat authorize development expense event member party sole discretion agree support jointly behalf jv investigatorsponsore clinical trial member party shall coordinate investigator seek conduct clinical trial agree appropriate grant support include limitation support form funding contribution drug product external outofpocket cost member party mark respect clinical trial shall treat authorize development expense clinical trial member party shall determine conduct sponsor support jointly pursuant precede sentence shall refer cofunded clinical trial clinical datum respect cofunde clinical trial shall deem joint knowhow provide case investigatorsponsore clinical trial clinical datum result cofunde clinical trial shall deem joint knowhow extent jv member party obtain right title interest clinical datum avoidance doubt contain section intend shall construe restrict prohibit member party conduct independently party clinical trial combination product clinical trial involve combination product product prior member partys commence clinical trial sponsor member party independently party applicable member party shall provide brief summary protocol member party representative jdc understand representative jdc shall approval right respect study protocol provide summary shall constitute confidential information disclose member party extent information provide summary satisfie criterion set forth section b receive member partys representative shall use summary purpose provide comment thereon disclose member party comment accept reject disclose member party sole discretion c receive member partys representative shall disclose summary person employee member party obligation x disclose summary use summary solely order assist member party representative provide comment thereon avoidance doubt member party provide summary respect clinical trial pursuant agreement shall construe effect cause activity respect clinical trial deem project activity purpose agreement c event member party determine conduct additional development activity alternative formulation presentation combination product conduct cause conduct additional activity external outofpocket cost member party markup respect activity shall treat authorize development expense formulation cmc datum limitation section gilead oversight jdc shall primary responsibility formulation manufacturing process development preparation cmc datum relate combination product contemplate development plan formulation development shall include limitation conduct formulation screen optimization scaleup technology transfer combination product field regulatory matter limitation section gilead oversight jdc participation bms describe section shall primary responsibility prepare file necessary regulatory documentation act liaison behalf jv communication regulatory authority territory relate obtain approval combination product field nda separate respective nda sustiva viread emtriva truvada gilead shall prepare file combination product regulatory documentation regulatory authority territory jv submission combination product regulatory documentation consist ind nda sndas cmc datum drug master file psur collectively key regulatory submission shall approve advance jdc shall delegate approval subcommittee group refer section g permit applicable law label combination product shall list agent follow order b gilead shall notify bms early reasonably practicable advance meeting face face teleconference communication representative regulatory authority territory concern combination product order provide bms opportunity present meeting review comment communication provide event shall gilead reasonable effort provide bms opportunity present meeting review comment communication require postpone meeting ensure bms attend meet postpone communication order ensure bms comment receive gilead advance submission regulatory authority case order enhance efficiency member party coordination regulatory matter concern combination product increase likelihood bms meaningful opportunity participate activity term agreement bms cause employee necessary regulatory expertise decisionmake authority dedicate fulltime basis serve conduit bms participation activity gilead shall promptly forward bms advance meeting copy document relevant information relate meeting notwithstanding contain agreement contrary meeting communication regulatory authority territory concern combination product bms gilead present member party participate member party shall lead matter relate respective single agent product double agent product ii meeting communication regulatory authority concern combination product member party meet communication member party participate member partys presence participation member party shall engage substantive discussion pertain member party single agent product double agent product case include limitation respect api consist efv tdf ftc case relate combination product c member party shall promptly forward member party write communication receive representative regulatory authority relate combination product bms shall provide gilead access copy include electronic copy request bms regulatory documentation include limitation nda sustiva gilead reasonably request connection solely purpose performance duty section section shall prohibit restrict member party communicate regulatory authority matter relate exploitation respective single agent product double agent product pharmaceutical product member party shall promptly notify member party label change member party respective single agent product double agent product result label change combination product communication regulatory authority potential label change combination product reasonably expect lead label change member party single agent product double agent product notwithstanding agreement contrary affect member party shall lead deal regulatory authority matter performance subcontract gilead bms shall perform respective development activity material compliance gcp glp gmp case extent applicable requirement applicable law long development plan effect shall use commercially reasonable effort perform development activity development plan efficiently expeditiously subject development budget member party subcontract performance respective development activity provide subcontract member party shall oversee performance subcontractor subcontract development activity manner reasonably expect result timely successful completion shall remain responsible performance development activity accordance agreement development plan record maintenance record gilead bms shall severally accordance respective allocation responsibility respect project activity maintain cause maintain combination product regulatory documentation final support record documentation therefor draft record documentation therefor require applicable law sufficient detail material compliance gcp glp gmp case extent applicable record shall complete accurate shall fully properly reflect work result achieve performance respective development activity manner appropriate regulatory purpose applicable use connection patent filing prosecution maintenance documentation record shall retain year ii long period require applicable law b access record member party shall right normal business hour reasonable notice inspect copy combination product regulatory documentation final support record documentation therefor generate maintain member party use receive member party solely connection performance development activity manner consistent development plan subject term condition section b member party shall right normal business hour reasonable notice obtain member party access copy scientific regulatory technical record documentation datum solely extent relate combination product member party single agent product andor double agent product case solely extent necessary order receive member party perform obligation respect development activity manner consistent development plan ii necessary receive member party confirm compliance andor comply glp gcp gmp extent applicable applicable law relate project activity andor iii necessary enable receive member party conduct reasonable diligence matter potentially give rise liability jv andor receive member party conduct defense andor jv respect liability extent fact circumstance event arisen give receive member party reasonable basis believe jv incur liability case use receive member party purpose set forth clause ii iii case clause iii immediately precede sentence shall require party provide datum documentation record event party interest matter case shall apply request shall writing shall state reason therefor development record request member party record documentation datum request shall right raise reasonable objection write response development record request include limitation base member partys interest protect disclosure request member party trade secret competitive business information objection assert member party shall promptly confer attempt address member partys concern reach resolution respect matter event member party unable agree mutually agreeable resolution member party shall right refer matter jdc event dispute ultimately determine threshold matter extent criterion set forth clause ii andor iii satisfied request member party shall determination respect extent disclosure information shall require make determination fact argument set forth development record request member party write response thereto shall right require receive member party abide term condition handle use nondisclosure member partys organization andor party information reasonable circumstance provide section member party shall right obtain member party access copy member party record documentation datum describe expressly permit pursuant agreement member party give consent sole discretion update development plan development budget gilead shall prepare submit jdc jfc prior start calendar year propose update development plan development budget calendar year ii prior start calendar year preliminary update development budget address budget issue general level incomplete subject change addition member party directly representative jdc propose update development plan development budget jdc time time appropriate light change circumstance change update shall subject approval jdc set forth section f annual update approve prior start calendar year annual interim update development plan development budget approve jdc subject section v applicable development plan development budget case shall continue effect approve recently update pursuant section update development plan shall cover item include initial development plan mutually agree member party development expense shall responsible cost incur sole discretion connection b performance development activity set initial development plan party agree jv shall bear jv expense incur gilead bms connection performance respective development activity extent meeting follow criterion authorize development expense development activity conduct pursuant development plan area responsibility relevant member party list development budget chargeable jv ii total expense area responsibility member party relevant period extent exceed correspond budget area period approve jdc iii expense external ofpocket cost gilead bms markup iv expense cost refer report gilead bms shall present meeting jdc calendar quarter anniversary launch combination product meet jdc semiannually report oral write write report shall require contain detail typically include executive summary describe development activity perform cause perform precede meeting report present case meeting jdc prior meeting calendar yearto date basis evaluate work perform relation goal timeline development plan ii development activity process future activity expect initiate thencurrent calendar year compare development plan iii case write report authorize development expense incur expect incur member party thencurrent calendar year compare development budget addition gilead bms shall report promptly jdc respective committee member material development respect development activity responsible perform development plan notwithstanding contain section contrary member party reporting obligation section shall automatically deem terminate respect period effect development plan development budget new product period date agreement anniversary effective date member party agree use commercially reasonable effort evaluate pursue arrangement codevelopment cocommercialization product comprising provide member party terminate effort mutual write agreement determine propose product commercially technically feasible agreement terminate unreasonably withhold furtherance forego notwithstanding agreement contrary period effective date anniversary effective date gilead shall shall cause affiliate territory contain party ii territory b bms shall shall cause affiliate territory contain combination proprietary party ii territory publication member party shall right publish present datum finding result project activity include limitation cofunde clinical trial subject right objection demand modification member party interest protect confidential information member party ii preserve intellectual property right member party jv andor iii assure publication presentation present datum finding fair accurate balanced manner accordance ethical medical andor scientific standard term agreement member party shall provide member party representative jdc review copy academic scientific medical publication presentation specifically relate combination product relate combined use efv ftc tdf member party proposes submit publication presentation result project activity provide notwithstanding contain section contrary term condition section shall apply publication presentation result directly indirectly study review publication presentation shall conduct purpose consider compliance standard set forth clause ii iii publication standard shall consider portion publication presentation modify delete order conform publication standard addition case publication presentation result cofunde clinical trial member party proposes submit publication presentation shall right member party agree publication presentation modify conform publication standard agreement shall unreasonably withhold delayed member party shall consider good faith comment provide member party respect publication presentation include limitation comment scientific medical nature case publication presentation result project activity member party shall right comment publication presentation provide member party propose publication presentation shall obligation accept comment extent necessary preserve intellectual property right member party jv shall free publish present case write copy propose publication presentation require provide review shall provide member partys representative jdc later submission publication presentation case abstract copy abstract shall provide soon reasonably practicable advance submission abstract party period b deadline submission publication presentation date completion publication presentation copy provide soon reasonably practicable advance submission deadline case propose publication presentation member party require review member party event member party fail reach agreement applicable publication presentation conclusion applicable review period result dispute member party respect publication presentation dispute refer member party jdc member party shall comply publication pursuant section standard academic practice authorship scientific publication recognition contribution party avoidance doubt contain section shall alter affect member partys confidentiality obligation pursuant section b subject compliance section agreement shall restrict member party provide information cofunde clinical trial conduct member party clinical trial registry clinical trial result database accordance applicable law industry practice purpose section b clinical trial registry mean list clinical trial initiate maintain federal government eg wwwclinicaltrialsorg independent organization eg phrma ii clinical trial result database mean database provide access clinical trial result physician patient general public maintain government regulatory authority independent organization eg phrma certain inspection member party shall involve member party extent feasible gcp glp gmp audit process facility performance development activity combination product include facility subcontractor extent permit pursuant term applicable subcontract permit applicable subcontractor shall consider good faith issue concern compliance safety efficacy issue respect combination product active pharmaceutical ingredient member party single agent product double agent product applicable raise member party reasonable basis result audits member party shall right normal business hour reasonable notice inspect member party facility facility subcontractor extent permit pursuant term applicable subcontract permit applicable subcontractor performance development activity combination product member party desiring inspection reasonable basis raise good faith compliance safety efficacy issue apart aforementioned audit inspection audit refer section shall subject reasonable restriction access confidential information trade secret inspect member party extent confidential information trade secret expressly require disclose member party member party pursuant agreement medical affair medical communication gilead bms shall determine independently utilize deploy respective medical science liaison activity relate combination product jdc shall develop approve presentation material use member party medical science liaison engage activity support promotion combination product medical science liaison shall use approve presentation material activity jdc shall develop member party shall implement procedure coordinate training member party medical science liaison approve presentation material b jdc shall develop guideline procedure determine provide appropriate response medical inquiry combination product include assign responsibility medical communication party shall develop set standard response document member party use respond medical inquiry combination product follow member party shall develop standard response document relate respective single agent product double agent product incorporate combination product ii gilead shall develop draft standard response document relate combination product substantially incorporate developed member party single agent product andor double agent product review comment approval jdc section manufacture supply clinical supply gilead shall manufacture manufacture subcontractor behalf jv clinical supply combination product quantity need clinical trial study require obtain initial approval nda connection manufacture gilead bms shall donate jv quantity ftc tdf case gilead efv case bms member party cost good supply gilead cost good manufacture clinical supply combination product shall chargeable jv commercial supply initial development plan designate initial commercial supplier combination product supplier shall source combination product supply purpose nda filing launch territory effective date jcc shall determine costefficient manner source commercial supply combination product include limitation alternate supplier term agreement jcc shall review annually appropriate source commercial supply combination product launch agree appropriate change member party propose interim change respect thereto time time review change jcc shall adopt failure likely material adverse effect combination product business gilead bms desire consider possible supplier combination product shall submit confidential write proposal jv consideration jcc alongside write proposal submit recognize reliable sufficiently capitalize party andor supply term pertain initial supplier proposal submit possible supplier shall include offer perform require tablete blister packaging label analytical testing storage activity respect commercial supply combination product jcc shall select person supply jv commercial supply combination product basis price quality reliability gmp compliance security supply relevant commercial consideration party select supplier jcc shall designate member party manage relationship supplier supply contract jv gilead bms supplier shall negotiate armslength basis shall contain term condition customary pharmaceutical industry modify appropriate combination product b jcc directly designate member party coordination jdc shall monitor manufacturing capacity forecast order combination product submit relevant supplier ensure adequate commercial supply combination product available meet demand therefor project jcc commercial unit volume forecast jcc shall prepare rolling unit volume forecast commencement forecast period shall update unit volume forecast basis jcc deem necessary appropriate c connection manufacture supplier commercial supply combination product jv gilead bms shall supply jv quantity ftc tdf case gilead efv case bms case form bulk active pharmaceutical ingredient pursuant accordance respective supply agreement consideration supply jv shall pay gilead bms respectively gilead transfer price bms transfer price jdc shall monitor order respective supply agreement assure consistency quantity ftc tdf efv order jv thereunder section commercialization activity copromotion obligation gilead bms shall use commercially reasonable effort perform territory commercialization activity member party require perform commercialization plan accordance commercialization budget applicable activity long commercialization plan effect member party shall require initial launch period extent applicable thereto subsequent launch period calendar quarter action applicable specified commercialization plan subject section shall apply subsequent launch period approve jec jcc applicable commercialization plan update pursuant section c ii subsequent launch period approve member party member party shall free engage engage long commercialization plan effect case sole discretion b gilead bms shall select independently target prescriber shall promote combination product c accordance section b gilead bms shall cause field force use fda approve product label insert subject section approve marketing material promote combination product statement claim combination product consistent applicable law fdaapprove product label insert gilead bms shall provide access sample combination product health care practitioner patient connection promotion combination product gilead bms shall detail combination product perform promotional activity agreement territory strict adherence regulatory professional requirement applicable law include extent applicable act fda guidance industrysupporte scientific educational activity pharmaceutical research manufacturers america code interaction healthcare professional office inspector general compliance program guidance pharmaceutical manufacturer american medical association guideline gift physicians industry pharmaceutical marketing research group guideline market research activity prescription drug marketing act amend pdma federal state local fraud abuse consumer protection false claim statute regulation include limited medicare state health program antifraud abuse amendment social security act safe harbor regulation find cfr et seq party member party shall treat sale representative engage detail combination product affiliate employee purpose include limitation federal state local tax employment law e end calendar quarter thereof fall initial launch period ii extent applicable thereto subsequent launch period iii period commence subsequent launch period mutually agree member party pursuant section clause ii iii refer collectively product detail period gilead bms shall furnish party write report form set forth annex h attach hereto set number detail conduct calendar quarter thereof territory number report shall determine accordance applicable selfreporting procedure detail customarily employ member party territory similarly detail similarly report hiv product target health care audience consistently apply f calendar year thereof fall product detail period subject term section f member party shall conduct x calendar quarter thereof specify commercialization plan calendar year thereof specify commercialization plan ie extent product detail period include calendar quarter calendar quarter shall calendar quarter applicable calendar year detail conduct member party calendar quarter member party detail conduct case order subject section g calendar year detail conduct member party calendar year notwithstanding agreement contrary member party shall ii failure member comply section f result shall subject g calendar quarter member party expect experience succeed calendar quarter thereof shall inform member party anticipate write notice promptly practicable later date report refer section e member party shall right succeed calendar quarter thereof anticipate succeed calendar quarter thereof give notice member party intent receive notice avoidance doubt member party give notice member party shall member party equal product multiply multiplied case shall distribution obligation gilead shall sole responsibility right fill order respect combination product behalf jv reason bms receive sale order combination product shall promptly forward order gilead order combination product reject gilead rejection commercially reasonable circumstance jcc shall determine jv shall respond request individual patient obtain prescription combination product unable afford health care provider behalf patient include limitation establish appropriate procedure response time shall apply respond request provide jcc shall structure applicable program manner evident health care provider patient participation jv appropriate member party program shall ensure procedure response times favorable patient favorable member party patient assistance program single agent product andor double agent product effective date jcc shall review arrangement patient assistance program annually agree appropriate change member party propose interim change respect thereto time time review change jcc shall adopt failure likely material adverse effect combination product business b limitation forego gilead shall perform function distributor respect sale combination product behalf jv include limitation inventory management control warehouse distribution invoicing collection sale proceed preparation sale record report customer relation service handle return accordance customary practice biopharmaceutical industry pursuant separate service agreement enter party effective date substantially term outline annex p c gileads relationship wholesale distributor combination product shall govern inventory management agreement reduce inventory fluctuation extent commercially feasible agreement cover gilead product field shall commercially reasonable respect relate thereto gilead shall ensure ii basis gilead shall use commercially reasonable effort inventory level combination product wholesale distributor subject fluctuation expect launch period combination product pricing combination product gilead shall sole responsibility act agent sell combination product behalf jv price define pursuant provision section set forth annex q b gilead bms shall appoint member pricing committee jv pricing committee representative member party representative shall employee member party time appointment time service pricing committee involve directly indirectly member partys affiliate provide purpose section duty solely respect account receivable analysis bookkeepe accounting shall deem involvement representative shall skill reasonably appropriate responsibility function member pricing committee representative member party representative shall member party furthermore member party covenant immediately individual service pricing committee short period employ member party affiliate assign function position involve directly indirectly price member partys affiliate product member party shall right approve member party propose representative representative pricing committee replacement therefor approval shall unreasonably withhold subject precede sentence member party shall right replace representative andor representative time time term agreement provide composition pricing committee change meet requirement set forth section b avoidance doubt pricing committee operating committee jv accordingly reference agreement operating agreement applicable ancillary agreement operating committee shall apply pricing committee pricing committee determine sole discretion retain independent legal counsel case expense counsel shall deem authorize expense c gilead bms shall responsible performance representative pricing committee compliance term section issue pricing committee shall review gilead bms shall bear expense relate pricing committee include limitation expense relate meeting pricing committee participation member party representative meeting communication member party connection meeting matter authority pricing committee travel meeting expense shall deem jv expense authorize expense pricing committee shall responsible ongoing basis gilead agent jv accordance section ii according respect define jv pricing committee shall meet quarterly meeting conduct telephone videoconference equipment long attendee able hear require time time serve applicable gilead agent jv gilead agent jv shall authority case e interpretation necessary representative pricing committee shall discuss matter representative attempt resolve matter consensus event consensus reach respect gilead agent jv shall f functional role representative pricing committee shall limited coordinate gilead agent jv ascertain ii asneede basis provide pricing committee case iii asneede basis specifically request respect provide pricing committee specifically limited pertinent representative shall agree necessary appropriate iv apply respect v ensure combination product case g member party request member write notice member party cause independent accounting expert select pursuant section confirm accuracy respect andor ii pricing committee include limitation case case member party pricing committee shall cooperate independent accounting expert independent accounting expert entry appropriate confidentiality agreement provide datum necessary requisite calculation write request member party calculation independent accounting expert shall audit second party mutually agree member party independent accounting expert party auditor shall notify jec respective determination notification shall contain information provide independent accounting expert andor party auditor member party calculation independent accounting expert pursuant section g shall bind pricing committee party provide event party auditor identifie discrepancy independent accounting expert calculation member party shall cause independent accounting expert party auditor confer agree final calculation advise member party write final agree calculation shall bind party request member shall bear fee cost independent accounting expert connection confirmation accuracy determination andor information independent accounting expert find discrepancy equal great case jv case discrepancy member party case discrepancy shall bear fee cost section g shall deem limit remedy available member party event breach provision section member party notwithstanding agreement contrary breach shall subject cure provision set forth section h information provide pricing committee pricing information shall consider confidential information disclose member party shall solely purpose purpose avoidance doubt exception confidentiality set forth section section b shall apply pricing information expressly permit pricing information shall disclose pricing committee representative counsel independent accounting expert party auditor select pursuant section g pricing information shall maintain pricing committee shall accessible person member price committee limit forego bms gilead shall cause representative pricing committee disclose person ii reference use directly indirectly information pricing committee prior launch combination product annually jec shall review recently modify pursuant section applicable light thenprevaile market condition jv marketing sale strategy appropriate jec shall recommend member party change jec action inaction section shall subject arbitration gilead bms mutually agree change propose jec change shall deem hereunder j gilead bms shall retain sole discretion respect pricesetting discount respective single agent product double agent product notwithstanding forego member party covenant shall shall directly indirectly solely primarily purpose national account gilead shall sole responsibility act agent conduct pricing activity behalf jv relate governmental organization aid drug assistance program correctional facility system manage care organization national account payor segment territory include limitation contract strategy contract creation activity shall define commercialization plan shall comply section respect pricing activity bms shall share commercialization activity correctional facility system national account performance subcontract gilead bms shall comply shall cause affiliate comply applicable law regulation approval conduct respective commercialization activity member party subcontract performance commercialization activity allocate commercialization plan provide subcontract member party shall oversee performance subcontractor subcontract commercialization activity manner reasonably expect result timely successful completion shall remain responsible performance commercialization activity accordance agreement commercialization plan provide gilead bms engage subcontractor include limitation contract sale organization perform detail combination product conflict avoidance gilead bms agree ensure initial launch period field force employee engage marketing combination product shall market territory territory marketing material jcc shall develop approve initial set advertising promotional material combination product jcc reach agreement respect material jec shall attempt resolve dispute issue relate material event jcc follow dispute jcc jec shall reach agreement respect material modify time time pursuant section approve marketing material subject subparagraph b member party shall use approve marketing material approve marketing material fdaapprove product label package insert promote combination product territory month follow launch jcc jec unable reach agreement material member party shall promote combination product territory fdaapproved product label package insert combination product b member party propose interim update approve marketing material time time independent annual review conduct pursuant section c jcc shall require consider shall adopt update satisfy follow condition update base relevant new scientific medical clinical datum relevant new regulatory legal development change fdaapprove label package insert combination product ii absence update use approve marketing material comply applicable law update satisfy condition require update c approximately launch jcc shall review appropriate update approve marketing material update shall include minimum require update jcc reach agreement require update propose member party matter shall subject dispute resolution section event jcc jec able reach agreement propose require update relate require update member party elect write notice member party promote combination product territory fdaapproved product label package insert ii approve marketing material modify reflect require update connection review conduct pursuant section c jcc appropriate change arise business consideration optional update propose member party event jcc reach agreement propose optional update dispute shall subject dispute resolution section provide event jcc jec able reach agreement propose optional update member party elect write notice member party promote combination product territory fdaapproved product label package insert ii approve marketing material optional update e review conduct pursuant section c jcc shall review recent revise marketing material annual basis shall require update consider optional update propose member party dispute jcc relate update shall resolve procedure set forth section c f jv shall right title interest approve marketing material notwithstanding agreement contrary member party shall use promotion combination product territory material fdaapprove product label insert approve marketing material jcc shall select marketing combination product advertising agency agency jv shall retain agency agency commercially reasonable term jcc shall develop implement oversee orderly systematic process involve representative legal medical regulatory function respective member party review approval advertising promotional material interaction fda allocation member party right responsibility shall set forth section development use trademark jcc shall select combination product trademark shall own jv subject applicable law jv shall include trademark gilead parent bms parent label packaging advertising material combination product territory jv shall comply notice mark requirement applicable intellectual property law protection enforcement trademark jv gilead bms notice mark requirement commercially reasonable circumstance insurance member party agree jv member party shall obligation event member party elect arise exploitation combination product member party shall sole right avoidance doubt contain section intend shall construe limit member partys jvs indemnity obligation pursuant section record maintenance record gilead bms shall severally accordance respective allocation responsibility respect project activity maintain retain cause maintain retain final record draft record document require applicable law respective commercialization activity cover commercialization plan year ii long period require applicable law b access record subject section b member party shall right respect record maintain member party member party commercialization activity cover commercialization plan normal business hour reasonable notice inspect copy record solely extent relate combination product solely extent necessary order receive member party perform obligation respect commercialization activity manner consistent commercialization plan ii necessary receive member party confirm compliance andor comply glp gcp gmp extent applicable applicable law relate project activity andor iii necessary enable receive member party conduct reasonable diligence matter potentially give rise liability jv andor receive member party conduct defense andor jv respect liability extent fact circumstance event arisen give receive member party reasonable basis believe jv incur liability case use receive member party purpose set forth clause ii iii case clause iii immediately precede sentence shall require party provide datum documentation record event party interest matter case shall apply request shall writing shall state reason commercial record request member party record documentation datum request shall right raise reasonable objection write response commercial record request include limitation base member partys interest protect disclosure request member party trade secret competitive business information objection assert member party shall promptly confer attempt address member partys concern reach resolution respect matter event member party unable agree mutually agreeable resolution member party shall right refer matter jcc event dispute ultimately determine threshold matter extent criterion set forth clause ii andor iii satisfied request member party shall determination respect extent disclosure information shall require make determination fact argument set forth commercial record request member party write response thereto right require receive member party abide term condition handle use nondisclosure member partys organization andor party information reasonable circumstance provide section member party shall right obtain member party access copy member party record documentation datum describe expressly permit pursuant agreement member party give consent sole discretion notwithstanding forego member party shall obligation respect pricing discount matter set forth section member party shall provide member party information extent relate price setting discount inventory management agreement member party restrict disclose pursuant applicable law confidentiality contractual arrangement party commercialization plan budget commercialization plan shall cover activity commercialization combination product territory shall conduct single member party coordinate member party activity shall conform collaboration principle provision section b initial commercialization plan attach hereto annex c cover period effective date initial launch period commercialization plan update shall contain budget member partys outofpocket expense member partys activity set forth commercialization budget initial commercialization plan cover member party territory initial launch period ii combination product initial launch period iii certain marketing commercialization activity combination product require conduct single member party coordinate member party provide effective date member party shall x supplement initial commercialization plan order assign member party respective responsibility execute activity refer clause iii revise initial commercialization plan commercialization budget amount set forth annex c respect period effective date commencement initial launch period report calendar yearcalendar quarter basis reflect timing amount contemplate annex c update commercialization plan shall cover include activity cover initial commercialization plan mutually agree member party c prior propose date filing approval nda combination product territory member party shall revise thencurrent commercialization plan commercialization budget amount set forth respect initial launch period report calendar yearcalendar quarter basis reflect timing amount contemplated thencurrent commercialization plan commercialization budget responsible member party determine shall prepare submit jcc jfc prior start calendar year propose update commercialization plan commercialization budget calendar year ii prior start calendar year preliminary update commercialization budget address budget issue general level incomplete subject change follow review discussion revision propose update jcc shall vote update prior start applicable calendar year bm shall prepare annual update responsibility shall rotate bms gilead yeartoyear basis annual schedule update calendar year subsequent launch period end long period agree member party addition member party directly representatives jcc propose interim update commercialization plan commercialization budget jcc time time appropriate light change circumstance annual interim update period commence calendar year contain end subsequent launch period shall approve jcc set forth section bii subject section vi propose update commercialization plan commercialization budget approve jec jcc applicable commercialization plan commercialization budget case shall continue effect approve recently update pursuant section c commercialization expense party agree jv shall bear jv expense incur gilead bms connection performance respective commercialization activity extent meet follow criterion authorize commercialization expense commercialization activity cover consistent commercialization plan area responsibility relevant member party list commercialization budget chargeable jv b total expense member party designate activity commercialization plan relevant period extent exceed aggregate set forth commercialization budget activity period c expense external outofpocket cost gilead bms markup internal cost include limitation internal cost incur relevant commercialization activity marketing combination product marketing proprietary product gilead bms notwithstanding limitation contain clause event member party reasonably believe cost efficiency jv reasonably expect achieve member party conduct commercialization activity respect combination product coordination activity conduct member party respect single agent product andor double agent product member partyie propose jcc member activity coordinate appropriate reasonable allocation relate cost combination product hand product product hand allocate combination product treat authorize commercialization expense proposal cost allocation proposal extent cost allocation proposal review jfc jcc pursuant sections bvii bviii respectively approve jec pursuant section ix modification jec approve jec allocation combination product approve cost allocate cost shall constitute authorized commercialization expense report gilead bms shall present meeting jcc calendar quarter second anniversary launch combination product meet jcc semiannually report oral write write report shall require contain detail typically include executive summary describe commercialization activity perform cause perform precede meeting report present case meet jcc prior meeting calendar yearto date basis evaluate work perform relation goal timeline commercialization plan ii commercialization activity process future activity expect initiate thencurrent calendar year compare commercialization plan iii case write report authorize commercialization expense incur expect incur member party thencurrent calendar year compare commercialization budget applicable addition gilead bms shall report promptly jcc respective committee member material development respect commercialization activity responsible perform commercialization plan notwithstanding contain section contrary member party reporting obligation section shall automatically deem terminate respect period effect commercialization plan andor commercialization budget section license grant technology license member party jv subject term condition agreement gilead grant jv sole royaltyfree license license shall exclusive bms affiliate party gilead affiliate right grant sublicense solely set forth section c pursuant section gilead technology exploit combination product active pharmaceutical ingredient thereof exploit active pharmaceutical ingredient thereof individually combination combination product worldwide b subject term condition agreement bms grant jv sole royaltyfree license license shall exclusive gilead affiliate party bms affiliate right grant sublicense solely set forth section c pursuant section bms technology exploit combination product active pharmaceutical ingredient thereof exploit active pharmaceutical ingredient thereof individually combination combination product applicable efv territory license sublicense jv member party subject term condition agreement jv grant follow license sublicense gilead nonexclusive royaltyfree sublicense right grant sublicense license grant jv section b nonexclusive royaltyfree license right grant sublicense joint technology joint invention right title interest jv gilead core improvement patent claim improvement additionally perpetual royaltyfree fully paidup irrevocable exclusive jv license right grant sublicense multiple tier right title interest jv gilead core improvement patent claim improvement case clause exploit combination product exploit efv active pharmaceutical ingredient individually combination combination product territory ii conduct world development activity support approval combination product territory iii import territory combination product efv active pharmaceutical ingredient exploitation territory case ii iii pursuant accordance agreement include limitation performance gilead obligation development plan commercialization plan case clause exploit improvement worldwide respect product contain tdf ftc active pharmaceutical ingredient combination active pharmaceutical ingredient exclude efv proprietary bms active pharmaceutical ingredient b bms nonexclusive royaltyfree sublicense right grant sublicense license grant jv section nonexclusive royaltyfree license right grant sublicense joint technology joint invention right title interest jv bms core improvement patent claim improvement additionally perpetual royaltyfree fully paidup irrevocable exclusive jv license right grant sublicense multiple tier right title interest jv bms core improvement patent claim improvement case clause exploit combination product exploit tdf ftc active pharmaceutical ingredient individually combination combination product territory ii conduct world development activity support approval combination product territory iii import territory combination product tdf ftc active pharmaceutical ingredient exploitation territory case ii iii pursuant accordance agreement include limitation performance bms obligation development plan commercialization plan case clause exploit improvement efv license agreement territory respect product contain efv active pharmaceutical ingredient combination active pharmaceutical ingredient exclude tdf ftc proprietary gilead pharmaceutical ingredient c gilead bms perpetual nonexclusive royaltyfree license right grant sublicense multiple tier joint technology joint invention include limitation joint knowhow consist clinical datum relevant experience information cmc datum finish product manufacture datum exploit worldwide basis case gilead efv license agreement territory case bms member party single agent product double agent product case ii pharmaceutical compound product combination product case ii combination agent gilead exclusive royaltyfree right grant sublicense multiple tier license grant jv section b joint technology joint invention include limitation joint knowhow consist clinical datum relevant experience information cmc datum finish product manufacture datum right title interest jv gilead core improvement patent claim improvement exploit combination product exploit active pharmaceutical ingredient thereof individually combination combination product worldwide territory canada europe conduct world development activity support approval combination product worldwide approval territory canada europe world import world combination product active pharmaceutical ingredient thereof individually combination combination product exploitation worldwide exploitation territory canada europe license continue effect long long gilead material breach condition set forth follow clause v section subject sentence section gilead shall use commercially reasonable effort obtain bm appropriate legally permissible public recognition bms role enable access combination product develop world include follow order preference inclusion bms licensor applicable manufacturer packaging label combination product sell provide use develop world b acknowledgement bms licensor applicable manufacturer supplier efv press release public announcement relate provision combination product develop world c acknowledgement bms licensor applicable manufacturer supplier efv website maintain cooperation gilead specifically promote enable provision combination product develop world provide party acknowledge gilead ensure require party regulatory authority consent approval recognition obtain ii provide section gilead shall cause sale jv combination product use sale outside territory iii bm prior write consent unreasonably withhold delay gilead shall grant sublicense license grant section utilize manufacture combination product person contract manufacture supply tablete combination product bms affiliate joint venture similar entity bms ownership interest person act behalf forego iv event gilead exploit combination product outside territory canada europe pursuant license grant section bms agree perform administrative ministerial act reasonably necessary useful order enable gilead satisfy obligation clause iii enable gilead exercise right license grant section gilead agree bms consent bms shall additional obligation include limitation obligation incur additional expense obligation result exploitation follow bms obligation provide section bms obligation pursuant section sentence section b sentence section bms obligation pursuant applicable law separate agreement member party include limitation applicable bms supply agreement v gilead shall cause sublicensee section comply obligation gilead clause iv failure sublicensee comply material respect obligation gilead shall deem failure gilead comply respect obligation gilead material breach clause v gilead license section shall terminate bms give notice gilead breach breach remain uncured day gilead receipt notice long period reasonably require cure breach provide gilead commercially reasonable effort effect cure clarity material breach clause v shall rise right cure termination agreement pursuant section agreement party acknowledge agree remedy specific performance set forth section shall available respect material breach gilead obligation section material breach bms obligation section div section section license right reference member party subject term condition agreement gilead grant bms nonexclusive right reference efv license agreement territory respect gilead knowhow consist clinical datum relevant experience information b nonexclusive royaltyfree fully paidup irrevocable license right grant sublicense multiple tier use gilead knowhow efv license agreement territory case b solely extent reasonably necessary enable bms exploit single agent product combination agent gilead single agent product double agent product efv license agreement territory manner consistent labeling approve marketing material combination product perpetual royaltyfree fully paidup irrevocable exclusive gilead affiliate license right grant sublicense multiple tier right title interest gilead affiliate bms core improvement patent claim improvement exploit improvement efv license agreement territory respect product contain efv active pharmaceutical ingredient combination active pharmaceutical ingredient exclude tdf ftc proprietary gilead pharmaceutical ingredient clarity gilead shall require transfer gilead knowhow bms pursuant section b subject term condition agreement bms grant gilead worldwide nonexclusive right reference respect bms knowhow consist clinical datum relevant experience information b worldwide nonexclusive royaltyfree fully paidup irrevocable license right grant sublicense multiple tier use bms knowhow case b solely extent reasonably necessary enable gilead exploit single agent product double agent product applicable combination agent bms single agent product manner consistent labeling approve marketing material combination product perpetual worldwide royalty free fully paidup irrevocable exclusive bms affiliate license right grant sublicense multiple tier right title interest bms affiliate gilead core improvement patent claim improvement exploit improvement respect product contain tdf ftc active pharmaceutical ingredient combination active pharmaceutical ingredient exclude efv proprietary bms active pharmaceutical ingredient clarity bm shall require transfer bms knowhow gilead pursuant section b right reference jv relate matter subject term condition agreement gilead bms grant jv non exclusive right reference territory regard gilead regulatory documentation bms regulatory documentation respectively purpose jvs secure maintain update approval agree provide sign statement effect accordance cfr g b subject term condition agreement jv grant bms nonexclusive right reference territory regard combination product regulatory documentation purpose bms secure maintain update nda sustiva product contain efv combination product agree provide sign statement effect accordance cfr g c subject term condition agreement jv grant gilead nonexclusive right reference territory regard combination product regulatory documentation purpose gilead secure maintain update nda viread emtriva truvada product contain tdf ftc combination product agree provide sign statement effect accordance cfr g long license grant gilead section remain effect jv shall member agree cause jv cooperate gilead combination product regulatory documentation available gilead include potentially file snda nda need change combination product label applicable qualify different presentation combination product export grant right reference thereto use securing approval fda export combination product secure approval regulatory authority use sale outside territory canada europe ii bms jv grant gilead right reference country worldwide outside territory canada europe solely purpose file approval combination product country right reference shall continue long license grant gilead section remain effect agree perform administrative ministerial act reasonably necessary useful order enable gilead avail right reference iii bms jv shall permit gilead designee provide copy combination product regulatory documentation datum information regulatory authority outside territory canada europe shall permit gilead obtain provide certificate pharmaceutical product combination product approve fda regulatory authority submission regulatory authority outside territory canada europe shall provide documentation consent necessary effectuate right reference permit gilead forego action clause ii combination product regulatory documentation combination product certificate pharmaceutical product clarity bms grant right clause ii iii shall construe bms grant right gilead bms technology outside applicable efv territory sublicense supply agreement supplier select pursuant section jv shall right grant supplier nonexclusive royaltyfree worldwide sublicense right sublicense joint technology license grant jv section b sole purpose manufacture combination product active pharmaceutical ingredient thereof supply jv trademark license member party jv subject term condition agreement gilead grant jv nonexclusive royaltyfree fully paidup license right sublicense multiple tier use territory trademark list annex f hereto gilead license trademark sole purpose exploitation combination product exploit active pharmaceutical ingredient thereof individually combination combination product territory ii gilead parent company logoidentifier use jv andor product label product package promotional material combination product pursuant section b subject term condition agreement bms grant jv nonexclusive royaltyfree fully paidup license right sublicense use territory trademark list annex g hereto bms license trademark sole purpose exploitation combination product exploit active pharmaceutical ingredient thereof individually combination combination product territory ii bms parent company logoidentifier use jv andor product label product package promotional material combination product pursuant section c member party shall responsible determine monitor step need order satisfy jvs use trademark ie gilead license trademark bms license trademark case meet commercially reasonable high quality standard specification instruction submit approve gilead bms respectively connection agreement gilead jv recognize bms right title interest bms license trademark gilead jv recognize agreement use bms license trademark connection agreement way confer gilead jv right title interest bms license trademark trademark intellectual property right own bm expressly provide agreement bms jv recognize gilead right title interest gilead license trademark bms jv recognize agreement use gilead license trademark connection agreement way confer bms jv right title interest gilead license trademark trademark intellectual property right own gilead expressly provide agreement e jv acknowledge goodwill generate jvs use gilead license trademark inure solely benefit gilead ii goodwill generate jvs use bms license trademark inure solely benefit bms trademark license jv gilead subject term condition agreement jv grant gilead nonexclusive royaltyfree fully paidup license country territory world exclude territory canada europe right sublicense multiple tier use combination product trademark sole purpose exploitation combination product exploit active pharmaceutical ingredient thereof individually combination combination product country territory provide license shall remain effect long gilead license pursuant section remain effect b bms gilead recognize jvs right title interest combination product trademark bms gilead recognize agreement use combination product trademark connection agreement way confer bms gilead right title interest combination product trademark trademark intellectual property right own jv expressly provide agreement c bms gilead acknowledge goodwill generate use combination product trademark inure solely benefit jv retain right license right specifically grant section expressly reserve licensing party license grant section sublicensable transfer assign licensee party connection permit assignment agreement party section combination product sale outside territory canada europe request gilead bms jv act purpose bms representative applicable shall negotiate good faith commercially reasonable arrangement take account relevant economic market condition relevant territory eg bms supplier transfer price combination product territory supply enable supply efv active pharmaceutical ingredient manufacture combination product case bm manufacturing enable party manufacture efv active pharmaceutical ingredient combination product case jv case sufficient allow gilead designee jv permit section b sell provide combination product use develop world territory outside territory canada europe meet anticipated demand therefor country b request gilead permit applicable law rule regulation consent bms consent unreasonably withhold delayed party shall cooperate enable cause jv combination product available export use sale develop world include limitation sale territory combination product export use sale develop world effort party shall negotiate good faith appropriate amendment agreement operating agreement consistent clause v section section c c payment respect supply efv applicable combination product bms jv pursuant section bms jv shall entitle additional financial compensation form license fee milestone payment royalty reason sale jv person authorize gilead combination product use outside territory canada europe reason jvs grant license section combination product sale europe party acknowledge agree combination product shall sold commercially distribute europe applicable covering sale distribution commence efv license agreement notwithstanding agreement contrary gilead agree exercise right grant section territory outside efv license agreement territory reach agreement efv licensor necessary gilead avoid infringe misappropriate intellectual property right efv licensor territory request gilead bms shall cooperate gilead effort reach agreement jv obligation sublicensee jv shall comply provision applicable sublicensee set forth efv license agreement form provide bms gilead pursuant section c license agreement deliver gilead bms pursuant sentence section c form deliver respectively include limitation provision respect report information record keep access record audit upstream licensor exclude payment obligation matter member party responsible section obligation effective date specifically identify annex respect refer annex shall use commercially reasonable effort effective date grant sublicense jv agreement require shall form substance reasonably acceptable section payment party royalty payment member party consideration supply gilead bms jv quantitie respective active pharmaceutical ingredient manufacture nonclinical supply combination product pursuant section c respective supply agreement consideration provision certain service hereunder subject adjustment pursuant section jv shall pay gilead gilead transfer price bms sub bms transfer price accordance section give calendar year pursuant section jfc shall calculate interim gilead transfer price kilogram tdf ftc bulk active pharmaceutical ingredient respectively ie applicable transfer price accordance annex k hereto kilogram bulk active pharmaceutical ingredient interim gilead unit transfer price ii interim bms transfer price kilogram efv active pharmaceutical ingredient ie applicable transfer price accordance annex k hereto kilogram efv active pharmaceutical ingredient interim bms unit transfer price case base respective working percentage calculate pursuant section ci estimate net sell price combination product determine jfc respect calendar year pursuant section cii relevant target yield active pharmaceutical ingredient calculate pursuant annex k hereto jfc shall inform gilead bms respective interim unit transfer price pursuant section ciii subject sentence section c gilead bms sub shall use thencurrent interim unit transfer price prepare invoice shipment bulk active pharmaceutical ingredient make pursuant section c supply agreement b actual gilead percentage actual bms percentage particular calendar year shall equal percent multiply fraction denominator sum net selling price truvada sustiva territory relevant calendar year numerator actual gilead percentage net selling price truvada territory relevant calendar year ii actual bms percentage net selling price sustiva territory relevant calendar year provide limitation obligation member party section j purpose calculate numerator denominator fraction actual gilead percentage actual bms percentage net selling price sustiva truvada relevant calendar year calendar year shall shall event termination agreement effective date fall date december calendar year determination actual percentage shall base period january calendar year effective date termination instead entire calendar year provision agreement shall apply mutatis mutandis period c jfc shall determine member party interim unit transfer price calendar year member party respective working percentage estimate net selling price target yield follow bms gilead shall agree write work bms percentage work gilead percentage calendar year shall equal respective actual percentage calendar year relevant datum calendar year inclusive subsequent calendar year respective working percentage shall equal actual bms percentage actual gilead percentage respectively immediately precede calendar year provide respect calendar year pende determination actual percentage immediately precede calendar year working percentage immediately precede calendar year shall remain effect time actual percentage immediately precede calendar year determine bms gilead shall agree write target yield efv tdf ftc calendar year subsequent calendar year relevant target yield efv tdf ftc shall calculate pursuant section dii annex k ii later subsequent calendar year jfc shall determine estimate net sell price combination product calendar year historical datum calendar year estimate net selling price iii member party respective working percentage estimate net selling price target yield calendar year jfc shall calculate member party interim unit transfer price accordance annex k shall notify member party write later day day applicable calendar year date member party receive notice jfc respect member party respective interim unit transfer price respect calendar year amount shall member party invoice jv transfer price shipment bulk active pharmaceutical ingredient pursuant section c applicable supply agreement calendar year notwithstanding forego calendar quarter basis jfc shall recalculate respective interim unit transfer price recalculate transfer price accordance annex k end recalculation shall working percentage target yield update net selling price determine annex event particular interim unit transfer price recalculate transfer price jv shall deliver reconciliation statement applicable member party set forth difference price multiply quantity active pharmaceutical ingredient member party invoice jv event particular interim unit transfer price great recalculate transfer price jv shall deliver reconciliation statement applicable member party set forth difference price multiply quantity active pharmaceutical ingredient member party invoice jv case relevant adjustment shall address cash netting mechanism provide section operating agreement shall settle cash netting day follow recalculation interim unit transfer price shall change result recalculation mention iv follow jv shall cause independent accounting expert calculate solely plan accounting bookkeeping purpose member party actual percentage base datum complete later respective percentage shall change result recalculation mention follow end calendar year jfc shall cause independent party accounting firm consultant mutually agree member party agree party independent accounting expert calculate actual percentage calendar year recalculate transfer price product yield determine pursuant section dii actual net selling price combination product determine pursuant section diii respect shipment bulk active pharmaceutical ingredient member party calendar year pursuant section c respective supply agreement follow follow end calendar year member party shall provide independent accounting expert datum necessary order calculation require pursuant section datum describe annex n ii follow end calendar year jfc shall calculate product efv yield product ftc yield product tdf yield case base actual yield supply combination product b provide independent accounting expert write confirmation calculation follow fullscale commercial manufacturing run jfc shall determine blended average product efv yield product ftc yield tdf product yield weight unit basis inform independent accounting expert thereof iii follow end calendar year jv shall cause independent accounting expert calculate actual net selling price combination product truvada sustiva calendar year b calculate actual gilead percentage actual bms percentage pursuant section b actual net selling price combination product truvada sustiva calendar year c recalculate gilead transfer price bms transfer price bulk active pharmaceutical ingredient shipment calendar year pursuant section accordance annex k iv follow end calendar year basis recalculate transfer price notify jv independent accounting expert jfc shall recalculate amount owe jv member party respect shipment receive jv calendar year pursuant section c respective supply agreement provide member party notice recalculate amount adjustment require pursuant section div aggregate invoice member party transfer price great aggregate owe member party jv transfer price recalculate pursuant section relevant adjustment shall address cash netting mechanism provide section operating agreement shall settle cash netting day follow recalculation e independent accounting expert shall bind commercially reasonable write confidentiality nonuse obligation member party independent accounting expert shall write request member party initiate member audit member party confirm accuracy datum provide independent accounting expert member party write request member party calculation independent accounting expert shall audit second party mutually agree member party independent accounting expert party auditor shall notify member party respective determination provide independent accounting expert party select audit independent accounting expert shall share member party information provide independent accounting expert andor party member party calculation independent accounting expert pursuant section e shall bind party provide event party auditor identifie discrepancy independent accounting expert calculation member party shall cause independent accounting expert party confer agree final calculation advise member party write final agree calculation shall bind party initiate member shall bear fee cost independent accounting expert connection confirmation accuracy datum independent accounting expert find discrepancy equal great case member party shall bear fee cost royalty payment party party patent infringe partys trade secret misappropriate solely direct result incorporation tdf ftc tdf ftc combination product gilead shall solely responsible loss royalty license fee payment obligation party shall qualify jv expense authorize expense connection infringement misappropriation include limitation obligation pursuant section party patent infringe partys trade secret misappropriate solely direct result incorporation efv combination product bms shall solely responsible loss royalty license fee payment obligation party shall qualify jv expense authorize expense connection infringement misappropriation include limitation obligation pursuant section royalty license fee payment gilead bms party connection license party patent party trade secret reasonably necessary performance member party obligation agreement shall qualify authorized commercialization expense authorize expense mode time payment jv shall bear authorize expense incur gilead bms member party shall calculate invoice jv respective authorize expense incur calendar quarter sufficient time ensure applicable invoice receive jv later day calendar quarter final invoice date jv shall obligation payment gilead bms account expense incur give calendar quarter invoice receive final invoice date b payment jv member party pursuant section bii payment member party agreement shall wire transfer electronic fund transfer united states dollars requisite bank account member party designate time time notice payor c member party shall calculate invoice jv time shipment transfer price shipment bulk active pharmaceutical ingredient pursuant section c applicable supply agreement applicable interim unit transfer price jv shall pay member party amount owe member party case bms bms sub pursuant section applicable cash netting day provide section operating agreement case shipment bulk active pharmaceutical ingredient pursuant applicable supply agreement calendar quarter give calendar year prior jfc give notice applicable interim unit transfer price member party provide shipment shall use interim unit transfer price immediately precede calendar year purpose invoicing shipment provide jfc determination new interim unit transfer price calendar year shipment occur pursuant section annex k jv shall recalculate invoice new interim transfer price calendar year time payment shall issue applicable member party reconciliation statement respect invoice reconcile difference original transfer price shipment transfer price shipment calculate new interim unit transfer price interest shall accrue delinquent payment date payment less prime rate interest publish wall street journal eastern united states edition plus basis point ii maximum rate interest permissible applicable law take consideration amount deem additional interest taxis jv shall responsible sale use excise value add similar taxis charge impose respect acquisition product member party andor payments jv member party pursuant section provide member party shall responsible taxis include taxis impose way withhold nature income franchise taxis base measured gross net income impose respect income jv shall pay withholding taxis similar charge impose governmental unit require withhold amount member party jv pursuant section proper tax authority proof payment taxis charge shall secure send member party evidence payment amount pay jv pursuant immediately precede sentence respect taxis member party responsible pursuant sentence section shall pay account member party deduct amount jv member party pursuant section section financial record financial record gilead shall complete accurate book record behalf jv pertain sale combination product include limitation book record net sale combination product detail require calculation behalf jv amount payable jv section identify purchase order detail customer sell combination product pertain authorize commercialization expense authorize development expense authorize expense gilead shall retain book record late year calendar quarter relevant sale relevant expense reimburse pursuant section b expiration applicable statute limitation tax purpose extension thereof c long period require applicable law gilead bms shall record authorize commercialization expense authorize development expense authorize expense incur late year calendar quarter invoice jv ii expiration applicable statute limitation tax purpose expiration thereof iii long period require applicable law gilead bms shall documentation support x year calendar quarter occur long period require applicable law audit record request bms gilead case member party shall permit independent certify public accountant reasonably acceptable member party reasonable time reasonable notice examine book record maintain member party applicable book record maintain gilead behalf jv pursuant section verify follow accuracy amount invoice member party jv pursuant section b authorize commercialization expense authorize development expense authorize expense charge member jv case period end year prior date request party accountant shall bound write commercially reasonable confidentiality nonuse obligation member party member party shall receive copy party accountant report audit shall disclose amount invoice charge correct incorrect amount underpayment overpayment report shall confidential information member party discrepancy shall rectify reconciliation payment underpay party overpay party case thirty day receipt notice thereof audit establish nonrequeste member party jv error invoicing payment detriment request member party equal great relevant amount period audit outofpocket cost audit shall qualify authorized expense case cost audit shall borne solely request member party shall qualify jv expense authorize expense bms gilead audit request section behalf behalf jv certain report bms satisfy internal reporting need gilead shall provide bms applicable time set forth annex financial datum describe annex section adverse event information exchange pharmacovigilance subject term agreement bms gilead guidance respective pharmacovigilance department equivalent thereof shall define finalize mutually acceptable guideline procedure follow member party respect receipt investigation recordation communication exchange member party adverse event report pregnancy report information concern safety combination product efv tdf ftc appropriate guideline procedure shall include agreement refer safety datum exchange agreement sdea enter member party prior early occur anniversary effective date ii dose combination product patient shall accordance enable party affiliate fulfill local international regulatory reporting obligation government authority furthermore agree procedure shall consistent relevant international council harmonization guideline say guideline conflict exist local regulatory safety reporting requirement case local reporting requirement shall prevail limitation forego sdea shall include provision state gilead shall primarily responsible comply applicable law collect report regulatory authority information adverse event associate use combination product ii gilead shall maintain global safety database combination product iii bms shall right review approve psur prepare gilead approval unreasonably withhold material communication addition notification require section sdea member party shall promptly provide notice member party material communication governmental agency concern safety combination product include limitation adverse drug reaction report copy material communication shall attach applicable notice section product recall notification recall event governmental agency authority issue request recall market withdrawal take similar action connection combination product event member party determines recall market withdrawal combination product necessary advisable member party shall advise member party thereof telephone member party shall notify promptly event issuance fda field alert similar alert member party case member party issue field alert shall notify member party time applicable governmental agency authority ii communication governmental agency authority potential recall market withdrawal combination product member party respective single agent product double agent product b receipt notice give pursuant sentence section member party shall cause respective representative business medical regulatory quality assurance legal function deem necessary member party convene initial meeting consider jv conduct recall case governmentmandate recall market withdrawal representative shall recommendation member party respect determination recommendation recall combination product respect time recall breadth extent level customer recall shall reach strategy notification related issue member party shall unreasonably object recall request member party member party shall right object recall request member party failure combination product meet specification therefor ii reasonable basis conclude material harm patient occur iii manufacture combination product manner comply act notwithstanding forego recall market withdrawal mandate governmental agency authority recall propose member party account member party single agent product double agent product member party cause jv accordingly gilead shall action behalf jv effectuate recall reasonable term member party determine meeting describe sentence section b liability member party jv expense describe section indemnity amount payable party pursuant section c member party commercial reason mutually determine withdraw combination product market reason market withdrawal relate efficacy safety withdrawal shall treat mandate government agency authority deal provide section b case jv shall receive fda approval cease sell combination product member party shall mutually determine recall combination product market set forth section shall construe restrict right member party timely report matter government agency action deem appropriate require applicable law recall expenses member party shall bear expense recall combination product proportion respective percentage respective external outofpocket cost recall markup shall qualify authorized expense provide member party shall bear expense recall incur reasonable manner extent recall cause member partys breach obligation agreement supply agreement supplier supply contract refer section gross negligence willful misconduct b occasion solely member party single agent product andor double agent product case expense recall shall include limitation expense notification destruction return recall combination product refund consumer amount pay recall combination product section intellectual property right ownership intellectual property gilead intellectual property expressly provide section party gilead shall right title interest gilead patent gilead knowhow gilead invention gilead regulatory documentation gilead shall disclose shall cause affiliate disclose bms bms core improvement promptly conceive discover develop b bms intellectual property expressly provide section b b party bms shall right title interest bms patent bms knowhow bms invention bms regulatory documentation bms shall disclose shall cause affiliate disclose gilead gilead core improvement promptly conceive discover develop c jv intellectual property expressly provide section b c party jv shall right title interest joint patent joint knowhow joint invention combination product regulatory documentation expressly permit agreement party include limitation jv shall license assign sell convey exploit right joint patent joint knowhow joint invention combination product regulatory documentation purpose member party shall disclose member party promptly write joint invention conceive discover develop behalf member party member party assign agree cause employee agent assign jv payment additional consideration member party right title interest joint invention prosecution patent gilead patent gilead shall sole right sole cost expense prepare file prosecute maintain gilead patent territory gilead shall sole discretion determine gilead patent shall list orange book respect combination product b bms patent bms shall sole right sole cost expense prepare file prosecute maintain bms patent territory bm shall sole discretion determine bms patent shall list orange book respect combination product c joint patent patent application joint patent claim joint invention shall file mutual write agreement member party solely accordance section c event member party desire file patent application joint patent claim joint invention member party shall propose file member party representative designate member party shall discuss consider matter event member party fail reach write agreement patent application file member party behalf jv party file cause file patent application ii event member party mutually agree write pursuant section ci patent application joint patent claim joint invention file gilead shall sole right obligation prepare file prosecute maintain joint patent jv country member party shall determine external outof pocket cost markup respect thereto shall treat authorize expense bms shall cooperate fully gileads preparation filing prosecution maintenance joint patent proceeding patent official office respect thereto cooperation shall include limitation promptly execute paper instrument require employee execute paper instrument reasonable appropriate enable gilead prepare file prosecute maintain joint patent country b promptly inform gilead matter affect preparation filing prosecution maintenance joint patent include limitation provide copy official correspondence receive bms patent office country respect joint patent gilead shall bms advise status joint patent filing request bms shall provide copy official correspondence documentation respect official action submission relate prosecution maintenance joint patent iii member party shall sole discretion determine mutual agreement joint patent shall list orange book respect combination product enforcement patent gilead patent party gilead shall sole right option sole cost expense respond infringement define respect gilead patent appropriate step include limitation file infringement suit take similar action gilead shall sole right option action respond infringement event party shall right action respond infringement respect gilead patent gilead request bms jv shall partys expense provide reasonable assistance gilead connection action respond infringement include limitation provide access relevant document evidence make employee available reasonable business hour join jv join action extent necessary allow gilead maintain action purpose section infringement shall mean infringement potential infringement gilead patent andor bms patent case action party connection product infringe combination product contain active pharmaceutical ingredient tdf ftc efv ii similar action shall include limitation response paragraph iv certification drug price competition patent restoration act know hatchwaxman act result attempt market generic version combination product paragraph iv certification avoidance doubt party acknowledge agree infringement gilead patent bms patent case infringe combination product outside scope agreement shall create right impose obligation party hereunder include right obligation action respond infringement b bms patent party bms shall sole right option sole cost expense respond infringement respect bms patent appropriate step include limitation file infringement suit take similar action bms shall sole right option action respond infringement event party shall right action respond infringement respect bms patent request bms gilead jv shall partys expense provide reasonable assistance bms efv licensor applicable connection action respond infringement include limitation provide access relevant document evidence make employee available reasonable business hour join jv join action extent necessary allow bms efv licensor maintain action c joint patent member party determine joint patent infringe party activity shall notify member party writing provide evidence infringement reasonably available gilead behalf jv shall right option respond infringement respect joint patent appropriate step include limitation file infringement suit take similar action shall notify bms consult bms time time suit action gilead elect sole discretion action respond infringement bms behalf jv shall right option respond infringement appropriate step include limitation file infringement suit take similar action shall notify gilead consult gilead time time suit action limit forego event gilead behalf jv receive paragraph iv certification respect combination product gilead shall notify bms receipt paragraph iv certification gilead election describe precede sentence gilead elect action respond infringement fail notify bm period bms shall right describe immediately precede sentence member party take action respond infringement shall provide reasonable assistance member party take action include limitation provide access relevant document evidence make employee available reasonable business hour join action extent necessary allow member party take action maintain action amount recover member party pursuant section c settlement judgment shall deem recover behalf shall pay jv reasonable outofpocket cost include reasonable attorney fee markup incur member party make recovery shall treat authorize expense paragraph iv certification member party shall notify member party writing receive paragraph iv certification respect combination product case bms sustiva case gilead viread emtriva truvada applicable infringement party right party initiate proceed jv member party allege conduct project activity infringe infringe partys patent misappropriate misappropriate partys trade secret proceeding arise direct result tdf ftc tdf ftc incorporate combination product case reference efv gilead shall defend hold jv bms harmless proceeding loss result proceed shall sole right obligation defend proceeding settle eg obtain license party gilead sole cost shall deem jv expense authorize expense bms shall reasonably cooperate gilead request expense defense andor settlement b claim arise direct result efv incorporate combination product case reference tdf ftc bms shall defend hold jv gilead harmless proceeding loss result proceed shall sole right obligation defend proceeding settle eg obtain license party bm sole cost shall deem jv expense authorize expense gilead shall reasonably cooperate bms request expense defense andor settlement c event clause b apply jec shall determine defend claim obtain license party term condition outofpocket cost markup shall deem authorize expense member party shall action behalf jv procedure set forth section shall apply indemnification member party section trademark gilead license trademark gilead shall sole right sole cost expense search clear file register prosecute maintain enforce gilead license trademark territory gilead shall sole right option sole cost expense respond infringement respect gilead license trademark appropriate step include limitation file infringement suit take similar action gilead shall sole right option prosecute maintain enforce gilead license trademark action respond infringement b bms license trademark bms shall sole right sole cost expense search clear file register prosecute maintain enforce bms license trademark territory bm shall sole right option sole cost expense respond infringement respect bms license trademark appropriate step include limitation file infringement suit take similar action bms shall sole right option prosecute maintain enforce bms license trademark action respond infringement c combination product trademark expressly provide section party agree jv shall right title interest combination product trademark gilead shall solely responsible searching clearing filing register prosecute maintain combination product trademark territory jv external outofpocket cost markup shall treat authorize expense member party reasonable basis believe party engage commercially significant infringement combination product trademark member party shall notify member party writing provide evidence infringement reasonably available gilead shall right option respond infringement potential infringement respect combination product trademark appropriate step include limitation file infringement suit take similar action shall notify bms consult bms time time suit action gilead elect sole discretion action respond infringement potential infringement thirty day gilead aware infringement potential infringement bms shall right option respond infringement potential infringement appropriate step include limitation file infringement suit take similar action shall notify gilead consult gilead time time suit action member party take action respond infringement potential infringement shall provide reasonable assistance member party take action include limitation provide access relevant document evidence make employee available reasonable business hour join action extent necessary allow member party take action maintain action amount recover member party pursuant section c settlement judgment shall deem recover behalf shall pay jv reasonable outofpocket cost include reasonable attorney fee markup incur member party make recovery shall treat authorize expense section confidentiality treatment confidential information provide section term agreement year agreement expiration termination party receive party shall hold strict confidence shall publish disclose directly indirectly party confidential information party affiliate collectively disclose party b permit pursuant section shall directly indirectly use confidential information disclose party purpose performance obligation exercise right agreement permit agreement operating agreement ancillary agreement c shall use level effort maintain confidentiality confidential information disclose party use confidential proprietary information event commercially reasonable effort permit disclosure party disclose confidential information disclose party extent disclosure required specific person entity applicable law rule regulation order court competent jurisdiction supranational federal national regional state provincial local governmental regulatory body competent jurisdiction provide receive party shall give notice disclose party give disclose party reasonable opportunity seek available limitation exemption protection available disclosure requirement reasonably cooperate effort disclose party provide exemption disclosure requirement obtain confidential information disclose response requirement shall limit information legally require disclose b require law opinion legal counsel receive party express opinion letter form substance reasonably satisfactory disclosing party shall provide disclose party business day prior receive partys disclosure confidential information pursuant section b c required applicable law regulation include limitation regulation fd relate security rule national association securities dealer new york stock exchange applicable association govern stock exchange member party stock list include limitation filing report form k q k securities exchange commission case procedure set forth section shall apply section applicable filing ii procedure set forth proviso section b shall apply form filing copy agreement gilead bms case securities exchange commission comply applicable law provide member party request confidential treatment commercial term material term hereof extent confidential treatment reasonably available member party ii solicit member party comment request confidential treatment case file member party shall use commercially reasonable effort account member party reasonable comment request e subject section receive party regulatory authority require connection filing application request regulatory approval comply requirement applicable law provide reasonable measure shall take assure confidential treatment information f receive party necessary file prosecute patent application prosecute defend litigation establish right enforce obligation agreement g receive party employee affiliate independent contractor legal counsel consultant auditor advisor bind confidentiality nonuse obligation protective section reasonably require confidential information performance member partys obligation enforcement member party right agreement include limitation matter describe section j provide receive party shall remain responsible failure person treat confidential information require section h receive party licensor respective technology pursuant contractual obligation licensor exist effective date obligation confidentiality nonuse protective section provide receive party shall remain responsible failure person treat confidential information require section receive party necessary filing tax return pursuant audit thereof j permit pursuant section section confidential information define confidential information party shall mean term agreement information invention provide behalf party party case section pricing committee connection discussion negotiation pertain agreement include mutual confidential disclosure agreement enter bristolmyer squibb company gilead sciences inc december course perform agreement mtta include limitation material term agreement datum knowledge practice process idea research plan engineering design drawing research datum manufacturing process technique scientific manufacturing marketing business plan financial personnel matter relate disclose party present future product sale supplier customer employee investor business avoidance doubt confidential information shall include information provide party party relate combination product mention party single agent product double agent product applicable provide information provide party party relate improvement core technology party shall deem confidential information party b exclusion notwithstanding forego information invention disclose party shall deem confidential information respect receive party purpose agreement know receive party affiliate obligation confidentiality nonuse time disclosure receive party ii generally available know public domain time disclosure receive party iii generally available know public domain disclosure receive party fault receive party affiliate iv disclose receive party affiliate obligation confidentiality nonuse party obligation disclose party disclose information invention v independently discover develop receive party affiliate evidence write record use confidential information belong disclose party specific aspect detail confidential information shall deem public domain possession party merely confidential information embrace general information public domain possession party combination confidential information shall consider public domain possession party merely individual element confidential information public domain possession party combination principle public domain possession party use subject section member party shall mention use insignia symbol trademark trade logotype party abbreviation adaptation thereof publication press release promotional material form publicity prior write approval member party instance purpose section approve marketing material shall deem approve member party restriction impose section shall prohibit member party make disclosure identify party require applicable law publicity term agreement party shall joint public announcement execution delivery agreement substantially form joint press release attach annex l hereto execution agreement b public disclosure joint press release pursuant section member party desire public announcement press release concern material term agreement member party shall reasonable prior advance notice propose text announcement member party prior review approval provide section b approval unreasonably withhold member party comment propose announcement shall provide comment soon reasonably practicable event business day receive propose announcement review member party shall right press release announce receipt approval subject review procedure set forth precede sentence member party shall require seek permission member party repeat information term agreement publicly disclose member party accordance section section event legally require press release public announcement disclosure member party question shall provide member party copy propose text notice practicable shall business day prior propose disclosure member party shall respond comment promptly practicable business day prior propose disclosure member party question shall consideration reasonable comment member party provide timely manner provide member party determine legally require disclosure regulation fd shall right disclosure time necessary comply regulation fd shall provide member party notice opportunity review comment practicable circumstance notification receive party shall notify disclose party immediately cooperate disclose party disclosing party reasonably request receive party discovery loss compromise disclosing party confidential information permit use notwithstanding provision agreement contrary regardless member party disclose party extent confidential information relate specifically combination product include confidential information consist combination product regulatory documentation member party shall right use confidential information connection exploitation combination product extent permit term condition agreement include limitation use accordance license grant jv member party section right reference grant jv member party section b c case b connection preparation andor submission regulatory authority require connection filing application request regulatory approval combination product world remedy party agree unauthorized use disclosure material confidential information receive party violation agreement cause severe irreparable damage disclose party money damage represent insufficient remedy event violation section notwithstanding agreement contrary disclosing party shall authorize entitle seek court competent jurisdiction injunctive relief preliminary permanent respect violation relief permit applicable law obtain relief make show insufficiency money damage irreparable harm receive party agree waive requirement disclose party post bond condition obtain relief section warranty indemnity representation warranty covenant member party represent warrants covenant member party effective date follow member party applicable power authority legal right enter agreement operating agreement ancillary agreement party perform obligation hereunder thereunder ii take necessary action require authorize execution delivery agreement operating agreement ancillary agreement party agreement operating agreement case ancillary agreement member party party execute deliver duly execute deliver behalf member party constitutes case ancillary agreement member party party duly execute deliver shall constitute legal valid binding obligation member party case ancillary agreement member party party duly execute deliver shall enforceable accordance term subject effect bankruptcy insolvency law general application affect enforcement creditor right judicial principle affect availability specific performance general principle equity enforceability consider proceeding law equity b member party aware pende threatened litigation receive communication allege member partys activity relate agreement violate conduct activity contemplate agreement party violate intellectual property right person give effect license grant agreement effective date member party deliver member party list set forth extent member partys knowledge product liability litigation ii intellectual property litigation reasonably likely material adverse effect member party single agent product double agent product combination product applicable right license grant member party member party jv hereunder respect product iii litigation investigation initiate warning letter receive regulatory authority include form letter case respect manufacturing case ii iii relate member party single agent product double agent product b litigation investigation currently pende pende warning letter receive time c necessary consent approval authorization regulatory governmental authority person require obtain member party connection execution delivery agreement performance obligation agreement obtain respect member party applicable execution delivery agreement operating agreement ancillary agreement party performance member partys obligation hereunder thereunder conflict violate material way requirement applicable law ii conflict violate provision article incorporation bylaw limited partnership agreement similar instrument member party applicable ii conflict violate breach constitute default require consent contractual obligation court administrative order member party bind additional representation warranty covenant bms bms represent warrant covenant gilead bms parent bms sub corporation limited liability company case duly organize good standing law state delaware ii power authority legal right operate property asset carry business conduct contemplate conduct agreement b bms affiliate debar subject debarment bms affiliate shall use capacity connection service perform agreement person debar pursuant section act subject conviction describe section bms agree inform gilead writing immediately person perform service agreement debar subject conviction describe section action suit claim investigation legal administrative proceeding pende knowledge bms threaten relate debarment conviction bms person perform service agreement c bms right grant license bms patent set forth section b prior effective date grant party right license respect bms patent conflict grant right license gilead jv hereunder bms patent subject encumbrance lien party encumbrance lien aggregate material adverse effect license right grant jv gilead agreement prior effective date bms deliver gilead copy financial term redact license similar grant right bms hand party hand pursuant bms obtain party license right respect bms patent ii pursuant bms grant party license right respect bms patent exploitation territory bms covenant agree agreement refer precede sentence include extension amendment renewal thereof shall effective date term agreement grant party right license respect bms patent conflict grant gilead jv hereunder judgment settlement amount respect thereto owe bms relate bms patent knowledge bm receive write notice proceed allege bms patent invalid unenforceable ii exploitation efv combination tdf ftc infringe party patent e knowledge bms information contain bms single agent product label nda bms single agent product represent material respect complete accurate reflection safety efficacy profile bms single agent product effective date bms shall use commercially reasonable effort maintain single agent product label bms regulatory documentation update need ensure information continues represent complete accurate reflection material respect safety efficacy profile single agent product understand agree bms make representation covenant gilead set forth section e solely purpose member party collaboration pursuant agreement purpose f quantity efv provide bms pursuant section manufacture reasonable care ii conform applicable efv bulk specification define bms supply agreement applicable certificate analysis time delivery iii convey bms good title free lawful security interest lien encumbrance bms affiliate party supplier applicable obtain approval require applicable regulatory authority manufacture efv use sustiva additional representation warranty covenant gilead gilead represent warrant covenant bms gilead parent gilead sub corporation limited liability company case duly organize validly exist good standing law state delaware power authority legal right operate property asset carry business conduct contemplate conduct agreement b gilead affiliate debar subject debarment gilead affiliate shall use capacity connection service perform agreement person debar pursuant section act subject conviction describe section gilead agree inform bms writing immediately person perform service agreement debar subject conviction describe section action suit claim investigation legal administrative proceeding pende knowledge gilead threaten relate debarment conviction gilead person perform service agreement c gilead right grant license gilead patent set forth section prior effective date grant party right license respect gilead patent conflict grant right license bms jv hereunder gilead patent subject encumbrance lien party encumbrance lien aggregate material adverse effect license right grant jv bms agreement prior effective date gilead deliver bms copy financial term redact license similar grant right gilead hand party hand pursuant gilead obtain party license right respect gilead patent ii pursuant gilead grant party license right respect gilead patent exploitation territory gilead covenant agree agreement refer precede sentence include extension amendment renewal thereof shall effective date term agreement grant party right license respect gilead patent conflict grant gilead jv hereunder judgment settlement amount respect thereto owe gilead relate gilead patent knowledge gilead receive write notice proceed allege gilead patent invalid unenforceable ii exploitation tdf ftc combination efv infringe party patent e knowledge gilead information contain label gilead single agent product double agent product nda gilead single agent product double agent product represent material respect complete accurate reflection safety efficacy profile gilead single agent product double agent product effective date gilead shall use commercially reasonable effort maintain single double agent product label gilead regulatory documentation update need ensure information continue represent complete accurate reflection material respect safety efficacy profile single double agent product understand agree gilead make representation covenant bms set forth section e solely purpose member party collaboration pursuant agreement purpose f quantitie ftc tdf provide gilead pursuant section manufacture reasonable care ii conform applicable product specification define gilead supply agreement applicable certificate analysis time delivery iii convey gilead good title free lawful security interest lien encumbrance gilead affiliate party supplier applicable obtain approval require applicable regulatory authority manufacture ftc tdf use viread emtriva truvada applicable disclaimer set forth section party disclaim warranty write oral express imply include limitation respect single agent product double agent product combination product active pharmaceutical ingredient combination product supply agreement technology license agreement include limitation warranty quality performance merchantability fitness particular use purpose avoidance doubt contain section shall operate limit invalidate warranty contain ancillary agreement indemnification jv jv shall indemnify member party affiliate respective officer director employee proceeding member party affiliate involve threaten involved arise exploitation combination product member partys affiliate performance obligation compliance agreement operating agreement sdea mtta ii loss incur indemnitee result proceeding b limitation forego clause proceeding member party affiliate involve threaten involved arise content approve marketing material extent approve marketing material member party b performance member partys duty section respect formulation manufacturing process development relate activity agreement c performance tax matter member duty operating agreement jvs use combination product trademark gilead license trademark andor bms license trademark ii loss incur indemnitee result proceeding case b extent proceeding arise loss cause indemnitee member partys affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea case b extent member party obligation indemnity loss proceeding pursuant section section case indemnification provide section shall deem exclusive right indemnify entitle applicable statute agreement vote jec expressly provide agreement include limitation section section loss incur jv shall borne member party accordance term operate agreement indemnification member party general member party indemnify member party shall indemnify jv member party affiliate respective officer director employee proceeding jv member party affiliate involve threaten involved arise indemnify member partys affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea ii content approve marketing material indemnify member party accordance section follow receipt notification member party accordance section member party elect use approve marketing material promotion combination product territory provide member party use approve marketing material promotion combination product territory b loss incur indemnitee result proceeding extent proceeding arise loss cause member partys affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea extent member party jv obligation indemnity loss proceeding pursuant section section section case indemnification provide section shall deem exclusive right indemnify entitle applicable statute agreement vote jec indemnification certain product liability relate matter gilead shall indemnify jv bm indemnify party proceeding jv bm indemnify party involve threaten involved arise personal injury death cause combination product design defect manufacture defect inherent characteristic thereof defect characteristic direct result incorporation combination product tdf ftc tdf ftc case reference incorporation combination product efv select product liability claim irrespective defect characteristic associate defect characteristic tdf andor ftc ii loss incur jv bms indemnify party case result proceeding extent proceeding arise loss cause bms affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea b bm shall indemnify jv gilead indemnify party proceeding jv gilead indemnify party involve threaten involved arise personal injury death cause combination product design defect manufacture defect inherent characteristic thereof defect characteristic direct result incorporation combination product efv case reference incorporation combination product tdf ftc select product liability claim irrespective defect characteristic associate defect characteristic efv ii loss incur jv gilead indemnify party case result proceeding extent proceeding arise loss cause gilead affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea c jv shall indemnify gilead indemnify party bms indemnify party proceeding gilead indemnify party bm indemnify party case involve threaten involved arise personal injury death cause combination product design defect manufacture defect inherent characteristic thereof defect characteristic direct result efv tdf andor ftc incorporate combination product b ultimately determined defect characteristic direct result efv hand tdf ftc hand incorporate combination product c defect characteristic direct result aspect combination product active ingredient claim b c select product liability claim ii loss incur gilead indemnify party bm indemnify party case result proceeding case extent proceeding arise loss cause member partys affiliate subcontractor gross negligence willful misconduct failure comply perform covenant agreement operating agreement sdea mtta breach inaccuracy representation warranty agreement operating agreement applicable sdea extent member party obligation indemnity loss proceeding pursuant section purpose section b c shall deem affiliate gilead provide bms shall great scope liability pursuant section less scope liability bms gilead pursuant section b ii scope liability gilead pursuant effective date indemnification procedure indemnify party agree indemnify party prompt write notice loss discovery fact include proceed indemnify party intend base request indemnification section case understood agree failure notice provide section shall relieve indemnify party indemnification obligation extent indemnify party actually materially prejudiced result failure notice b party shall furnish promptly party copy paper official document receive respect proceeding indemnify party shall reasonably cooperate request expense indemnify party defense proceeding c respect loss relate solely payment money damage shall result indemnify party subject injunctive relief adversely affect indemnify party manner indemnify party shall acknowledge write obligation indemnify indemnify party agreement indemnify party shall sole right defend settle dispose proceeding term indemnify party shall deem appropriate respect loss address section c indemnify party shall acknowledge write obligation indemnify indemnify party agreement indemnify party shall sole right control defense relevant proceeding provide indemnify party shall obtain write consent indemnify party shall unreasonably withhold prior cease defend settle dispose proceeding result thereof indemnify party responsible payment money damage cost respect indemnify party contest challenge contest challenge obligation indemnify ii indemnify party subject injunctive equitable relief remedy payment money indemnify party iii indemnified party adversely affect e furthermore respect section c indemnify party shall entitle control proceeding notifie indemnify party thirty day delivery notice indemnify party section f indemnify party shall liable loss result settlement disposition proceeding indemnify party reach write consent indemnify party g allocation member party jv liability loss proceeding determine court law shall consider jec jec reach agreement allocation unanimous member vote unanimous write consent member member party shall right refer dispute arbitration pursuant section dispute resolution procedure section shall apply dispute arise section g h outofpocket expense reasonably incur indemnify party connection proceeding shall reimburse calendar quarter basis indemnify party prejudice indemnifying party right contest indemnify party right indemnification subject refund event indemnify party ultimately hold obligated indemnify indemnify party limitation damage breach section party shall liable special indirect incidental consequential damage include limitation lose profit contract warranty negligence tort strict liability arise breach failure perform provision agreement provide party shall liable provide party shall liable provide breach intentional arise act omission constitute gross negligence section intend shall operate limit partys obligation indemnity respect loss award party proceed section ancillary agreement reference agreement ancillary agreement sdea obligation ancillary agreement shall construed include scope indemnification obligation party agreement liability arise ancillary agreement obligation ancillary agreement employee party agree party action take omit take employee member party affiliate capacity member jec operating committee pricing committee action take omit take employee member party affiliate respect project activity shall attribute member party accordingly claim member party jv arising action inaction shall assert directly member party affiliate individual employer member party jv case waif claim individual section term termination term term agreement shall commence effective date shall continue terminate mutual agreement party accordance section certain litigation agreement shall terminate notice give member party member party event governmental authority seek obtain temporary restraining order preliminary injunction enjoin transaction contemplate agreement institute litigation seek relief respect transaction applicable law territory termination nda filing delay member party terminate agreement notice member party nda combination product field file december b nda combination product field approve december material default member party breach member party fail comply perform material respect material obligation contain agreement operating agreement act omission member party cause failure jv comply perform material respect material obligation contain agreement operating agreement default material default member party nonbreache member party shall right breach member party notice specify nature material default breach member party shall period day receipt notice fully cure material default manner reasonably acceptable nonbreache member party period member party shall discuss good faith appropriate adjustment cancellation member party respective obligation agreement permit continuation agreement jv mutually agreeable basis avoidance doubt nonbreache member party sole discretion deliver notice material default breach member party prior completion dispute resolution procedure set forth section case day cure period refer precede sentence shall begin run receipt notice shall run concurrently procedure b breach member party cure material default pursuant section member party discussion pursuant sentence section lead mutually agreeable restructuring agreement nonbreache member party breach member party mutually agree desirable practicable withdraw combination product market territory nonbreache member party shall right terminate agreement notice breach member party give thirty day cessation member party discussion pursuant sentence section termination shall effective withdrawal member party shall cooperate cause jv effect withdrawal promptly practicable applicable law c termination agreement pursuant section b nonbreache member party shall right seek damage account material default arbitration pursuant section express remedy nonbreache member party pursuant section shall addition remedy favor non breach member party applicable jv provide agreement operating agreement applicable bms guarantee agreement gilead guarantee agreement applicable party acknowledge member party enter agreement operating agreement reliance member party continued compliance performance obligation agreement operating agreement accordingly member party agree material default cause severe irreparable damage nonbreache member party jv applicable money damage represent insufficient remedy event material default notwithstanding agreement contrary nonbreache member party shall authorize entitle seek arbitrator section remedy specific performance respect material default relief permit applicable law obtain relief make show insufficiency money damage breach member party agree waive requirement nonbreache member party post bond condition obtain relief termination generic launch member party continue member party terminate agreement notice member party terminate member party event launch territory generic version single agent product double agent product terminate member party generic version launch continue member party delivers notice termination thirty day generic version launch termination shall effective day calendar quarter notice give consequence termination termination pursuant section b member party terminate agreement pursuant section b license sublicense grant right reference section member party jv shall terminate ii right reference license grant section b shall survive solely extent necessary order licensee member party support label single agent product andor double agent product applicable approve effective date termination iii license grant section b shall survive iv license grant right reference section jv member party shall survive date jv dissolve intangible property define operating agreement distribute kind member party pursuant section c operating agreement v gilead breach member party license right grant gilead section respect combination product outside territory canada europe shall survive event license right shall deemed grant bms directly gilead vi jv shall dissolve accordance operating agreement connection dissolution combination product trademark shall sell member bidding process vii operating agreement ancillary agreement shall terminate expressly provide agreement viii member party shall promptly event thirty day arrangement return disposal member partys option confidential information tangible intangible form x copy retain solely archival purpose confidential information relate survive license right describe b termination pursuant section termination agreement pursuant section jv shall dissolve follow term condition shall apply license grant right reference section terminate member party jv shall survive trademark license grant section shall survive extent necessary enable continue member party identify terminate member party label combination product andor combination product regulatory documentation require applicable law b gilead terminate member party license grant section jv gilead shall terminate c license sublicense grant section jv terminate member party shall terminate section b applicable c gilead terminate member party sublicense grant section shall address set forth clause f license grant right reference member party member party section shall survive e right reference jv terminate member party section b c shall survive f gilead terminate member party sublicense right reference grant gilead section respect combination product outside territory canada europe shall survive ii continue member party shall pay cause jv pay terminate party manner set forth section b subject mutatis mutandis section respect period effective date termination thereof determine pursuant follow formula net sale net selling price case determine applicable yearly period net sale combination product net selling price combination product net selling price continue member party single agent product double agent productnet selling price combination product multiply follow percentage follow month period commence effective date termination jv pay member party shall pay amount owe member party pursuant section bii day end calendar quarter relevant net sale invoice payment shall accompany write report provide detailed breakdown calculation amount pay relevant period iii terminate member party election shall promptly notify continue member party writing shall pursuant license andor supply agreement contain follow term term member party mutually agree enable continue member party manufacture quantity efv tdf ftc case bulk active pharmaceutical ingredient form use manufacture combination product use territory event terminate member party shall automatically deem grant royaltyfree nonexclusive license continue member party party designee shall reasonably acceptable terminate member party terminate member party patent cover manufacture information invention manufacture behalf terminate member party manufacture ingredient sole purpose ingredient manufacture combination product territory provide reasonable technical assistance continue member party party designee choice recipient shall subject prior approval terminate member party approval unreasonably withhold delayed continue member partys expense terminate member party thencurrent standard term condition b continue supply jv designee nonexclusive basis quantity efv tdf ftc case bulk active pharmaceutical ingredient form continue member party request manufacture combination product territory transfer price supply equal cost good notwithstanding forego terminate member party elect pursuant clause b continue supply applicable bulk active pharmaceutical ingredient determine cease manufacture ingredient desire terminate aforementioned supply arrangement continue member party time continue member party manufacture manufacture combination product event terminate member party elect cease manufacture ingredient desire terminate supply arrangement terminate member party shall x continue member party write notice prior cease manufacture terminate agreement grant continue member party license describe clause z provide continue member party technical assistance describe clause event terminate member party jv continue member party enter supply arrangement bulk active pharmaceutical ingredient pursuant sentence section biii jv continue member party case desire terminate supply arrangement receive terminate member party license describe clause technical assistance describe clause jv continue member party case shall provide write notice thereof terminate member party jv continue member party shall responsible party royalty payable terminate member party respect supply provide terminate member party pursuant section biii iv jv shall change remove terminate member party continue member party shall shall cause jv include trademark terminate member party labeling packaging advertising material combination product connection jvs business respect combination product v terminate member party shall promptly event thirty day arrangement return disposal continue member partys option confidential information tangible intangible form x copy retain solely archival purpose confidential information relate survive license right pursuant section bi vi expressly provide operating agreement andor ancillary agreement operating agreement ancillary agreement shall terminate vii jv shall immediately discontinue use terminate member partys trademark license grant terminate member party jv use terminate member partys trademark shall immediately revert terminate member party viii avoidance doubt pricing provision contain section shall terminate right bankruptcy right license grant pursuant agreement jv bms gilead shall deem purpose section n united states bankruptcy code license right intellectual property define section united states bankruptcy code party agree jv bms gilead licensee right agreement shall retain fully exercise right election united states bankruptcy code party agree event commencement bankruptcy proceed jv member party united states bankruptcy code nonsubject party shall entitle complete duplicate complete access nonsubject party deem appropriate intellectual property embodiment intellectual property possession shall promptly deliver commencement bankruptcy proceeding non subject party write request therefor party subject proceeding elect continue perform obligation agreement b deliver clause follow rejection agreement behalf party subject proceeding write request therefor nonsubject party provision section prejudice right non subject party arise bankruptcy code applicable law accrue right survive obligation termination expiration agreement shall prejudice right shall accrue benefit party prior termination expiration termination expiration shall relieve party obligation expressly indicate survive termination expiration agreement b limit contain section section provision shall implement member party modify payment pursuant section bii e second sentence thereof e second sentence thereof apply survive provision survive right license shall survive termination expiration agreement reason section general provision force majeure party shall hold liable responsible party deem default breach agreement failure delay fulfil perform term agreement payment amount agreement failure delay cause result cause reasonable control non perform party include limitation fire flood embargo shortage epidemic quarantine war act war war declare terrorism insurrection riot civil commotion act god act omission delay act governmental authority nonperforme party shall notify party force majeure day occurrence give write notice party state nature event anticipate duration action take avoid minimize effect suspension performance shall great scope long duration necessary nonperforme party shall use period suspension performance commercially reasonable effort remedy inability perform provide event suspension performance continue ninety day date force majeure commence party shall meet discuss good faith proceed order accomplish collaboration principle purpose agreement force majeure shall include failure commit sufficient resource financial project activity general market economic condition notice notice request report statement communication party specify section c shall write shall refer specifically agreement shall deliver personally send nationallyrecognize overnight courier send register certify mail postage prepay return receipt request follow respective address address specify notice time time relevant party gilead gilead sciences inc lakeside drive foster city attn evp cfo copy gilead sciences inc lakeside drive foster city attn vp general counsel covington burl street san francisco attn james c snipes esq bms bristolmyers squibb worldwide medicine group route province line road princeton nj attn vice president senior counsel corporate business development copy hughe hubbard reed llp battery park plaza new york ny attn ellen friedenberg esq communication shall deem give deliver personally deliver recipient normal business hours ii business day dispatch send nationallyrecognize overnight courier proof delivery obtain iii rd business day follow date mailing send mail understand agree section intend govern daytoday business communication necessary party perform duty course term agreement agreement require permit give notice member party notice give bms parent behalf bms sub gilead parent behalf gilead sub assurance party shall duly execute deliver cause duly execute deliver instrument cause ministerial administrative similar act thing include limitation file assignment agreement document instrument necessary party reasonably request connection agreement carry effectively provision purpose hereof well assure confirm unto party right remedy agreement successor assign term provision hereof shall inure benefit bind party respective successor permit assign expressly permit pursuant section member party prior write consent member party assign transfer right interest subcontract delegate obligation agreement provide member party consent assign right delegate duty agreement affiliate directly indirectly whollyowne subsidiary gilead parent bms parent case provide assign member party shall remain primarily secondarily derivatively liable timely performance affiliate obligation agreement provide set forth clause ii assignment delegation shall terminate automatically time affiliate cease whollyowne directly indirectly gilead parent bms parent case ii member party consent assign right delegate duty agreement contract operation law party acquirer event change control member party permit successor assignee right andor obligation hereunder permit assignee shall write deliver party time assignment expressly assume performance right andor obligation jv assign agreement prior write consent member party purport assignment transfer subcontract delegation member party jv violation term section shall null void legal effect b event change control member party transferring member party transferring member party shall member party write notice thereof day identify party acquirer time change control party acquirer market territory compete product commercially available effective date write notice member party election transferring member party thirty day member partys receive write notice change control party acquirer shall party acquirer fail performance obligation payment obligation member party agreement shall terminate extent minimum obligation reasonably require jv obtain maintain approval combination product territory b gilead act agent sell combination product behalf jv perform obligation respect pricing discount combination product pursuant section c member party supply jv bulk active pharmaceutical ingredient pursuant section applicable supply agreement ii commercialization plan budget include minimum commercialization expenditure andor shall terminate iii member party shall right promote market commercialize combination product territory coordination member party agreement include obligation reach agreement form approve marketing material govern law agreement shall govern construe accordance law state delaware reference rule conflict law thereof arbitration dispute member party member party jv relate arise validity interpretation construction compliance breach agreement operating agreement ancillary agreement agreement contemplate agreement member party affiliate jv andor member party affiliate party shall expressly provide agreement operating agreement ancillary agreement agreement refer initially jec provide section resolve provide section subject limitation section resolve exclusively bind arbitration accordance cpr institute dispute resolution rule nonadministere arbitration hold washington dc proceeding member party jv member party shall act behalf jv external outofpocket cost markup incur member party shall deem jv expense authorize expense proceed section shall arbitrator election member party write business day receive notice referral arbitration shall panel arbitrator member party shall appoint arbitrator mutual agreement member party agree appointment arbitrator thirty day receipt demand arbitration member party shall relevant number arbitrator require qualification appoint cpr institute dispute resolution provide member party elect panel arbitrator member party shall right appoint arbitrator require qualification arbitrator shall appoint cpr institute dispute resolution arbitrator shall year significant management level experience biopharmaceutical industry include responsibility legal matter year substantial experience attorney represent work biopharmaceutical client inhouse outside counsel commercial litigation transactional matter shall directly indirectly affiliate member party member partys affiliate shall direct indirect interest kind resolution relevant issue section shall apply dispute properly refer arbitration accordance section section g hereof section operating agreement respect jec b fee expense payable respect arbitration section reasonable legal fee prevail party shall borne nonprevaile party determine arbitrator arbitration ruling award shall final bind party c dispute refer bind arbitration pursuant section shall schedule discovery briefing argument arbitrator decision render soon practicable referral member party shall submit arbitrator comprehensive proposal resolution dispute include arbitration involve allegation breach member party obligation agreement operating agreement ancillary agreement agreement contemplate agreement member party affiliate jv andor member party affiliate party proposal damage arbitrator shall decide favor proposal make modification thereto decision arbitrator shall base proposal complie nearly agreement relevant development plan commercialization plan relevant principle reflect plan include limitation collaboration principle agreement include limitation section shall preclude member party seek interim provisional relief include temporary restraining order preliminary injunction interim equitable relief concern dispute member party prior dispute resolution procedure set forth section necessary protect interest member party section shall specifically enforceable waiver party failure enforce time period time provision agreement exercise right remedy constitute waiver provision right remedy prevent party enforce provision exercise right remedy exercise right remedy constitute election prevent exercise right remedy right remedy cumulative severability provision agreement obligation jv payment pursuant section hold invalid illegal unenforceable respect full extent permit applicable law provision hereof shall remain force effect shall liberally construe order carry intent party nearly possible b party agree use good effort negotiate provision replacement provision hold invalid illegal unenforceable consistent applicable law accomplish nearly possible original intention party respect thereto full extent permit applicable law party waif provision law render provision hereof prohibit unenforceable respect counterpart agreement execute number counterpart shall deem original take shall constitute instrument construction context require singular shall include plural plural singular use gender shall applicable gender word hereof hereunder word similar import shall construe refer agreement include annexe hereto entirety particular provision caption agreement convenience reference way define describe extend limit scope intent agreement intent provision contain agreement reference agreement matter action subject mutual agreement mutual consultation member party word similar import shall construe agreement member party shall agree matter action language agreement shall deem language mutually choose party rule strict construction shall apply party status party set forth expressly agreement operating agreement party shall right enter agreement action behalf party shall represent person right authority status bms sub gilead sub member jv agreement shall construe establish partnership joint venture relationship party member party shall party beneficiary ancillary agreement member party party purpose enforce jvs right thereunder standstill period commence effective date continue fifth anniversary effective date bms shall shall cause affiliate bms acquire offer agree acquire directly indirectly beneficial ownership equity security gilead right option acquire beneficial ownership act concert respect security right option person b participate directly indirectly solicitation proxy vote term regulation promulgate united states securities exchange act amended exchange act participant election contest term define rule promulgate exchange act initiate propose solicit stockholder gilead approval stockholder proposal c form join participate encourage formation group meaning section exchange act respect vote security gilead deposit security gilead voting trust subject security gilead agreement arrangement respect vote security e public announcement respect submit proposal offer condition extraordinary transaction involve gilead security asset f seek encourage support effort influence control management board director business policy gilead understand agree section f shall apply exercise bms right obligation agreement operating agreement ancillary agreement applicable g encourage assist person undertake foregoing action h action reasonably expect require gilead public announcement possibility event describe clause g section provide section e g shall deem prohibit bms acquire merger stock purchase percent vote security thereof party beneficial ownership equity security gilead right option acquire beneficial ownership ii beneficial ownership percent class equity security gilead right option acquire beneficial ownership employee benefit plan bms affiliate diversify mutual pension fund manage independent investment adviser pension plan establish benefit employee bms affiliate stock portfolio control bms affiliate invest gilead affiliate company provide bms affiliate directly indirectly request trustee administrator investment adviser fund plan portfolio acquire gilead equity security provide section shall effect shall bind bms manner time gilead shall public announcement enter letter intent definitive agreement party acquirer provide change control gilead nonsolicitation employee period commence effective date continue term agreement member party agree affiliate participate responsible development commercialization combination product pursuant agreement shall recruit solicit induce employee member party hivvirology sale force include manager terminate employment member party employ consult member party employee fulltime employee member party employment pursuant write agreement atwill purpose forego recruit solicit induce shall deem mean x general solicitation party placement specialist firm eg headhunter general solicitation employment include response general advertisement case x specifically target employee party affiliate entire agreement agreement include annexe hereto operating agreement ancillary agreement agreement contemplate agreement include limitation safety datum exchange protocol constitute effective date entire agreement party respect subject matter hereof prior contemporaneous understanding agreement write oral party respect subject matter include mutual technology transfer agreement enter bristolmyer squibb company gilead sciences inc february mtta mutual confidential disclosure agreement enter bristolmyer squibb company gilead sciences inc december amend superseded entirety provide right obligation party mtta mutual confidential disclosure agreement accrue effective date shall survive agreement shall amend respect whatsoever agreement write fully execute party prior effective date gilead bms consent jurisdiction party purpose enforce award section seek injunctive equitable relief permit section irrevocably submit nonexclusive jurisdiction united states district court district columbia court purpose action suit proceed arise agreement operating agreement ancillary agreement b agree raise objection time lay maintain venue action suit proceeding court irrevocably waive claim action suit proceed bring inconvenient forum irrevocably waive right object respect action suit proceeding court jurisdiction party party agree service process summon notice document register mail party notice address provide agreement shall effective service process action suit proceeding court respect matter submit jurisdiction section party set forth section party expressly refer agreement covenant representation contain benefit party benefit party signature follow intentionally leave blank intentionally leave blank witness whereof party cause collaboration agreement duly execute deliver date write gilead sciences inc bristolmyers squibb company b john c martin b tamar howson john c martin phd tamar howson president chief executive senior vice president officer corporate business development gilead holding llc er squibb son llc b john f milligan b charles linzner john f milligan phd charles linzner president assistant secretary bristolmyers squibb gilead sciences llc gilead holdings llc member b john f milligan john f milligan phd president er squibb sons llc member b charles linzner charles linzner assistant secretary iannexe collaboration agreement annex initial committee member alliance manager annex b development plan development budget effective date annex c commercialization plan commercialization budget effective date annex bms patent annex e gilead patent annex f gilead license trademark annex g bms license trademark annex h quarterly detail report annex manner calculation net selling price annex j calculation cost good annex k calculation transfer price annex l joint press release annex certain financial datum annex n datum provide independent accounting expert pursuant section annex jv obligation sublicensee annex p key term service agreement annex q pricing annex r list country comprise develop world iannex initial committee member alliance manager gilead sub bms sub joint executive committee jec j oint executive committee jec joint development committee jdc j oint development committee jdc joint commercialization committee jcc j oint commercialization committee jcc joint finance committee jfc j oint finance committee jfc alliance manager lliance manager denote initial chairperson aannex b development plan development budget effective date bannex c commercialization plan commercialization budget effective date cannex bms patent patent exclusively license bms merck dannex e gilead patent eannex f gilead license trademark country mark app reg file reg date class usa truvada application file usa viread usa emtriva fannex g bms license trademark country mark app reg file reg date class sustiva puerto rico sustiva gannex h quarterly detail report illustrative purpose period end detail activity report run date product fdc brand x hannex manner calculation net selling price net selling price product relevant period country shall express dollar daily dose product shall equal quotient aggregate net sale country product period recognize revenue united states generally accept accounting principle effect time time consistently apply divide ii number daily dose product unit revenue recognize united states generally accept accounting principle effect time time consistently apply period sell country plus number daily dose product country ship period provide consistent definition net sale party intent practice bms gilead calculation net sale shall harmonize process calculate net selling price deduction payment rebate compensation give bms gilead connection respect sale product shall treat deduction gross invoice calculation net sale b bms gilead payment provide compensation similar purpose respect product treat item accounting purpose deduction revenue purpose calculation net selling price annex item shall deduction gross invoice calculation net sale party example iannex j calculation cost good cost good mean respect manufacture acquisition product equal calculation cost good specific product mutually agree writing member update calendar year jannex k calculation transfer price k k k kannex l joint press release bristolmyer squibb contact gilead science contact david rosen media amy flood media john elicker investors susan hubbard investors bristolmyers squibb gilead science establish joint venture develop commercialize fixeddose combination hiv medicine collaboration develop oncedaily antiretroviral fixeddose regimen new york ny foster city date bristolmyer squibb company nyse bmy gilead sciences inc nasdaq cid gild today announce detail joint venture develop commercialize fixeddose combination bristolmyer squibb sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate united states approve new product complete highly active antiretroviral therapy haart treatment regimen hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider joint venture establish company kind field hiv therapy work necessary coformulate sustiva truvada oncedaily combination product ongoing continue joint venture bristolmyers squibb gilead sciences llc company work partnership complete development regulatory filing fixeddose regimen subject receive marketing approval fixeddose regimen company share responsibility commercialize product united states company provide fund fieldbased sale representative support promotional effort combination product bristolmyers squibb gilead receive revenue future net sale percentage relative contribution represent individual product comprise fix dose combination guideline issue department health human service dhhs list combination emtricitabine tenofovir disoproxil fumarate efavirenz preferred nonnucleoside reverse transcriptase inhibitor nnrtibase treatment use appropriate patient take antihiv medicine important patient aware individual hiv medication take combination regimen cure hiv infection prevent pass hiv gilead bristolmyer squibb share steadfast commitment addressing need people live hivaid world today announcement signal significant progress lcommon goal comment john c martin phd president chief executive officer gilead sciences landmark partnership reflect dedication gilead bristolmyer squibb bring deliver simplify therapy physician patient look forward work bristolmyer squibb team ensure novel therapeutic advancement reach physician people live hivaid rapidly possible decade bristolmyer squibb leader field hiv significant investment innovative scientific research unwavere commitment find new well treatment option help improve life people hiv say peter r dolan chairman chief executive officer bristolmyer squibb company please leverage leadership hiv collaboration gilead help advance management disease development potentially convenient treatment option early secretary health human service tommy thompson address need new product help advance simplify treatment people hivaid encourage member industry work create fixeddose combination help achieve goal additionally early year food drug administration issue new guideline expedite approval new combination product hiv availability simplify treatment regimen hivaid important ability progress fight disease secretary thompson say pleased collaboration effort bristolmyer squibb gilead partnership create fixeddose combination hiv medication represent important advance collective effort deliver simplify therapy people live hiv important safety information sustiva sustiva prescription medicine combination medicine treat people infect human immunodeficiency virus type hiv sustiva cure hiv help prevent pass hiv sustiva take hismanal astemizole propulsid cisapride verse midazolam halcion triazolam ergot medicine example wigraine cafergot vfend voriconazole list medicine complete patient discuss prescription nonprescription medicine vitamin herbal supplement health preparation particularly st johns wort taking plan healthcare provider patient take sustiva tell doctor right away effect condition include severe depression strange thought angry behavior report small number patient report suicide known sustiva cause patient tell doctor history mental illness drug alcohol dizziness trouble sleep drowsiness trouble concentrate andor unusual dream common feeling tend away take sustiva week woman pregnant breastfeed take sustiva rash common effect usually go away change treatment rash problem child child develop rash doctor contact right away patient tell doctor liver disease seizure take medicine seizure test check liver drug level blood need change body fat see patient take hiv medicine cause longterm effect change know time common effect include tiredness upset stomach vomit diarrhea take sustiva food increase medicine body increase frequency leffect sustiva take stomach preferably bedtime effect bothersome united states prescribing information available wwwsustivacom truvada truvada combine emtriva emtricitabine viread tenofovir disoproxil fumarate tablet take day combination antiretroviral agent united states truvada indicate combination antiretroviral agent nonnucleoside reverse transcriptase inhibitor protease inhibitor treatment hiv infection adult safety efficacy study truvada tablet emtriva viread combination ongoing component truvada study individually multidrug regimen find safe effective emtriva lamivudine tc comparable structure resistance profile efficacy safety multidrug regimen exist datum use lamivudine viread combination extrapolate support use truvada tablet treatment hiv infection adult treatmentnave patient truvada consider alternative combination viread lamivudine patient benefit oncedaily regimen treatmentexperience patient use truvada guide laboratory testing treatment history study result demonstrate effect truvada clinical progression hiv recommend truvada component triple nucleoside regimen truvada emtriva viread drug contain lamivudine include combivir epivir epivirhbv epzicom trizivir twohundre eightythree patient receive combination therapy emtriva viread non nucleoside reverse transcriptase inhibitor protease inhibitor week ongoing clinical study base limited datum new pattern adverse event identify increase frequency establish toxicity additional safety information emtriva viread combination antiretroviral agent emtriva viread lactic acidosis severe hepatomegaly steatosis include fatal case report use nucleoside analogue combination antiretroviral viread emtriva truvada indicate treatment chronic hepatitis b virus hbv infection safety efficacy drug establish patient coinfecte hbv hiv severe acute exacerbation hepatitis b report patient discontinue viread emtriva hepatic function monitor closely clinical laboratory followup month patient discontinue viread emtriva truvada coinfecte hiv hbv appropriate initiation antihepatitis b therapy warrant change body fat observe patient take viread emtriva truvada antihiv medicines cause long term health effect condition unknown viread united states viread indicate combination antiretroviral agent treatment hiv infection indication base analyse plasma hiv rna level cd cell count control study viread treatmentnave adult treatment experience adult study result demonstrate effect viread clinical progression hiv use viread consider treat adult patient hiv strain expect susceptible tenofovir assess laboratory testing treatment history ldrug interaction observe didanosine atazanavir lopinavirritonavir coadministere viread dose adjustment necessary datum available recommend dose adjustment didanosine patient weigh kg patient atazanavir lopinavirritonavir plus viread monitor vireadassociated adverse event require discontinuation coadministere viread recommend atazanavir mg give ritonavir mg atazanavir ritonavir coadministere viread renal impairment include case report renal impairment occur patient underlie systemic renal disease patient take concomitant nephrotoxic agent case appear patient identify risk factor decrease bone mineral density bmd lumbar spine hip see use viread clinical significance change bmd biochemical marker unknown followup continue assess longterm impact common adverse event occurring percent patient receive viread antiretroviral agent clinical trial include asthenia pain abdominal pain headache nausea diarrhea vomit rash rash pruritis maculopapular rash urticaria vesiculobullous rash pustular rash flatulence dizziness depression percent patient discontinue participation gastrointestinal event emtriva united states emtriva indicate combination antiretroviral agent treatment hiv infection adult indication base analyse plasma hiv rna level cd cell count control study week duration antiretroviral nave patient antiretroviraltreatmentexperience patient virologically suppress hiv treatment regimen antiretroviraltreatmentexperience patient use emtriva consider adult hiv strain expect susceptible emtriva assess genotypic phenotypic testing adverse event occur percent patient receive emtriva antiretroviral agent clinical trial include abdominal pain asthenia weakness headache diarrhea nausea vomit dizziness rash rash pruritis maculopapular rash urticaria vesiculobullous rash pustular rash allergic reaction approximately percent patient discontinue participation event adverse event report similar frequency emtriva control treatment group exception skin discoloration report high frequency emtriva treat group skin discoloration manifest hyperpigmentation palm andor sol generally mild asymptomatic mechanism clinical significance unknown bristolmyer squibb bristolmyers squibb global pharmaceutical relate healthcare product company mission extend enhance human life decade bristolmyer squibb company global leader science infectious disease invest consistently innovative research lead development important treatment people hivaid visit bristolmyer squibb world wide web wwwbmscom gilead sciences gilead sciences biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease worldwide company seven market product focus research clinical program antiinfective headquarter foster city gilead operation north america europe australia visit gilead world wide web wwwgileadcom lforwardlooking statement bristolmyer squibb forwardlooke statement press release contain forwardlooke statement term define private security litigation reform act product development forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome result differ materially current expectation risk guarantee combination product submit regulatory approval receive regulatory approval approve commercially successful forwardlooking statement guarantee forwardlooke statement press release evaluate uncertainty affect bristolmyer squibb business particularly identify cautionary factor discussion bristolmyer squibb annual report year end december quarterly report form q bristolmyer squibb undertake obligation publicly update forwardlooke statement result new information future event gilead forwardlooke statement press release contain forwardlooke statement term define private security litigation reform act forwardlooke statement include statement approval licensure combination product statement involve risk uncertainty cause result differ materially set forth statement include risk relate ability company successfully complete ongoing study support approval combination product willingness regulatory authority grant regulatory approval combination product base datum study forwardlooke statement guarantee actual result differ materially project gilead undertake obligation publicly update forwardlooke statement result new information future event forwardlooke statement press release evaluate uncertainty affect gilead business particularly mention cautionary statement company year end december periodic report form q form k lannex certain financial datum annual budget report quarterly projection report later weekly sale report actual report times base mannex n datum provide independent accounting expert pursuant section provide bms annual basis provide gilead annual basis provide jv designee annual basis nannex jv obligation sublicensee oannex p key term service agreement term sheet focus certain key aspect service agreement discuss term condition include definitive service agreement enter jv gilead parent pursuant section collaboration agreement agreement distribution service agreement service agreement jv gilead parent pursuant gilead parent provide certain distribution service combination product territory behalf jv distribution service distribution service provide gilead parent behalf jv include limitation inventory management control warehouse storage order invoicing collection sale proceed customer relation service return jcc oversee gilead parent activity service agreement gilead parent provide distribution service accordance customary practice biopharmaceutical industry gsp gmp applicable law compensation term service agreement continue term collaboration agreement early terminate accordance article collaboration agreement p miscellaneous service agreement contain additional provision relate matter provision consistent provision collaboration agreement bms gilead parent mutually agree pannex q price qannex r list country comprise develop world african country algeria angola benin botswana burkina faso burundi cameroon cape verde central african republic chad comoros cte divoire democratic republic congo djibouti egypt equatorial guinea eritrea ethiopia gabon gambia ghana guinea guineabissau kenya lesotho liberia libya madagascar malawi mali mauritania mauritius morocco mozambique namibia niger nigeria republic congo rwanda tom prncipe senegal seychelles sierra leone somalia south africa sudan swaziland tanzania togo tunisia uganda zambia zimbabwe nonafrican country united nations list develop country afghanistan antigua barbuda bahamas bangladesh barbado belize bhutanbolivia cambodia cuba dominica dominican republic el salvador fiji grenada guatemala guyana haiti honduras indonesia iran islamic rep iraq jamaica jordan kiribati laos lebanon maldives mongolia myanmar naura nepal nicaragua oman pakistan papua new guinea philippines saint kitts nevis saint lucia samoa saudia arabia solomon islands sri lanka st vincent grenadines suriname syrian arab republic timorleste trinidad tobago tonga tuvalu vanuatu vietnam yemen rexhibit fourth amendment license agreement fourth amendment license agreement fourth amendment effective th day april effective date gilead sciences inc triangle pharmaceuticals inc delaware corporation principal place business lakeside drive foster city company emory university notforprofit georgia corporation office south oxford road ne atlanta georgia licensor amend certain term certain license agreement date april licensor company amend amendment license agreement date amendment amend second amendment license agreement date july second amendment amend amendment license agreement date license agreement amend second amendment refer agreement licensor company wish clarify fair equitable formula net selling price license product contain active ingredient license compound compound license compound licensor company wish clarify definition relate expand access program company global access program good valuable consideration receipt sufficiency acknowledge party company licensor agree follow definition use exist definition term fourth amendment define shall meaning ascribe agreement amendment definition agreement amend provide section delete entirety replace follow net selling price product include licensed product shall mean respect particular fiscal quarter gross invoice price ie total invoice price prior deduction pursuant clause iv pay purchas product include distributor company affiliate sublicensee company sublicensee party authorize company sell product shall include distributor collectively seller plus applicable value property service receive consideration sale product discount include cash quantity discount chargeback payment rebate grant manage health care organization federal state local government agency purchaser reimburser trade customer ii credit allowance actually grant claim damage good rejection return license product include recall iii freight postage ship transportation insurance charge actually allow pay delivery license product extent bill iv taxis income taxis dutie governmental charge levied absorb impose sale license product include limitation valueadde taxis governmental charge measure billing include billing adjust rebate refund notwithstanding forego section amount receive company affiliate sublicensee sale license product company affiliate sublicensee resale shall include computation net selling price hereunder b purpose section distributor shall mean party seller grant time term right sell distribute license product ii sell license product hospital andor pharmacy sale use patient party resale hospital andor pharmacy sale use patient iii payment company company affiliate calculate basis percentage profit share party sale license product purpose calculate net selling price distributor shall deem sublicensee company affiliate net selling price quantity license product sell distributor shall calculate base invoice distributor company andor affiliates andor sublicensees affiliate company distributor customer c license product sell form combination product contain active ingredient addition license compound combination product net selling price combination product purpose determine royalty payable agreement calculate multiply actual net selling price combination product fraction aab net selling price stock keep unit comparable formulation dosing combination product license product contain relevant license compound sole active ingredient sell separately country relevant fiscal quarter b net selling price stock keep unit comparable formulation dosing combination product active ingredient sell separately country relevant fiscal quarter clarity active ingredient include license compound additional b term calculate manner shall include denominator fraction shall aab b countrybycountry basis active ingredient combination product sell separately say country net selling price purpose determine royalty payable agreement combination product shall calculate multiply actual net selling price combination product combination product license product contain relevant license compound sole active ingredient sell separately country relevant fiscal quarter c net selling price combination product country relevant fiscal quarter countrybycountry basis license product contain license compound sole active ingredient sell separately say country relevant fiscal quarter active ingredient combination product sell separately say country relevant fiscal quarter net selling price combination product shall calculate multiply actual net selling price combination product fraction dc net selling price stock keep unit comparable formulation dosing combination product product contain active ingredient sole active ingredient c net selling price combination product country relevant fiscal quarter countrybycountry basis license product contain license compound sole active ingredient sell separately active ingredient combination product sell separately country relevant fiscal quarter net selling price purpose determine royalty combination product shall deem net selling price combination product multiply fraction numerator number license compound combination product denominator number active ingredient combination product intentionally leave blank sale sell shall mean sale transfer exchange disposition license product gift subsequent registration give country registration require seller sale transfer exchange disposition party seller sale license product shall deemed consummate occur receipt payment purchase b delivery license product purchas common carrier c release license product consignment transfer exchange dispose gift transfer exchange gift disposition occur notwithstanding forego definition sale extent company distribute license product treatment ind expand access program global access program extent actual net selling price exceed fully absorb cost therefor distribution consider sale actual net selling price exceed fully absorb cost distribution shall deem sale deem net selling price prior application section c purpose section difference actual net selling price fully absorb cost therefor new section add global access program shall mean program company provide licensed product government agency notforprofit nongovernmental organization physician pharmacy patient identify country reduce cost country identify exhibit c hereto exhibit amend time time party fully absorb cost shall mean equal company cost directly allocate production license product distribute treatment ind expand access program global access program consist direct labor include resource utilize support company manufacture operation ii material iii reasonable allocation overhead facility expense include depreciation expect life building equipment administrative cost directly support company manufacture operation treatment ind distribution program expand access program global access program applicable calculate company accordance reasonable cost accounting method consistent way company allocate cost product iv thirdparty cost amendment provision agreement provision agreement definition amend follow section delete entirety replace follow commence fda registration license product end expiration second calendar year follow year fda registration grant company credit solely run royalty pay pursuant section reasonable cost incur company date hereof include reimbursement licensor pursuant section inter part patent prosecution activity define connection litigation interference opposition inter part action pertain validity enforceability allowability subsistence license patent company practice license patent infringe party patent end second calendar year credit shall exceed year onehalf royalty payment hereunder year commence calendar year follow year fda registration grant credit shall exceed year onehalf annual minimum payment year cost shall credit payment licensor agreement section right audit sentence insert include record reasonably necessary verify accuracy net selling price fully absorb cost prior require furnish company pursuant section agreement general term unamended term agreement remain effect expressly amend remain term agreement shall remain force effect entire agreement agreement amend fourth amendment constitute entire agreement licensor company subject matter contain conflict event conflict provision agreement fourth amendment provision fourth amendment shall govern control governing law fourth amendment shall govern construe accordance law state georgia regard conflict law principle counterpart fourth amendment execute number counterpart shall deem original shall constitute instrument survival provision provision fourth amendment reason hold ineffective unenforceable illegal condition shall affect validity enforceability remain portion hereof provide party shall negotiate good faith replace ineffective unenforceable illegal provision effective replacement soon practical witness whereof licensor company execute fourth amendment authorize officer date write emory university todd sherer asst vp director ott date gilead sciences inc john f milligan executive vp cfo date april e xhibit c global access program country algeria kenya togo angola lesotho tunisia benin liberia uganda botswana libya zambia burkina faso madagascar z imbabwe burundi malawi cameroon mali cape verde mauritania afghanistan central african republic mauritius bahamas chad morocco bangladesh comoros mozambique bhutan congobrazzaville namibia cambodia cote divoire niger guyana democratic republic congo nigeria haiti djibouti rwanda kiribati egypt sao tome principe laos equatorial guinea senegal maldive eritrea seychelles myanmar ethiopia sierra leone nepal gabon somalia samoa gambia south africa solomon islands ghana sudan tuvalu guinea swaziland vanuatu guinea bissau tanzania yeman exhibit subsidiary gilead sciences inc subsidiary country incorporation avid corporation united states bristolmyers squibb gilead sciences llc united states gilead biopharmaceutics ireland corporation ireland gilead holdings llc united states gilead sciences holdings llc united states gilead sciences gmbh germany gilead sciences sarl france gilead sciences srl italy gilead sciences sl spain gilead sciences lda portugal gilead sciences limited ireland gilead sciences ltd united kingdom gilead sciences international ltd united kingdom gilead sciences pty limited australia gilead sciences nz new zealand gilead sciences bv netherlands gilead sciences canada inc canada gilead sciences hellas epe greece gilead sciences luxembourg sarl luxembourg gilead vintage park llc united states leaf shield insurance limit bermudaexhibit consent independent register public accounting firm consent incorporation reference registration statement form nos pertain stock option plan employee stock purchase plan nonemployee director stock option plan equity incentive plan gilead sciences inc nexstar pharmaceuticals inc incentive stock plan nexstar pharmaceuticals inc director option plan vestar inc stock option plan triangle pharmaceuticals inc stock incentive plan option agreement date august triangle pharmaceutical inc daniel g welch registration statement form nos gilead sciences inc relate prospectus report date march respect consolidated financial statement schedule gilead sciences inc gilead sciences inc management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting gilead sciences inc include annual report year end december ernst young llp palo alto california march exhibit certification john c martin certify review annual report gilead sciences inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rule f df registrant design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluate effectiveness registrant disclosure control procedure present annual report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change registrant internal control financial reporting occur registrant recent fiscal quarter materially affect reasonably likely materially affect registrant internal control financial reporting registrant certify officer disclose base recent evaluation internal control financial reporting registrant auditor audit committee registrant board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect registrant ability record process summarize report financial information b fraud material involve management employee significant role registrant internal control financial reporting registrant certify officer indicate annual report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weakness john c martin date march john c martin president chief executive officerexhibit certification john f milligan certify review annual report gilead sciences inc base knowledge annual report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover annual report base knowledge financial statement financial information include annual report fairly present material respect financial condition result operation cash flow registrant period present annual report registrant certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rule f df registrant design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate registrant include consolidated subsidiary known entity particularly period annual report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluate effectiveness registrant disclosure control procedure present annual report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change registrant internal control financial reporting occur registrant recent fiscal quarter materially affect reasonably likely materially affect registrant internal control financial reporting registrant certify officer disclose base recent evaluation internal control financial reporting registrant auditor audit committee registrant board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect registrant ability record process summarize report financial information b fraud material involve management employee significant role registrant internal control financial reporting registrant certify officer indicate quarterly report significant change internal control factor significantly affect internal control subsequent date recent evaluation include corrective action regard significant deficiency material weaknesse john f milligan date march john f milligan executive vice president chief executive officerexhibit certification pursuant requirement set forth rule ab securities exchange act amended exchange act section chapter title united states code usc adopt john c martin chief executive officer gilead sciences inc company john f milligan chief financial officer company certify good knowledge company annual report period end december certification attach exhibit annual report fully complie requirement section section securities exchange act amend information contain annual report fairly present material respect financial condition result operation company period cover annual report witness whereof undersigned set hand hereto th day march date march john c martin john f milligan john c martin john f milligan chief executive officer chief financial officer certification accompanie relate deem file security exchange commission incorporate reference filing gilead sciences inc securities act amend securities exchange act amend date irrespective general incorporation language contain filing